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Zusammenfassung 
Foamy Viren oder Spumaretroviren gehören zur Familie der Retroviridae, unterscheiden sich 
jedoch deutlich von allen übrigen Retroviren (Orthoretroviren). Das Genom in infektiösen 
Viren besteht aus DNA und nicht aus RNA. Zudem wird Pol, das Vorläuferprotein der viralen 
Enzyme, von einer eigenen mRNA unabhängig von Capsid- und Matrix-Proteinen translatiert. 
Schließlich bleibt die virale Protease mit der Reversen Transkriptase verbunden, während sich 
die Proteasen von Orthoretroviren selbst abspalten. Gereifte Spumaretroviren enthalten somit 
ein Protease-Reverse Transkriptase (PR-RT) Protein, das drei katalytische Aktivitäten vereint: 
Proteolyse, DNA Polymerisation and RNase H Aktivität. 
In dieser Arbeit wurden rekombinante PR-RTs von zwei verschiedenen Foamy Viren (dem 
Prototyp Foamy Virus und dem Simian Foamy Virus aus Makaken) gereinigt und miteinander 
verglichen. Unsere Ergebnisse zeigen, dass sich die enzymatischen Aktivitäten und die 
biophysikalischen Eigenschaften der beiden Proteine ähneln. Sie unterschieden sich jedoch 
bezüglich ihres Resistenzverhaltens gegenüber Azidothymidin. Dieser Nukleosidinhibitor ist 
in der Lage die Replikation von Foamy Viren zu hemmen, indem er die DNA Polymerisation 
terminiert. Während Prototyp Foamy Viren keine Resistenz gegen Azidothymidin 
entwickelten, gelang es, Azidothymidin-resistente Simian Foamy Viren zu isolieren. Vier 
Mutationen im Bereich der Reversen Transkriptase wurden identifiziert, die für diese 
Resistenz verantwortlich sind. Um den molekularen Mechanismus der Resistenz aufzuklären, 
wurden die entsprechenden rekombinanten PR-RT-Enzyme in vitro analysiert. Es wurde 
nachgewiesen, dass die Resistenz der Viren auf der Fähigkeit beruht, den bereits eingebauten 
Inhibitor mit Hilfe von ATP wieder zu entfernen. 
Obwohl retrovirale Proteasen nur als Homodimere aktiv sind, zeigten analytische 
Ultrazentrifugation und Größenausschlußchromatographie, dass die PR-RTs des Simian 
Foamy Virus aus Makaken und des Prototyp Foamy Virus in Lösung als inaktive Monomere 
vorlagen. Die dreidimensionale Struktur der separaten Protease-Domäne des Simian Foamy 
Virus wurde durch Kernspinresonanzspektroskopie bestimmt. Sie weist die typische Faltung 
einer Monomeruntereinheit anderer retroviraler Proteasen auf. Darüber hinaus belegten 
Messungen paramagnetischer Relaxationsverstärkungen der Protease-Domäne mittels 
Kernspinresonanzspektroskopie die Ausbildung von transienten Homodimeren.  
Diese Arbeit zeigt weiterhin, dass bestimmte purinreiche RNA-Sequenzen der Foamy Viren 
in der Lage sind, die Protease zu aktivieren. Chemische Analysen der entsprechenden RNA-
Sekundärstrukturen deuteten auf die Ausbildung von charakteristischen Haarnadelschleifen-
Strukturen hin. Retardations- und chemische Proteinquervernetzungsexperimente bewiesen 
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zudem die Ausbildung von stabilen PR-RT Dimeren in Gegenwart dieser RNA-Sequenzen. 
Auf Grundlage der vorgestellten in vitro Experimente wird ein Modell für den Ablauf des 
Zusammenbaus der Viruspartikel von Foamy Viren vorgeschlagen.  
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Summary 
Foamy viruses or spumaretroviruses belong to the family of retroviridae but differ in several 
aspects from other retroviruses (orthoretroviruses). Viral particles contain DNA not RNA. 
The Pol protein, the precursor of the viral enzymes, is translated from a separate mRNA 
independently of the capsid and matrix proteins. The protease remains covalently bound to the 
reverse transcriptase, while in orthoretroviruses the protease is cleaved off autocatalytically. 
Thus, in mature spumaretroviruses a protease-reverse transcriptase protein (PR-RT) with 
three different catalytic activities is found: proteolysis, DNA polymerization and RNase H 
activity. 
In this work, the recombinant PR-RTs from the prototype foamy virus and a simian foamy 
virus isolate from macaques were purified and compared. The biophysical and enzymatic 
properties of the two enzymes were similar. However, their behavior towards the nucleoside 
inhibitor azidothymidine is different. This nucleoside analog inhibits the replication of foamy 
viruses by terminating polymerization. Prototype foamy virus was not able to develop 
resistance against azidothymidine, but we succeeded in the generation of an azidothymidine-
resistant simian foamy virus. Up to four mutations within the reverse transcriptase were found 
to be necessary to confer high resistance against azidothymidine. To characterize the 
mechanism of resistance, the corresponding recombinant PR-RTs were investigated in vitro. 
The data reveal that the azidothymidine resistance is based on the excision of the incorporated 
inhibitor in the presence of ATP. 
Retroviral proteases are only active as homodimers. In this work, analysis of the PR-RT of 
prototype foamy virus and simian foamy virus isolated from macaques by analytical 
ultracentrifugation and size exclusion chromatography indicate, that foamy virus proteases are 
stable and inactive monomers in solution. The three-dimensional structure of the simian 
foamy virus protease domain was determined by nuclear magnetic resonance spectroscopy 
and revealed the typical folding of a monomer subunit of retroviral proteases. Furthermore, 
nuclear magnetic resonance analysis by paramagnetic relaxation enhancement suggested the 
formation of transient protease homodimers under native conditions. 
Finally, it is shown that polypurine rich sequences of the foamy virus RNA are able to 
activate protease activity. Chemical analysis of the secondary structure of these RNA 
sequences indicated a characteristic hairpin loop structure. Retardation and protein 
crosslinking experiments prove the formation of stable PR-RT dimers in the presence of the 
polypurine RNA sequences. Based on these in vitro data we propose a model for foamy virus 
assembly.
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1 Introduction 
1.1 Foamy viruses 
Until the 1960s the “Central Dogma” of molecular biology, meaning that there is an 
irreversible flow of information in the cell from deoxyribonucleic acid (DNA) to ribonucleic 
acid (RNA) to protein, was incontrovertible. However, this changed with the discovery of 
reverse transcription in retroviruses confirming an earlier proposal, which postulated that 
retroviruses indeed generate DNA copies of their RNA genome (Temin, 1964; Baltimore, 
1970; Temin & Mizutani, 1970). All retroviruses share this unique behavior. 
Since many retroviruses cause diseases in animals as well as in humans, researchers always 
have had a special interest in this family of viruses. Representatives are the oncogenic murine 
leukemia virus (MLV) and, most famous, the human immunodeficiency virus (HIV) causing 
the acquired immunodeficiency syndrome (AIDS). On the other hand, a distinct group of 
retroviruses, the so-called foamy viruses (FVs) (Figure 1.1), have not been associated with 
any disease and thus appear to be less dangerous (reviewed in Meiering & Linial, 2001).  
 
 
Figure 1.1:  Electron microscopy of Prototype FV budding from the plasma membrane of 
human embryonic lung fibroblasts (Meiering & Linial, 2001). 
Phylogenetically, FVs are set apart from all other retroviruses (Figure 1.2) and form their own 
subfamily of Spumaretrovirinae (spumaretroviruses). All remaining retroviruses are 
combined in the second subfamily of Orthoretrovirinae (orthoretroviruses) (Rethwilm, 2005). 
FVs are widespread in vertebrates, especially in apes. Transmission occurs through biting and 
licking. They are the oldest known vertebrate RNA viruses having existed for at least 65 
million years in primate populations (Switzer et al., 2005).  
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Figure 1.2: Phylogenetic tree of retroviruses. 
The tree is based on the RT sequence of the viruses depicted in parenthesis (modified 
from Coffin et al., 1997). 
FVs can infect humans, but there appears to be no human-to-human transfections and patients 
stay healthy. Humans reported to be infected with FVs have either been bitten by an ape or 
have been infected working with FVs in a laboratory (reviewed in Meiering & Linial, 2001). 
Still, FVs integrate their genes into the host cell’s genome as all retroviruses do. These 
features make FVs a potential tool as vectors in molecular biology carrying recombinant 
genetic material and possibly for gene therapeutic approaches as well. Moreover, prominent 
characteristics in the FV replication and life cycle might enable us to better understand 
retroviral behavior in general.  
Research on FVs focuses on two different species: a simian FV derived from macaques 
(SFVmac) and the prototype FV (PFV), originally isolated from humans but most probably 
originating from chimpanzee (Herchenröder et al., 1994). The main focus of this work is put 
on these species as well. 
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1.2 Virus and life cycle 
The most obvious difference between FVs and orthoretroviruses is that infectious FV particles 
contain double-stranded DNA instead of single-stranded RNA (Figure 1.3) (Moebes et al., 
1997; Yu et al., 1999; Roy et al., 2003). In fact this has been the main reason to establish a 
special subfamily for FVs. Consequently, this means that reverse transcription of the viral 
RNA into DNA has to occur during assembly or budding of the virus particle – at a late time 
point in the viral life cycle. In orthoretroviruses virions harbor RNA and reverse transcription 
occurs early in the life cycle (Goff, 2007).  
 
Figure 1.3: The FV virion. 
 In this schematic figure the relative locations of the viral proteins in the viral particle are 
shown. DNA is shown in purple, Env in green, Gag in red and the proteins resulting 
from protease cleavage of Pol in blue. PR-RT: protease-reverse transcriptase; IN: 
integrase. 
The organization of the FV genome is typical for complex retroviruses (Figure 1.4). Long 
terminal repeats (LTR) enframe the complete genetic information. Three characteristic 
retroviral genes are found in the genome:  
- gag (capsid and matrix proteins), 
- pol (viral enzymes) and 
- env (envelope glycoproteins). 
These genes are transcribed from a promoter (P) in the 5’ LTR region. Interestingly, each of 
these genes is translated from a separate mRNA. This is in clear contrast to all other 
retroviruses where Gag and Pol are derived from the same mRNA. Translation in FVs 
therefore leads to the polyproteins Gag, Pol and Env, whereas in orthoretroviruses Gag, Gag-
Pol and Env are synthesized (Rethwilm, 2003; Rethwilm, 2005; Linial, 2007). To obtain 
mature virus particles, a protease (PR) has to cleave the polyproteins into the different 
proteins. This is either catalyzed by the viral protease PR (Gag and Pol) or by cellular PRs 
(Env). Remarkably, there is only a single PR cleavage site within the Pol polyprotein of FVs 
located between the reverse transcriptase (RT) and integrase (IN). A second cleavage site 
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separating PR and RT, which is present in orthoretroviruses, is missing (Pfrepper et al., 1998; 
Flügel & Pfrepper, 2003). Thus, the FV enzymes consist of a combined PR-RT and a separate 
IN (Figure 1.4).  
 
Figure 1.4: FV genome and Pol polyprotein. 
 Top: Organization of the FV genome and coding regions together with the 5’ and 3’ 
promoter (right-angled arrows). Bottom: The Pol polyprotein including protease (PR), 
reverse transcriptase (RT) and integrase (IN) and its processing by PR. 
Typical for FV is a second internal promoter (IP) located in the env gene. Starting from this 
promoter tas and bel2 are transcribed resulting in the two nonstructural proteins Tas and Bet. 
Bet is translated from a spliced mRNA of tas and bel2 (Löchelt et al., 1994). While Tas is a 
transactivator of transcription (Mergia et al., 1990; Rethwilm et al., 1991) the function of Bet 
is yet unclear but the protein might be an antagonist of the APOBEC 3C protein, which is part 
of the cellular immune response (Löchelt et al., 2005; Russell et al., 2005; Perkovic et al., 
2009). 
 
Figure 1.5: Schematic life cycle of FV. 
 Viral DNA is indicated in purple, genomic RNA in yellow, Env in green, Gag in red and 
Pol in blue. (Budding of viral particles from the membrane of the endoplasmatic 
reticulum is not shown.) A detailed description is given in the text below. 
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Figure 1.5 gives an overview of the life cycle of FVs. First, DNA-containing virions bind to a 
yet unknown receptor and penetrate the cell. Uncoating is achieved by cleavage of Gag by 
cellular protease. The viral DNA and IN are imported into the nucleus where integration of 
the DNA into the host cell genome is catalyzed by the viral IN enzyme. The integrated 
provirus serves as a template for transcription and translation of the viral RNA and proteins 
by viral and cellular factors (reviewed in Linial, 2007).  
So far, assembly of the virus particle is poorly understood. Capsid formation appears to occur 
in the cytoplasm (Eastman & Linial, 2001) and glycoproteins are added on either the 
membrane of the endoplasmatic reticulum or the plasma membrane (Goepfert et al., 1999; 
Meiering & Linial, 2001). However, it is still unclear at which time point RNA is reverse 
transcribed and how assembly of the viral RNA, the Gag and especially the Pol proteins 
works. The latter is a problem, which is not faced by orthoretroviruses, as Gag and Pol are 
expressed as a fusion protein. Orthoretroviral Gag harbors a localization signal and therefore 
localization of Pol is achieved simultaneously (Coffin et al., 1997). 
Recently, two components critical for incorporation of Pol into the FV virion were identified. 
It has been shown that the C-terminus of Gag is required for Pol encapsidation (Stenbak & 
Linial, 2004; Lee & Linial, 2008). Additionally, Peters et al. (2008) demonstrated that parts of 
the viral nucleic acid sequence play an important role for the same process. These sequences 
are located in the central polypurine tract (cPPT) within the pol open reading frame. In FVs as 
well as lentiviruses the cPPT is present in addition to the 3’ polypurine tract (PPT) upstream 
of the 3’ LTR (Kupiec et al., 1988; Arhel et al., 2006). The PPT is important for synthesis of 
the viral DNA. In the FV cPPT there are four polypurine rich sequences (A-D), whose lengths 
vary between nine to twelve bases. While the role of D is unclear, C is required for regulation 
of gene expression, and encapsidation of Pol is dependent on A and B (Peters et al., 2008). At 
the end of the FV life cycle, viral particles bud from the cell.  
Although it is not exactly known at which time point the polyproteins are processed or reverse 
transcription of the genomic RNA occurs, in infectious viral particles all these processes are 
finished. Characteristic for FV particles is an immature looking core and prominent surface 
spikes (Linial, 2007). 
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1.3 Reverse transcriptases 
The key enzyme within the retroviral life cycle is the RT. It is responsible for synthesis of 
double-stranded DNA starting from a single-stranded RNA template – a rather complex 
procedure. Thereby three different reactions have to be catalyzed: 
- RNA-dependent DNA polymerization, 
- DNA-dependent DNA polymerization and 
- cleavage of the RNA strand in an RNA/DNA hybrid. 
While synthesis of DNA is catalyzed by the RT’s polymerase activity, cleavage of RNA is 
due to the RNase H domain at the C-terminus of the RT.  
For synthesis of double stranded DNA a transfer RNA (tRNA) primer has to bind to the viral 
primer binding site (PBS) of the (+) strand RNA (Figure 1.6, step 1). FVs use the cellular 
tRNALys1, 2 (Maurer et al., 1988), while other retroviruses make use of other tRNAs (e. g. 
tRNALys3 in HIV-1 (Raba et al., 1979; Wain-Hobson et al., 1985)). Polymerization of the (-)-
strand DNA starts at the PBS and stops when the end of the 5’ LTR is reached (step 2). Thus, 
this region forms an RNA/DNA hybrid and serves as a substrate for RNase H. Degradation of 
the RNA in the hybrid leads to a single stranded stretch of DNA, whose “repeated” sequence 
(R’) is complementary to the “repeated” sequence (R) in the 3’ LTR of the RNA and thus the 
two R regions can hybridize (first jump, step 3) (Goff, 2007). 
Polymerization of the (-)-strand DNA can be completed, while the RNase H simultaneously 
degrades the RNA in the resulting hybrid (step 4). However, not all of the copied RNA is 
degraded. The PPT RNA is not cleaved by the RNase H and is used as a primer for DNA (+)-
strand synthesis. Polymerization of the (+)-strand DNA stops after 18 bases of the tRNA 
primer have been copied and the first modified nucleotide of the tRNA is reached. The RNase 
H degrades the RNA of the tRNA/DNA hybrid (step 5). Removal of the tRNA primer creates 
a single stranded (+)-strand DNA stretch that is complementary to the PBS of the (-) DNA 
(step 6). Hence, these two parts can bind to each other (second jump, step 7). Now 
polymerization of the both DNA strands can be completed (step 8) (Goff, 2007).  
In consequence the RNA is converted into double stranded DNA. Caused by the two jumps 
during replication the sequences upstream of the PBS and downstream of the PPT are doubled 
and form the LTRs on both sides of the DNA. The LTRs not only ensure the correct 
transcription of the viral DNA since the LTR encodes the viral promoter, but they are also 
recognized by the viral IN and are of great importance in the integration process. 
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Figure 1.6: Reverse transcription of the retroviral genome. 
 The retroviral genome and the cell-derived tRNA are shown in red, the DNA strands 
produced are depicted in black. LTR: long terminal repeats; PPT: polypurine tract; R: 
repeated sequence of the LTR; PBS: primer binding site; sequences complementary to R 
and PBS are designated R’ and PBS’, respectively. For detailed explanation see text 
above. 
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1.3.1 The polymerase domain of the PR-RT enzyme 
The polymerase domain of the RT can synthesize a DNA copy from a DNA or RNA 
template. In vitro, the primer used for this reaction can be either DNA or RNA. The structure 
of the polymerase domain of retroviral RTs is similar to that of other polymerases (e.g. T7 
and Klenow polymerase) and resembles a right hand (Figure 1.7). Consequently, the 
subdomains were called fingers, palm and thumb. The domain connecting the polymerase and 
RNase H domains was named “connection domain” (Coffin et al., 1997).  
 
Figure 1.7: Crystal structure of the HIV-1 RT. 
 The two subunits (p51 and p66) of HIV-1 RT are displayed. p51 is shown in light grey, 
the subdomains of p66, which are named based on the analogy to a right hand, are color 
coded: fingers (blue), palm (red), thumb (green), connection domain (light yellow) and 
RNase H (black). The polymerase active site Tyr-Met-Asp-Asp is highlighted as yellow 
sticks (picture generated from PDB 1HMV with MacPyMOL). 
The overall folding of the polymerase domain is similar across all retroviral species (Coffin et 
al., 1997; Goff, 2007). However, while in some species the RT is a heterodimer (e.g. p66 and 
p51 in HIV) the RT of FV and MLV consists of a single polypeptide chain. The active site 
with the conserved Tyr-X-Asp-Asp motif is located in the palm subdomain. The central part 
surrounding the active site represents the phylogenetically most conserved portion of the 
retroviral genome (Coffin et al., 1997). The two Asp residues of this motif in combination 
with a third Asp bind two divalent metal ions and catalyze polymerization with a carboxylate-
chelate two-metal-ion catalytic mechanism (reviewed in Sarafianos et al., 2009). The active 
site sequence present most frequently is Tyr-Met-Asp-Asp, but in FVs and MLV Tyr-Val-
Asp-Asp is found (Linial, 2007). Surprisingly, in FVs a Val to Met amino acid exchange 
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showed only minor differences in RT activity in vitro but completely abolished virus 
infectivity (Rinke et al., 2002). 
In HIV, the thumb region appears to be rather flexible and moves about 30° upon substrate 
binding. In its closed form it touches the tip of the fingers (Rodgers et al., 1995; Hsiou et al., 
1996). Primer/template binding of RT can be imagined as a right hand closing around the 
substrate like a grip. Binding of the primer/template perfectly positions the 3’ end of the 
primer at the active site of the polymerase (Jacobo-Molina et al., 1993). An incoming 
deoxynucleotide-triphosphate (dNTP) then binds to the nucleotide-binding site. This is 
followed by a conformational change of the protein where the finger domain closes down on 
the dNTP (Huang et al., 1998). Thus, the !-phosphate of the dNTP is aligned with the 3’ 
hydroxyl group of the primer. The chemical reaction catalyzed by bivalent metal ions leads to 
the formation of a phosphodiester bond between the incoming nucleotide and the primer 
(Steitz, 1998). The pyrophosphate (PPi) generated is released by an opening of the fingers. 
Translocation of the primer finally results in a free nucleotide-binding site and polymerization 
can proceed.  
 
Figure 1.8: Chemical Structure of the nucleoside inhibitor azidothymidine (AZT). 
Since human cells do not depend on RT, anti-retroviral therapy – in particular AIDS therapy - 
early concentrated on inhibiting RT activity of the virus. To date several therapeutic agents 
targeting RT are available. Interestingly, only the two nucleoside inhibitors tenofovir and 
azidothymidine (AZT, 3’-azido-3’-deoxythymidine, Figure 1.8) are known to inhibit FV RT 
(Moebes et al., 1997; Rosenblum et al., 2001; Lee et al., 2006). AZT is similar in structure to 
the nucleoside thymidine, but lacks the 3’ hydroxyl group. Thus, polymerization is terminated 
after incorporation of AZT-5’-monophosphate (AZTMP) into the synthesized DNA chain. 
Unfortunately, HIV is able to escape AZT treatment by developing resistance.  
Two different mechanisms of resistance have been shown for HIV- 1 and 2. HIV-2 RT can 
distinguish between AZT-5’-triphosphate (AZTTP) and thymidine-5’-triphosphate (TTP) 
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(Boyer et al., 2006) by as few as two mutations located in the RT gene (Q151M/I/L and 
K70R) (Rodes et al., 2000). The situation for HIV-1 is more complex and is still discussed to 
some extent. Altogether, high level AZT resistance in HIV-1 is achieved by five mutations in 
the RT gene (M41L, D67N, K70R, T215Y/F and K219E/Q) (Larder & Kemp, 1989). The 
mechanism of resistance is based on the excision of incorporated AZTMP, which reactivates 
polymerization. The excision reaction was proposed to take place either in the presence of 
inorganic PPi representing the back reaction of polymerization (Arion et al., 1998) or in the 
presence of adenosine-5’-triphosphate (ATP) (Meyer et al., 1998; Meyer et al., 1999).  
 
1.3.2 The RNase H domain of the PR-RT enzyme 
As mentioned before the RNase H domain of retroviral RTs is responsible for degradation of 
the RNA in an RNA/DNA hybrid. Removal of the tRNA primer and the PPT are special 
functions of the RNase H. Activity and specificity of the RNase H are finely tuned. 
The tertiary folding of retroviral RNase H domains is similar to other known RNase H 
proteins like RNase HI of Escherichia coli (E. coli) or Thermus thermophilus. In principle, 
the RNase H domains consist of 5 "-strands and 4 to 5 !-helices (Figure 1.9). When 
comparing various RNase H domains, the presence or absence of a positively charged so-
called C-helix is the most obvious difference (reviewed in Schultz & Champoux, 2008). The 
C-helix can be found in FV and MLV, but not in HIV. The exact function of this helix is 
unclear. It has been suggested to have structural importance in MLV RNase H (Telesnitsky et 
al., 1992; Lim et al., 2002) and to participate in effective substrate binding in E. coli RNase H 
(Kanaya et al., 1991). Interestingly, HIV RNase H expressed separately was shown to be 
inactive. However, a recombinant HIV RNase H harboring the C-helix of MLV at the N-
terminus was active (Stahl et al., 1994; Keck & Marqusee, 1995).  
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Figure 1.9: Crystal structure of the RNase H domain of MLV. 
 The RNase H domain of Moloney MLV lacking the C-helix is shown. The conserved 
acidic residues of the active site are shown in red, a coordinated Mg2+ ion is depicted in 
grey and the residues belonging to the primer grip are highlighted in yellow (picture 
generated from PDB 2HB5 with MacPyMOL). 
The second important region of the RNase H is called primer grip. This region is found in all 
retroviral RNase H domains structurally investigated so far. It contributes significantly to the 
positioning and binding of the substrate at both the DNA polymerase and RNase H active site. 
Contacts between the primer grip of the RNase H and the nucleotides of the DNA strand, base 
paired with RNA, are formed at positions -4 to -9 relative to the scissile phosphate (Sarafianos 
et al., 2001). Close to the primer grip is the active site of the RNase H. It is highly conserved 
and consists of a Glu and three Asp. The distance between the polymerase and the RNase H 
active site is about 17 to 18 base pairs. Most likely, two divalent metal ions, Mg2+ and/or 
Mn2+ are coordinated and are required for RNase H activity. Recent studies suggest that one 
ion activates a nucleophilic water molecule, the second ion stabilizes the transition state 
intermediate (Schultz & Champoux, 2008). 
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1.4 Retroviral proteases 
In FVs, PR is part of the multifunctional PR-RT enzyme emerging from Pol after IN is 
cleaved off. In orthoretroviruses PR is expressed as part of a Gag-Pol polyprotein but is 
excised from the precursor by cuts performed at its C- and N-terminus. Depending on the 
virus, mature PR therefore is either present as a separate protein or as part of PR-RT.  
Without any known exceptions retroviral PRs belong to the well-characterized family of 
aspartic PRs (Katoh et al., 1987; Katoh et al., 1989). This family also includes mammalian 
PRs like rennin and pepsin. Eukaryotic PRs consist of two highly similar domains. In 
contrast, retroviral PRs are active as symmetric homodimers (Pearl & Taylor, 1987). Upon 
dimerization two Asp residues each originating from one monomer constitute the active site. 
Analysis of different structures of retroviral PRs shows that even though there are large 
differences in the amino acid sequence, the overall folds are quite similar (Figure 1.10a) 
(Wlodawer et al., 1989; Wlodawer & Gustchina, 2000; Dunn et al., 2002). 
 a b 
 
Figure 1.10: Structural template and amino acid orientation in the active site of retroviral PRs. 
(a) Cartoon overview of the typical folding of the symmetric homodimer of retroviral 
PRs. The active site is formed by the two B1 loops. D1 is also-called “flap”. (b) The 
rigid network structure of the “fireman’s grip” involves the Asp-Thr-Gly triad of the 
active site. One subunit is shown in green, the second subunit in grey, amino acids of the 
second subunit are labeled with a (‘). Hydrogen bonds are depicted as thin lines 
(modified from Dunn et al., 2002). 
Four structural elements are characteristic for retroviral PRs but may vary slightly in different 
species. A hairpin (A1) is followed by a large B1 loop containing the catalytic Asp, then a 
short helix (C1) forms the connection to a second large hairpin, which is called “flap” (D1). A 
monomer is formed by duplication of this hairpin-loop-helix-hairpin motif (A2, B2, C2 and 
D2). Thus an active, dimeric retroviral PR consists of a single structural motif, which is 
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repeated four times. For dimerization, the contacts in the flap region, the active site and most 
importantly a four stranded "-sheet formed by the N- and C-terminal regions are significant. 
The structures of retroviral PRs solved so far show a distinct orientation of the residues in the 
conserved Asp-Ser/Thr-Gly active site motif (Fig. 1.10b). The active site is stabilized by a 
rigid network of hydrogen bonds, the so-called “fireman’s grip”. The #O of the conserved 
Thr, which is replaced by Ser in FV and Rous sarcoma virus, is bridged with a hydrogen bond 
to the main chain NH of the Thr within the opposing monomer. Moreover, it donates a 
hydrogen bond to the mainchain carbonyl group oxygen one residue prior to the catalytic Asp 
on the opposite active site loop. In consequence, the carboxylate groups of the two catalytic 
Asp are almost co-planar. They are bridged by a water molecule, which is required for 
hydrolysis of the peptide bond in the substrate (reviewed in Davies, 1990). Studies showed 
that stabilization of the dimer is strongly depending on the presence of a Thr in the active site 
motif. Exchange of Thr to Ser in HIV-1 PR significantly destabilized the dimer (Ingr et al., 
2003).  
Regulation of PR activity is essential within the retroviral life cycle. Premature processing of 
the polyproteins prior to virus assembly would result in incomplete packaging whereas a loss 
of PR activity would lead to immature viral particles. Recent results for HIV-1 revealed a 
possible mechanism for PR regulation. The uncleaved PR within the Gag-Pol polyprotein 
appears to lack proper activity due to inefficient dimerization (Tang et al., 2008). Localization 
of Gag-Pol in the cell during virus assembly by the Gag packaging signal activates PR und 
thus enables viral maturation. For this regulation of HIV-1 PR activity the Gag sequence at 
the N-terminus of PR - the so-called transframe region - is important. Elongation of HIV-1 PR 
at the N-terminus in vitro alters PR activity dramatically (Tessmer & Kräusslich, 1998; Louis 
et al., 1999; Louis et al., 2000; Pettit et al., 2003; Chiu et al., 2006; Louis et al., 2007), while 
C-terminal extensions do not have any significant effects (Wondrak et al., 1996; Cherry et al., 
1998a; Cherry et al., 1998b). Therefore a „free“ N-terminus of HIV-1 PR appears to be 
needed for proper formation of the four-stranded "-sheet formed by both N- and C-termini. 
However, regulation of PR activity in FV has to be different. Pol expression in FV is 
independent of Gag and PR does not harbor an N-terminal extension. Moreover, contradicting 
results regarding the dimerization state of FV PR have been published. An early publication 
by Benzair et al. (1982) described SFVmac PR to be monomeric, while Pfrepper et al. (1998) 
predicted a dimeric PFV PR. In summary, regulation of FV PR is an interesting and 
promising field for research. 
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2 Objectives 
Some of the main differences between FV and other retroviruses are related either to the 
synthesis or the activity of PR-RT, which is key to the retroviral life cycle and therefore its 
behavior is of broad interest. This work focuses on the catalytic activities of PFV and 
SFVmac PR-RT, the molecular basis of resistance of SFVmac against AZT and the regulation 
of PR activity in PFV and SFVmac. 
 
The first aim of this work is to analyze the biochemical and biophysical behavior of PFV and 
SFVmac PR-RT. Thus, the recombinant PR-RTs should be purified and their secondary 
structure as well as their enzymatic activities (proteolytic activity, DNA polymerization and 
RNase H activity) compared in vitro.  
 
A major problem in retroviral therapy is resistance of the viruses against drug treatment. HIV, 
for example, is able to escape treatment with the nucleoside inhibitor AZT. Details on how 
this resistance works are still being discussed. As AZT is one of two known inhibitors of FV 
replication, it is the goal of this thesis to use FV as a model organism to investigate AZT 
resistance of retroviruses. The objective of this study is to generate AZT resistant FV in vivo 
and to elucidate the molecular processes involved in resistance in vitro. 
  
Retroviral PRs are crucial for correct processing of the viral proteins and thus for the 
retroviral life cycle. In FVs, where expression and processing of PR differs from other 
retroviruses, little was known about their PRs. This thesis investigates the structure and the 
factors important for the regulation of FV PRs. 
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3 Synopsis 
3.1 Comparison of foamy virus PR-RT catalytic activities 
PR and RT of FVs are unique among retroviral enzymes. In contrast to the Orthoretrovirinae, 
PR and RT are located in a single polypeptide chain – even after maturation of the viral 
particle is complete (Pfrepper et al., 1998; Flügel & Pfrepper, 2003). Therefore, the PR-RT 
enzyme harbors the essential catalytic activities associated with PR and RT: proteolysis as 
well as DNA polymerase and RNase H activity. PR-RT plays a central role in the viral life 
cycle and thus is of great interest in FV research. 
So far in vivo as well as in vitro studies of FV PR-RT focused mainly on two species: one 
from a human isolate (PFV), probably originally derived from chimpanzees, and one of 
simian origin (SFVmac). In this work, the PR-RT of PFV and SFVmac were compared with 
biophysical and biochemical methods to elucidate their differences and similarities. 
Recombinant PFV and SFVmac PR-RT were analyzed by circular dichroism and both 
enzymes appeared to be predominantly folded. In addition, similar !-helical and "-sheet 
contents were predicted for both enzymes (publication A, Figure 1A and Table 1). 
 
Protease 
To detect proteolytic activity a substrate was designed by inserting the SFVmac Pol cleavage 
site, which is located between RT and IN, between the immunoglobulin binding domain B1 of 
the streptococcal protein G (GB1) and the green fluorescent protein (GFP). Upon cleavage of 
the GB1-GFP fusion protein the resulting GB1 and GFP products were analyzed by gel 
electrophoresis. Surprisingly, the salt concentration in the assay had to be elevated to 2 to 3 M 
NaCl to obtain proteolytic activity (publication A and E). Nevertheless, comparable activity 
was observed for the two different PR-RTs (Figure 3.1) although the substrate constructed to 
test PR activity harbored the SFVmac Pol cleavage site (YVVH!CNTT), which differs from 
the PFV Pol cleavage site (YVVR!CNTT) by one amino acid. 
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Figure 3.1: PR activity assays of SFVmac and PFV PR-RT. 
 10 $M of the substrate GB1-GFP harboring the SFVmac Pol cleavage site between GB1 
and GFP was incubated with 10 $M PFV or SFVmac PR-RT at 37 °C for 16 h in 50 mM 
Na2HPO4/NaH2PO4 pH 7.4, 0.5 mM DTT and 3 M NaCl. Reaction products were 
analyzed by 19 % sodium dodecylsulfate polyacrylamide gelelectrophorseis. +: positive 
control; S: uncleaved substrate. The sizes of standard proteins are indicated on the left 
(Publication A, Figure 2). 
 
Polymerase 
RTs can make use of either a DNA- or RNA-strand as a template for DNA synthesis. Both 
activities are indispensable for transforming the single-stranded viral RNA genome into the 
double-stranded DNA needed for integration. Without proper polymerization activity 
retroviruses cannot replicate and inhibition of RT is a powerful tool in antiretroviral therapy. 
Characterization of the polymerization activity of the PR-RTs from PFV and SFVmac was 
performed using a DNA primer and a homopolymeric RNA (poly(rA)) or a heteropolymeric 
DNA substrate (single-stranded M13-DNA), respectively. In both experiments no significant 
differences in the behavior of PFV and SFVmac PR-RT were observed. Michaelis-Menten 
parameters obtained from polymerization on the homopolymeric poly(rA) substrate in the 
presence of radioactively labeled TTP were virtually identical (publication A, Table 2). Time 
dependent primer elongation on the heteropolymeric single-stranded M13 substrate revealed 
similar polymerization behavior (publication A, Figure 4). Moreover, KD-values for binding 
to a DNA/DNA or DNA/RNA substrate were determined. Despite a somewhat higher affinity 
of PFV PR-RT for the DNA/RNA substrate (10 nM) all values measured were in a similar 
range of 30 to 45 nM (publication A, Table 2; publication C, Table 2). In conclusion, the 
polymerization behavior of PFV and SFVmac PR-RT did not differ significantly. 
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RNase H 
The third activity associated with PR-RT is the digestion of RNA in a DNA/RNA hybrid 
catalyzed by the RNase H domain. RNase H activity is needed in the replication process of 
retroviruses to remove the RNA-strand from the DNA/RNA hybrid to enable polymerization 
of the DNA (+)-strand. 
RNase H activity of PFV and SFVmac PR-RT was analyzed using two different substrates. 
First Michaelis-Menten parameters were measured with a blunt ended DNA/RNA substrate 
containing a fluorescent dye at the 3’ end of the RNA and a quencher at the 5’ end of the 
DNA (publication A, Table 3). Additionally, endonucleolytic RNase H cleavage sites were 
identified using a 40mer RNA/24mer DNA substrate (publication A, Figure 5B). The results 
indicate that the kinetic parameters and the cleavage sites of the two enzymes are comparable. 
In summary, it was shown in this work that PFV and SFVmac PR-RT exhibit similar 
biophysical and biochemical properties in vitro. 
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3.2 Resistance of foamy virus against azidothymidine 
Since most retroviruses are associated with serious diseases, the inhibition of retroviral 
replication is a major goal in retrovirus research. Thus, the RT enzyme is an ideal target for 
antiretroviral therapy, because its catalytic activity is pivotal for virus replication. Regrettably, 
retroviruses and especially HIV are able to escape drug treatment by developing resistance. 
Treatment of patients therefore requires new and better drugs. Understanding the mechanism 
involved in drug resistance is key for the development of new drugs. To our knowledge FVs 
are not pathogenic (reviewed in Meiering & Linial, 2001). Nevertheless, FV could serve as a 
model organism to elucidate the mechanisms of resistance against selected drugs important 
for other retroviral species.  
AZT is one of two nucleoside inhibitors known to impair FV replication (Moebes et al., 1997; 
Rosenblum et al., 2001; Lee et al., 2006). AZT terminates DNA polymerization due to its 3’ 
azido group (Figure 1.8), which leads to DNA chain termination. In recent years a lot of effort 
has been put into characterizing the resistance of HIV against AZT. Surprisingly, AZT 
resistance in HIV-1 and HIV-2 is based on different mechanisms. In resistant HIV-2 the RT 
can discriminate between the incorporation of the natural nucleotide thymidine-5’-
monophosphate (TMP) and AZTMP (Boyer et al., 2006), while HIV-1 RT removes 
incorporated AZTMP from an already terminated primer. The latter gave rise to a number of 
questions, since PPi (Arion et al., 1998) and ATP (Meyer et al., 1998; Meyer et al., 1999) 
were discussed as possible factors necessary for the excision of AZTMP (Figure 3.2). 
 
Figure 3.2:  Schematic representation of AZTMP removal from a terminated primer.  
Removal of AZTMP by RT from an AZTMP terminated primer in resistant HIV-1 was 
suggested to be catalyzed either in the presence of PPi (left) (Arion et al., 1998) or ATP 
(right) (Meyer et al., 1998; Meyer et al., 1999). While removal of AZTMP with PPi 
restores AZTTP, excision with ATP leads to formation of the dinucleotide 3’-azido-3’-
deoxythymidin-(5’)-tetraphospho-(5’)-adenosine (AZT-P4-A). DNA is shown as blue 
lines, phosphate as orange circles, adenosine as a green square and AZT as a red triangle. 
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Publication B describes the attempt to generate AZT resistant PFV and SFVmac. Four non-
silent mutations leading to AZT resistance in the RT gene of SFVmac were identified: 
K211I, I224T, S345T and E350K. 
Viruses containing these four mutations showed no replication defects in the absence of AZT 
and were able to replicate in the presence of AZT concentrations as high as 1 mM. In contrast, 
generation of AZT resistant PFV failed. Remarkably, even though the sequence identity of 
PFV and SFVmac PR-RT exceeds 90 % and their biophysical as well as biochemical behavior 
are highly similar (see 3.1), insertion of the resistance mutations from SFVmac into the PFV 
RT gene did not result in AZT resistant PFV (publication B, Table 2, Virus M108). 
After having identified the AZT resistance mutations in SFVmac the molecular mechanism of 
resistance was investigated (publication C). Two different SFVmac PR-RTs resistant to AZT 
were tested in vitro and compared with wildtype (WT) PR-RTs: 
- mt4, harboring all four mutations (K211I, I224T, S345T, E350K), and  
- mt3 (K211I, S345T, E350K), lacking the I224T mutation. 
WT SFVmac PR-RT has a polymorphism at the amino acid at position 224 of the PR-RT 
gene and either Ile or Thr can be found. AZT resistant SFVmac always contained a Thr at 
position 224. In the absence of AZT a recombinant virus containing the mt3 mutations 
replicated only poorly, but the virus tolerated the addition of 50 $M AZT to the medium 
(publication B, Table 2, virus BK37-IITK). The mutation I224T was identified in vitro to be 
important for polymerization activity of SFVmac PR-RT in the absence of AZTTP (Figure 
3.3a; see also publication C, Table 1). WT PR-RT activity was threefold higher than that of 
mutant mt3, however polymerization activity of mt3 could be restored by introducing the 
fourth mutation. This finding implies that the I224T mutation does not contribute to the 
mechanism of AZT resistance itself, but is needed to increase polymerization activity of PR-
RT in resistant viruses. The in vivo results confirm this interpretation. 
To investigate whether AZT resistance is based on the discrimination between AZTMP and 
TMP at the level of incorporation either a homopolymeric poly(rA)/oligo(dT) or a 
heteropolymeric single-stranded M13 DNA substrate was used (Figure 3.3a and b, 
respectively). Polymerization was analyzed in the absence and in the presence of increasing 
amounts of AZTTP. Despite the fact that SFVmac harboring the mutations corresponding to 
mt4 or mt3 replicated in the presence of high AZT concentrations (publication B, Table 2), the 
mutant recombinant PR-RTs purified from E. coli were sensitive to the addition of AZTTP. 
Compared to the WT PR-RT, polymerization activities of the mutant enzymes measured on 
the homopolymeric substrate with different AZTTP concentrations were impaired 
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(Figure 3.3a). Polymerization on M13 DNA in the presence of AZTTP led to termination 
products, which got shorter when higher AZTTP concentrations were applied. Similar to the 
activities on poly(rA)/oligo(dT) mt4 and mt3 appeared to be somewhat more affected by 
AZTTP than the WT (Figure 3.3b).  
These experiments argue against a mechanism of resistance based on discrimination between 
AZTMP and TMP. They are reminiscent of HIV-1 RT (Krebs et al., 1997), where the AZT 
resistance was also not visible in steady-state polymerization assays or during pre-steady-state 
analyses and could only be detected with an AZTMP-terminated primer/template substrate 
(Arion et al., 1998; Meyer et al., 1998; Meyer et al., 1999). 
 
Figure 3.3:  Polymerization activities in the presence of AZTTP.  
 (a) Specific activities were measured on 6 nM of poly(rA)/oligo(dT) with 12 nM of 
various SFVmac PR-RTs as indicated, 150 $M TTP and 0, 0.5, 5, 30 or 150 $M AZTTP. 
The reaction was stopped after 10 min at 37 °C. (b) Chain termination by AZTMP 
incorporation during DNA polymerization with 6 nM M13 single-stranded DNA, 
150 $M dNTP and 85 nM SFVmac PR-RTs within 10 min at 37 °C. Either no AZTTP 
(lanes 1), 5 $M (lanes 2) or 50 $M (lanes 3) of AZTTP was added. DNA size markers 
are indicated on the left. 
*: Indicates a mutation in PR-RT leading to loss of proteolytic activity. This D24A 
mutation does not influence polymerization activities (Publication C, Figure 2). 
It has been shown for AZT resistant HIV-1 RT that AZTMP can be excised from an AZTMP-
terminated primer/template either in the presence of PPi or ATP (Figure 3.2) (Arion et al., 
1998; Meyer et al., 1998; Meyer et al., 1999). To test these two possibilities an AZTMP 
terminated primer/template was incubated with the WT or mutated PR-RTs in the presence of 
PPi or ATP. Excision of AZTMP from the terminated and [32P] labeled primer leads to a DNA 
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product one nucleotide shorter than the AZTMP-primer. The reaction products were separated 
by denaturing gel electrophoresis and quantified by densitometry. Time dependent 
experiments undoubtedly showed that excision reactions with PPi were relatively slow and 
did not differ between the WT and mutant PR-RTs. In contrast, excision in the presence of 
ATP did not result in deblocking of the terminated primer with WT PR-RT, but the mt4 and 
mt3 PR-RTs were able to reactivate polymerization (Figure 3.4). 
 
Figure 3.4: Time dependent AZTMP removal in the presence of PPi or ATP. 
Top: In a mixture containing 10 nM of an AZTMP-terminated primer/template labeled 
with [32P] at the 5’ end of the primer either 100 $M NaPPi (left) or 5 mM ATP (right) 
were present. Reactions were started by addition of 20 nM of the different PR-RTs and 
stopped at the time points indicated. The upper bands represent the AZTMP-primer, the 
lower bands the reactivated primer without AZTMP. Lane C: no enzyme added. Bottom: 
Densitometric quantification of AZTMP removal by PPi or ATP. The percentage of 
remaining terminated primer is shown.*: Indicates a mutation in PR-RT leading to loss 
of proteolytic activity. This D24A mutation does not influence polymerization activities 
(publication C, Figures 3 and 4). 
The results obtained in this work clearly show that the mechanism of AZT resistance of 
SFVmac is based on the excision of incorporated AZTMP in the presence of ATP. 
Interestingly, excision of AZTMP in HIV-1 has been associated with the selection of an 
aromatic amino acid (Phe or Tyr) at position 215 (see chapter 1.3.1). It was suggested that the 
adenine moiety of the incoming ATP forms %-% interactions with the aromatic ring of the 
exchanged amino acid (Boyer et al., 2001; Boyer et al., 2002a; Boyer et al., 2002b; 
Sarafianos et al., 2002; Smith et al., 2005). However, in AZT resistant SFVmac no mutation 
leading to an aromatic amino acid is selected. Consequently, in SFVmac either an aromatic 
amino acid present at a different position serves to bind ATP or the mechanism of ATP 
binding or ATP-mediated excision differs from that of HIV-1. Unfortunately, the sequences 
of SFVmac and HIV-1 RT reveal a homology of only 21 %. Thus, it is difficult to identify a 
putative aromatic amino acid homologous to Phe or Tyr 215 in AZT resistant HIV-1 RT. 
Structural data are necessary to clarify this problem. 
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3.3 Regulation of protease activity in foamy viruses 
3.3.1 Transient dimerization of foamy virus protease 
Despite the fact that retroviral PRs play a crucial role in virus maturation und thus in 
infectivity of retroviruses, little is known about their regulation. However, PR activity has to 
be regulated, because premature processing of the polyproteins would result in packaging 
defects. On the other hand, incomplete processing would lead to non-infectious viral particles. 
It has been shown in this work (chapter 3.1) that PFV and SFVmac PR activity is only 
achieved under very high salt concentrations of 2 to 3 M NaCl – conditions, which are very 
likely not present in vivo. Analysis of PFV and SFVmac PR-RT revealed monomeric proteins 
(publication E, Figure 3 and publication A, Figure 1B, respectively), although all retroviral 
PRs investigated so far have been shown to be only active as homodimers (Pearl & Taylor, 
1987). A separately expressed and purified 12.6 kDa PR-domain of SFVmac (SFVmac 
PRshort) behaved like a monomer also (publication E, Figure 2) even though catalytic activity 
was measurable and comparable to SFVmac PR-RT.  
These results are consistent with a previous publication on SFVmac PR-RT by Benzair et al. 
(1982) and contradict Pfrepper et al. (1997), who predicted a dimeric PFV PR. Solution 
structure determination of SFVmac PRshort by nuclear magnetic resonance (NMR) 
spectroscopy (publication D and E) further confirmed the monomeric status of FV PRs 
(Figure 3.5; see also Publication E, Figures 5 and 6). 
 
Figure 3.5: Solution structure of SFVmac PRshort in comparison to a structural template of 
retroviral PRs. 
  (a) A cartoon representation of the SFVmac PRshort monomer is shown. The catalytic 
Asp of the active site motif is displayed in stick mode. (b) Cartoon overview of the 
typical folding of the symmetric homodimer of retroviral PRs (Dunn et al., 2002). The 
active site is formed by the two B1 loops. 
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The solution structure of SFVmac PRshort reveals a monomeric protein but the folding is 
highly similar to the monomer subunits of known retroviral PR dimers (Dunn et al., 2002). 
Starting from the N-terminus a characteristic hairpin-loop-helix-hairpin motif (A1, B1, C1 
and D1) is followed by an additional hairpin-loop-helix motif (A2, B2 and C2). This is rather 
typical for retroviral PRs (Figure 3.5b; see also chapter 1.4). The main differences between 
the SFVmac PRshort structure and the dimeric retroviral PR structures solved so far are found 
at the dimerization interface. Contacts between the subunits in homodimeric PRs are formed 
at the active site loop (B1) containing the “fireman’s grip”, the D1 hairpin or “flap” region 
and the N- and C-termini (see chapter 1.4) (Dunn et al., 2002). 15N relaxation data 
characterize the D1 hairpin to be quite flexible on the ps-ns timescale (publication E, Figure 
6). The most flexible region in the SFVmac PRshort structure, however, are the N- and C-
termini. In the symmetric homodimer of retroviral PRs the termini form a four-stranded 
intermonomeric "-sheet, which contributes significantly to the stability of the dimer (Ishima 
et al., 2001). Consequently, since SFVmac PRshort is monomeric, this "-sheet is missing. 
Thus, the catalytic center cannot be formed, because both subunits contribute essential 
residues to form the active site, e.g. the catalytic Asp and the residues of the fireman’s grip 
(see chapter 1.4, Figure 1.10b).  
Structural data and quaternary structure analysis raise the question how catalytic activity of 
FV PRs is achieved. Folding of the monomer subunit indicates that the active form of FV PR 
is also the dimer. To confirm this hypothesis SFVmac PR-RT and PRshort activity was tested 
in the presence of cholic acid, a putative dimerization inhibitor of HIV-1 PR (publication F, 
Figures 1 and 2). Publication F shows binding of cholic acid at the proposed dimerization 
interface of SFVmac PRshort with a KD of approximately 5 mM and loss of proteolytic 
activity of SFVmac PR-RT and PRshort in the presence of cholic acid with an IC50 value of 
about 0.7 mM and 0.6 mM, respectively. These data imply dimerization of FV PRs. 
Specific transient dimerization of SFVmac PRshort was finally proven by paramagnetic 
relaxation enhancement (PRE). In this experiment two species of SFVmac PRshort were 
mixed. One SFVmac PRshort species was 15N-labeled and corresponding signals were 
measured by NMR. An SFVmac PRshort which was randomly labeled at the &-amino groups 
of its Lys residues with the spin label 1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate N-
hydroxysuccinimide ester (oxyl-1-NHS) was added to the 15N-labeled species. Contacts 
between amide protons of the 15N species and the spin label of the second species, lead to a 
dramatic enhancement of transverse relaxation rates of the protons close to the spin label. For 
SFVmac PRshort amino acids with increased relaxation rates were found to be explicitly 
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located within or close to the proposed dimerization interface (Figure 3.6; see also 
publication F, Figures 3 and 4). Amide protons of residues far from the dimerization interface 
did not exhibit significant changes in transversal relaxation rates, demonstrating that transient 
dimerization of SFVmac PRshort is structure specific. 
 
 
Figure 3.6: Transient contacts formed by SFVmac PRshort. 
 Model of a hypothetical SFVmac PRshort dimer. The left half of the dimer represents the 
15N labeled monomer with color-coded PREs upon addition of spin labeled PRshort. 
PREs > 20 Hz are colored in red and PREs > 10 Hz in orange. Spin labeled Lys residues 
are highlighted in green on the right monomer subunit (publication F, Figure 3c).  
 
3.3.2 Activation of foamy virus protease by nucleic acid sequences 
The data presented so far have shown that the PR of PFV and SFVmac PR-RT is inactive 
under low salt conditions due to inefficient dimerization. Activity was only measured at high 
salt concentrations of 2 to 3 M NaCl (see chapter 3.1). It is obvious that these conditions do 
not reflect the situation in living cells but somehow create an environment that facilitates 
dimerization, probably by hydrophobic interaction of the two monomers. Recently, transient 
dimerization of the HIV-1 PR in the Gag-Pol precursor was shown (Tang et al., 2008). This 
mechanism prevents activation of PR before virus assembly. Packaging of the Pol proteins in 
HIV-1 is mediated by RNA binding of Gag within the Gag-Pol polyprotein (reviewed in Goff, 
2007) and this process probably activates PR. Since FVs express Gag and Pol independently, 
Pol packaging and PR regulation have to be different. 
The aim of this work is to clarify how regulation of PR activity is achieved in FV. During 
virus assembly the inactive PR-RT of FV has to be activated due to dimerization and 
therefore components important for encapsidation of Pol might play an essential role in PR 
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regulation as well. Apart from the C-terminus of Gag (Lee & Linial, 2008) special nucleic 
acid sequences on the viral RNA have been determined to be important for Pol uptake 
(Heinkelein et al., 2002b; Peters et al., 2008). Two cis-acting sequences, CasI and CasII, have 
been identified to play a role in the transfer of FV vectors (Erlwein et al., 1998; Heinkelein et 
al., 2002a; Heinkelein et al., 2002b; Linial & Eastman, 2003), indicating an important 
function in virus assembly. 
The cPPT, which accomodates the A to D elements, is included in this CasI-CasII sequence 
(Figure 3.7a). It has been shown that the A, B, C and D elements of the cPPT are critical for 
Pol uptake in vivo (Peters et al., 2008) (see chapter 1.2). 
 
Figure 3.7: Comparison of PFV and SFVmac purine rich elements and schematic 
representation of RNA fragments used. 
  (a) Representation of the polypurine rich sequences of PFV and SFVmac. The core 
sequences are highlighted. (b) Overview of the RNAs examined for PR activation. The 
relative positions of the polypurine sequences A to D and the lengths of different RNAs 
are displayed (publication G, Figure 1). 
In publication G different RNA sequences derived from PFV CasI-CasII were tested for their 
ability to activate proteolytic activity of PFV and SFVmac PR-RT (Figure 3.7b). Although 
RNAs in general had a small stimulatory effect on PR, truncation of the CasI-CasII RNA at 
the 5’ and the 3’ end revealed that the A- and B-element of the cPPT are the essential factors 
for PR regulation (Figure 3.8; see also publication G, Figure 2).  
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Figure 3.8: Proteolytic activities of PFV PR-RT in the presence of various RNAs. 
 Activity assays were performed with 0.5 $M of RNA as indicated, 2.5 $M PFV PR-RT 
and 10 $M substrate GB1-GFP (see 3.1) at 37 °C for 2 h in 50 mM Na2HPO4/NaH2PO4 
pH 6.4 and 100 mM NaCl. Reaction products were separated on 10 % BisTris gels. S: 
uncleaved substrate; M, molecular weight standard. The sizes of the standard proteins are 
indicated on the left (publication G, Figure 2a).  
Analysis of the secondary structure of AB-RNA by selective 2’ hydroxyl acylation analyzed 
by primer extension (SHAPE) revealed a distinct folding of the polypurine elements A and B. 
Both are located in a hairpin loop structure where the region at the 3’ side of the loop is 
almost exclusively formed by purines (publication G, Figure 3). PPT structures in HIV have 
been demonstrated to form distinct secondary structures with bents and deviations from 
typical Watson-Crick base pairs (Fedoroff et al., 1997; Sarafianos et al., 2001). Although 
definite data of the PFV RNA-AB structure are missing, a distinct folding of the AB-element 
of the FV cPPT can be assumed (publication G, Figure 3). 
Binding of PFV and SFVmac PR-RT to RNA was analyzed by electrophoretic mobility shift 
assays (EMSAs). Shifts corresponding to multiple binding of the PR-RTs were obtained 
independently of the RNA sequence (publication G, Figure 4). Crosslinking experiments 
revealed that in the presence of RNA dimers and even tetramers are formed (publication G, 
Figure 5). Protein crosslinking and EMSA are in good agreement with PR activity assays, 
where all RNA sequences had at least a low stimulatory effect on PR activity. However, RNA 
containing the A- and B-element is required to form stable PR-RT dimers with high 
proteolytic activity. 
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Figure 3.9: Model of FV assembly. 
 A model for the assembly of FV at the plasma membrane is shown. Binding of Pol to the 
AB-element within the cPPT of the viral RNA results in Pol uptake (Heinkelein et al., 
2002a; Peters et al., 2008). The RNA binds to the C-terminus of Gag (Lee & Linial, 
2008). Simultaneously, Pol dimerization is achieved which leads to PR activation 
(publication G). Pol is cleaved into PR-RT and IN, cleavage of Gag is not shown. The 
time point of reverse transcription remains unclear, but in infectious viral particles the 
RNA is reverse transcribed into DNA by PR-RT. Pol is shown in blue, Gag in red, Env 
in green, RNA in yellow and DNA in purple. 
From the data presented in this work a model for FV assembly can be proposed (Figure 3.9). 
Due to inefficient dimerization the PR in Pol is inactive in the cytoplasm of the host cell 
(publication F). While packaging of the viral RNA is mediated by the C-terminus of Gag (Lee 
& Linial, 2008), binding of Pol to the AB-element of the cPPT of the viral RNA (Heinkelein 
et al., 2002b; Peters et al., 2008) leads to correct localization and proper dimerization of Pol 
(publication G). PR is activated and through cleavage of Gag and Pol mature viral particles 
are obtained. In this model the exact time point of reverse transcription is still missing. 
Further studies on PR-RT and especially Pol are needed to answer this question. 
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4 List of abbreviations 
AIDS acquired immunodeficiency syndrome 
ATP adenosine-5’-triphosphate 
AZT 3’-azido-3’-deoxythymidine 
AZTMP 3’-azido-3’-deoxythymidine -5’-monophosphate 
AZTTP 3’-azido-3’-deoxythymidine -5’-triphosphate 
AZT-P4-A 3’-azido-3’-deoxythymidine-(5’)-tetraphospho-(5’)-adenosine 
cPPT central polypurine tract 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide-triphosphate 
E. coli Escherichia coli 
EMSA electrophoretic mobility shift assay 
FV foamy virus 
HIV human immunodeficiency virus 
GB1 immunoglobulin binding domain B1 of the streptococcal protein G 
GFP green fluorescent protein 
IN integrase 
IP internal promoter 
LTR long terminal repeats 
MLV murine leukemia virus 
mRNA messenger ribonucleic acid 
NMR nuclear magnetic resonance 
P promoter 
PBS primer binding site 
PFV prototype foamy virus 
PPi pyrophosphate 
PPT polypurine tract 
PR protease 
SFVmac PRshort PR domain of SFVmac 
PRE paramagnetic relaxation enhancement 
R repeated region 
RNA ribonucleic acid 
RT reverse transcriptase 
SHAPE selective 2’ hydroxyl acylation analyzed by primer extension 
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SFVmac simian foamy virus from macaques 
tRNA transfer ribonucleic acid 
TMP thymidine-5’-monophosphate 
TTP thymidine-5’-triphosphate 
WT wildtype 
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Biophysical and enzymatic properties of the
simian and prototype foamy virus reverse
transcriptases
Maximilian J Hartl1, Florian Mayr1, Axel Rethwilm2, Birgitta M Wöhrl1*
Abstract
Background: The foamy virus Pol protein is translated independently from Gag using a separate mRNA. Thus, in
contrast to orthoretroviruses no Gag-Pol precursor protein is synthesized. Only the integrase domain is cleaved off
from Pol resulting in a mature reverse transcriptase harboring the protease domain at the N-terminus (PR-RT).
Although the homology between the PR-RTs from simian foamy virus from macaques (SFVmac) and the prototype
foamy virus (PFV), probably originating from chimpanzee, exceeds 90%, several differences in the biophysical and
biochemical properties of the two enzymes have been reported (i.e. SFVmac develops resistance to the nucleoside
inhibitor azidothymidine (AZT) whereas PFV remains AZT sensitive even if the resistance mutations from SFVmac
PR-RT are introduced into the PFV PR-RT gene). Moreover, contradictory data on the monomer/dimer status of the
foamy virus protease have been published.
Results: We set out to purify and directly compare the monomer/dimer status and the enzymatic behavior of the
two wild type PR-RT enzymes from SFVmac and PFV in order to get a better understanding of the protein and
enzyme functions. We determined kinetic parameters for the two enzymes, and we show that PFV PR-RT is also a
monomeric protein.
Conclusions: Our data show that the PR-RTs from SFV and PFV are monomeric proteins with similar biochemical
and biophysical properties that are in some aspects comparable with MLV RT, but differ from those of HIV-1 RT.
These differences might be due to the different conditions the viruses are confronted with in dividing and non-
dividing cells.
Background
Foamy viruses (FVs) belong to the family retroviridae,
but differ in several aspects from orthoretrovirinae: (a)
reverse transcription occurs before the virus leaves the
host cell [1,2], (b) the pol-gene is expressed from a sepa-
rate mRNA [3-5], and (c) the viral protease is not
cleaved off from the Pol polyprotein. Only the integrase
is removed from Pol [6,7]. Thus, the FV reverse tran-
scriptase harbors a protease, polymerase and RNase H
domain (PR-RT) (for review see [8,9]).
Only recently, studies have focused on the biochem-
istry of the PR-RTs of FVs. Although the PR-RTs from
simian foamy virus from macaques (SFVmac) and from
the prototype foamy virus (PFV) exhibit more than
90% sequence homology at the protein level (79.5%
identity; LALIGN, http://www.ch.embnet.org), some
differences in their behavior have been reported. Bacte-
rially expressed PFV PR-RT harbors many characteris-
tics of orthoretroviral RTs; however, FV enzymes
exhibit some peculiar features [10-16]. In comparison
to human immunodeficiency virus type 1 (HIV-1) RT,
PFV PR-RT appears to be a more processive polymer-
ase [11]. This is probably due to differences in virus
assembly. FV Pol packaging has been reported to
require interactions of Pol with specific sequences in
the RNA genome [17], and it has been suggested that
there is a lower number of FV Pol molecules in the
virus particle as compared to orthoretroviruses [11].
As a consequence, a highly processive polymerase is
essential to enable synthesis of the complete double
stranded genome.
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One antiretroviral drug that has been shown to inhi-
bit FV replication is azidothymidine (AZT) [1,18,19].
In in vivo experiments SFVmac acquired high resis-
tance to AZT by four mutations within the RT
sequence [14,20]. PFV, however, did not develop resis-
tance to AZT, and the introduction of the SFVmac
mutations into the PFV RT gene did not result in
viruses resistant to the nucleoside inhibitor [20].
Regarding the high amino acid homology of the two
enzymes, this result was not to be expected. In
SFVmac, the mechanism of resistance is due to the
removal of already incorporated AZT-monophosphate
(AZTMP) in the presence of ATP and thus resembles
that of HIV-1 RT [14,21,22].
It has been shown previously that retroviral PRs are
only active as homodimers. To create the active center,
each subunit of the homodimer contributes catalytic
residues located in the conserved motif DT/SG [23].
However, SFVmac PR-RT behaves as a monomer in
solution, but nevertheless exhibits PR activity. Catalytic
PR activity could only be observed at NaCl concentra-
tions of 2-3 M [15], indicating that hydrophobic inter-
actions might promote dimerization. Furthermore, by
prevalent methods the separately expressed 12.6 kDa
PR domain was also found to be monomeric but active
[15]. Only further analyses using NMR paramagnetic
relaxation enhancement proved that transient, lowly
populated dimers are being formed (Hartl MJ, Schwei-
mer K, Reger MH, Schwarzinger S, Bodem J, Rösch P,
Wöhrl BM: Formation of transient dimers by a retro-
viral protease, submitted). Contradicting results were
obtained by gel filtration analysis with a purified C-
terminally extended 18 kDa PR domain of PFV, which
indicated that PFV PR might be dimeric [6].
To clarify these issues and to shed more light on the
properties of SFVmac and PFV PR-RT, we set out to
purify both enzymes from bacterial lysates and directly
compare their secondary structure, oligomerization
state, and activities.
Results and Discussion
Protein purification
Overexpression of PFV PR-RT in E. coli resulted in partial
degradation by cellular proteases. Thus, we could not
adopt the purification protocol established for SFVmac
PR-RT [14]. Instead, we had to set up a new purification
procedure for PFV PR-RT which includes Ni-affinity
followed by hydrophobic interaction chromatography to
remove the PR-RT degradation products. The yields were
much lower than for SFVmac PR-RT. Nevertheless, pure
soluble protein (> 95% purity, as judged from SDS-polya-
crylamide gels) could be obtained.
Biophysical properties
To exclude that the purified PR-RTs are partially or com-
pletely unfolded, we analyzed the secondary structure of
PFV and SFVmac PR-RT by circular dichroism (CD) spec-
troscopy. The shape of the CD spectra obtained for the
two enzymes was highly similar, implying comparable
ratios of a-helices and b-strands (Fig. 1A). In both cases,
the curves showed a broad minimum between 205 nm
and 222 nm, characteristic for a mixture of a-helical and
b-strand structures, and high ellipticity near 200 nm.
Thus, the spectra are indicative of predominantly folded
proteins. Although the spectrum obtained for SFVmac
PR-RT deviates slightly from that of PFV PR-RT, the cal-
culated values (Table 1) confirm the accordance in the
secondary structure contents of PFV and SFVmac PR-RT.
However, crystal structure analyses will be necessary to
obtain more information on the structural similarities and
differences of the two enzymes. The three-dimensional
structure will probably also shed more light on the differ-
ences between PFV and SFVmac PR-RT in developing
AZT-resistance.
Contradicting data have been published on the mono-
mer/dimer status of FV PRs. PFV PR expressed sepa-
rately was suggested to be dimeric [6], whereas we have
shown by various analyses, like size exclusion chromato-
graphy and analytical ultracentrifugation that the full
length PR-RT protein as well as the separate PR domain
of SFVmac are monomeric, and only transient PR
dimers are being formed [15] (Hartl MJ, Schweimer K,
Reger MH, Schwarzinger S, Bodem J, Rösch P, Wöhrl
BM: Formation of transient dimers by a retroviral pro-
tease, submitted).
Previous results obtained by sucrose density gradient
analyses with PR-RT purified from SFVmac particles
also indicated that the protein is monomeric [24]. To
clarify the monomer/dimer status of PFV PR-RT, we
performed size exclusion chromatography (Fig. 1B). Our
data revealed a single peak, which corresponded to a
molecular mass of 85.4 kDa. This is in good agreement
with the theoretical molecular mass of the monomeric
PFV PR-RT of 86.5 kDa. Moreover, no dimer peak
Table 1 CD values
enzyme a-helix (%) b-sheet (%) b-turns (%) random coil (%) total (%)
PFV PR-RT 22 30 20 27 99
SFVmac PR-RT 22 29 20 28 99
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could be detected, indicating that under native condi-
tions PFV PR-RT, like SFVmac PR-RT is monomeric to
a great extent (> 95%).
PR activity
Activity of retroviral PRs is only achieved when a sym-
metric homodimer is formed, since each subunit pro-
vides a conserved aspartate residue to form the active
center [23,25,26]. To detect residual PR activity we used
a substrate, denoted GB1-GFP, that consists of a fusion
protein between the immunoglobulin binding domain
B1 of the streptococcal protein G (GB1) and the green
fluorescent protein (GFP) enframing the natural
SFVmac Pol cleavage site YVVH↓CNTT. Although in
PFV Pol the His is exchanged by Asn, this substrate
could also be used for PFV PR-RT, because retroviral
PRs are able to recognize different cleavage sites.
A concentration of 3 M NaCl was used in the assay
since under these conditions SFVmac PR-RT revealed
the highest PR activity, and no activity was detected
when low salt concentrations (ca. 0.2 - 0.4 M NaCl)
were applied [15]. Fig. 2 illustrates that both proteins
were capable of almost completely cleaving the pro-
vided substrate even though the offered sequence is
different from the naturally occurring cleavage site in
PFV Pol.
Size exclusion chromatography and PR activity assays
revealed a new feature special to spumaretrovirinae. FVs
appear to express a monomeric PR domain within the
Pol polyprotein which is catalytically inactive. In vitro
dimerization of the PR domain is inducible at high salt
concentrations. This effect might be caused by a hydro-
phobic dimerization interface, which under high ionic
strength disfavors the monomeric state.
Recently published results suggest that HIV-1 PR in the
Gag-Pol precursor is only present as a transient dimer
due to an inhibitory effect of the transframe region,
which is located N-terminally of the PR domain [27].
Since there is no Gag-Pol fusion protein in FVs, an N-
terminal extension of the PR does not exist. Thus, the
regulation of the FV PR activity has to be different. We
have shown recently, that SFVmac PR forms transient
dimers at low salt concentrations. Obviously, in vivo PR
activation cannot be achieved by increasing the NaCl
concentration to 3 M, indicating that an additional cellu-
lar and/or viral factor must be involved in PR activation.
Characteristics of polymerization
A key step in the retroviral life cycle is the reverse tran-
scription of the genomic RNA into double stranded (ds)
DNA. For formation of dsDNA, the RT catalyzes RNA-
and DNA-dependent DNA polymerization to synthesize
the (-) and (+)-strand, respectively.
To further characterize the PR-RT enzymes, we per-
formed polymerization assays on the homopolymeric
poly(rA)/oligo(dT)15 substrate and on heteropolymeric
single-stranded M13 DNA. The incorporation of 3H-
TTP was used to determine Michaelis-Menten para-
meters. Comparison with values already published for
SFVmac PR-RT for homopolymeric substrates revealed
fairly similar KM- and kcat-values for the two enzymes.
Moreover, the KM-values for homo- and heteropoly-
meric substrates are comparable (Table 2) [14].
The KM values determined here for FV PR-RTs are ca.
5-30 fold higher than those published for HIV-1 RT
[28-30]. A recent publication compares the pre-steady-
state kinetics of PFV PR-RT with those of HIV-1 and
Figure 1 Biophysical properties of PFV and SFVmac PR-RT. (A)
Far UV circular dichroism (CD) spectra of wild-type SFVmac
(continuous line) and PFV PR-RT (dotted line) were acquired at 20°C
using a band width of 1 nm, a sensitivity of 100 mdeg and a data
density of 5 points/nm in a 0.1 cm cell with 0.5 μM of each enzyme
in 25 mM Na2HPO4/NaH2PO4 pH 7.4, and 5 mM NaCl. (B) Size
exclusion chromatography of PFV PR-RT using an S200 HR 10/30
column. The run was performed with 10 nmol PFV PR-RT in 50 mM
Na2HPO4/NaH2PO4 pH 7.4, 300 mM NaCl and 0.5 mM DTT. The inset
shows the fit to the data obtained for the molecular masses of the
standard proteins (open circles), which was used for the
determination of the molecular mass of PFV PR-RT (closed circle).
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murine leukemia virus (MuLV) RT [31]. Although the
kpol values of the three enzymes are similar, the disso-
ciation constants (KD) for dNTP binding are about 10 -
80 fold higher with PFV PR-RT as compared to HIV-1
RT, but are comparable to the affinities obtained for
MuLV RT [31]. These kinetic data together with our
results reveal different polymerization properties of
HIV-1 RT and FV PR-RTs. The data imply that DNA
polymerization of FV PR-RTs is poor at low dNTP con-
centrations. One reason for the differences observed
might be the fact that in contrast to FV, HIV-1 can
replicate in non-dividing cells, where dNTP concentra-
tions are low. In such an environment, polymerization
efficiency can be improved by RTs with high affinities
for dNTPs [31].
A qualitative analysis of DNA polymerization was per-
formed by using a heteropolymeric single stranded M13
DNA as a template together with a radioactively 5’ end
labeled primer and saturating dNTP concentrations of
150 μM. The polymerization products were compared
on a denaturing polyacrylamide/urea gel (Fig. 3). The
results confirmed the kinetic data foreshadowed in
Table 2, revealing a somewhat higher polymerization
efficiency of PFV-PR-RT.
Since polymerization activities are also dependent on
nucleic acid substrate affinities, we determined KD-
values of the two FV PR-RTs for DNA/RNA and
DNA/DNA by fluorescence anisotropy. In each of
these experiments a 24/40 mer primer/template (P/T)
substrate was used containing a fluorescent dye
Figure 2 PR activity assay. Reaction products were analyzed by 19% SDS-PAGE. 10 μM GB1-GFP substrate harboring a FV PR cleavage site
between GB1 and GFP was incubated with 10 μM SFVmac PR-RT or PFV PR-RT, respectively, at 37°C for 16 h in reaction buffer (50 mM
Na2HPO4/NaH2PO4 pH 7.4, 0.5 mM DTT, 3 M NaCl). C, control, substrate cleavage with TEV protease; (-), uncleaved substrate; M, molecular weight
standard. The sizes of the standard proteins are indicated on the left.
Table 2 Kinetic parameters of the polymerization activities of SFVmac and PFV PR-RT
enzyme KD
DNA/RNA
(nM)
KD
DNA/DNA
(nM)
KM
1)
(TTP/rAdT)
(μM)
kcat
1)
(TTP/rAdT)
(s-1)
KM
2)
(dNTPs/M13)
(μM)
kcat
2)
(dNTPs/M13)
(s-1)
PFV PR-RT 9.9 (± 1.6) 44.4 (± 3.0) 45 (± 12) 7.1 (± 0.9) 46 (± 9) 3 (± 0.3)
SFVmac PR-RT 32.4 (± 4.2)3) 36.4 (± 2.4)3) 40.1 (± 4.0)3) 5.5 (± 0.3)4) 45 (± 3) 4 (± 0.1)
1) KM and kcat-values, respectively, determined for TTP on the homopolymeric substrate poly(rA)/oligo(dT).
2) KM and kcat-values, respectively, determined for dNTPs on a heteropolymeric single stranded M13 substrate
3) Data adopted from [14]
4) vmax-value used for kcat calculation derived from [14].
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(Dy-647) at the 5’ end of the template strand (Table 2,
Fig. 4). For both enzymes, the affinity for the DNA/
RNA P/T appeared to be higher than for DNA/DNA.
This effect was far more pronounced for PFV PR-RT
with a 4-fold lower KD-value for the DNA/RNA sub-
strate. Comparison with HIV-1 RT shows an unex-
pected difference, i.e. the affinities of HIV-1 RT for
nucleic acid substrates are much higher. For DNA/
DNA or DNA/RNA substrates KD-values of approxi-
mately 2 nM have been determined [32-34].
RNase H activity
The third enzymatic activity associated with PR-RT is its
RNase H activity, which is responsible for degradation of
the RNA strand of an RNA/DNA hybrid and is indis-
pensable in the reverse transcription process.
Polymerization-independent RNase H activity was
tested on two different substrates. First, Michaelis-Men-
ten-parameters were determined on a blunt-ended
RNA/DNA substrate containing a fluorescent dye on
the 3’ end of the RNA and a quencher on the 5’ end of
the DNA. Upon cleavage of the RNA the fluorescent
dye is released from the quencher resulting in an
increase in fluorescence intensity. By varying substrate
concentrations, KM- and kcat-values for RNase H activ-
ities were calculated (Table 3). SFVmac and PFV PR-RT
showed KM-values of 18.1 nM and 17.1 nM, respec-
tively. These are in the range of HIV-1 RT (25 nM) [35]
Figure 3 DNA-dependent DNA polymerase activity on a
heteropolymeric substrate. Reactions were carried out at 37°C for
the times indicated on top with 6 nM of the M13 P/T substrate, 85
nM of PFV or SFV PR-RT and 150 μM of each dNTP, analyzed by
denaturing gel electrophoresis on a 10% sequencing gel and
visualized by phosphoimaging. DNA size markers are marked on the
right. - RT, assay without enzyme;
Figure 4 Determination of KD-values by fluorescence
anisotropy measurements. 15 nM of a fluorescently labeled DNA/
DNA (black circle) or DNA/RNA (black square) P/T substrate was
titrated with PFV PR-RT at 25°C. The curves show the best fit to a
two component binding equation [14] describing the binding
equilibrium with KD-values shown in Table 2.
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and E. coli RNase H (16 - 130 nM, depending on the
substrate) [36]. Provided that indeed FV PR-RTs are less
abundant in the virus particle, it is remarkable that the
FV RNase H activities were not higher than those of
HIV-1 RT.
To determine the endonucleolytic RNase H cleavage
sites of the two PR-RTs qualitatively, a 40 mer RNA
hybridized to a 24 mer DNA was used (Fig. 5). A fluor-
escent dye at the 5’ end of the RNA allowed visualiza-
tion of the cleavage products after separation on 15%
sequencing gels. Our time course experiments indicated
that with both enzymes a primary endonucleolytic clea-
vage at position -19 was followed by a 3’ > 5’ directed
processing reaction leading to shorter RNA products
(Fig. 5). Primary RNase H cleavage sites in the RNA at
positions 15 -20 nucleotides away from the primer ter-
minus of the hybrid were also detected for the RTs of
orthoretrovirinae like HIV-1 and RSV [37-42]. They are
directed by the 3’-end of the DNA-primer which binds
to the active site of the polymerase [43,44]. While RSV
RT appears to lack a 3’ > 5’ directed processing activity
[37], SFVmac and PFV PR-RTs (Figure 5B) as well as
HIV-1 and MoMLV RTs degrade the RNA to 8 mers or
smaller products [41,45].
Conclusions
Our data reveal small differences of FV PR-RTs in their
catalytic activities and biophysical properties. The KM-
values determined for HIV-1 RT are 5-30 fold lower
than those for FV PR-RTs. These deviations in kinetic
behavior might be based on the fact that HIV-1 can
replicate in non-dividing cells. Remarkably, both FV PR-
RTs are monomeric in solution, implying that transient
dimers need to be formed in order to obtain PR activity.
Transient dimerization has been demonstrated recently
for SFVmac PR and was suggested to play a role in the
regulation of a timely activation of PR activity (Hartl
MJ, Schweimer K, Reger MH, Schwarzinger S, Bodem J,
Rösch P, Wöhrl BM: Formation of transient dimers by a
retroviral protease, submitted). Small structural and con-
sequently catalytic variations between the two FV PR-
RTs might account for the differences observed (e.g. in
the resistance to the nucleoside inhibitor AZT.) Further
structural and functional analyses will be necessary to
elucidate these findings.
Methods
Plasmid construction and protein purification
For SFVmac PR-RT, gene expression and protein purifi-
cation were performed as described previously [14]. The
plasmid pET101TOPO-PFV-PR-RT-6His was con-
structed using the Champion™ pET Directional TOPO®
Expression kit (Invitrogen, Darmstadt, Germany). The N-
terminus of the PFV PR-RT starts with the amino acids
MNPLQLLQPL corresponding to the N-terminus of the
PR gene. The C-terminus contains a 6 × His tag and
exhibits the following amino acid sequence: ATQG-
SYVVNA-6His. The plasmid was transformed into the
Escherichia coli (E. coli) strain BL21 (DE3) pREP4:
GroESL [46], expressing E. coli chaperone proteins to
facilitate folding of heterologous proteins. Cells were
grown at 37°C in LB medium supplemented with 100 μg/
ml ampicillin and 34 μg/ml kanamycin to an optical den-
sity of 600 nm (OD600) of ca. 0.8. The temperature was
reduced to 16°C until an OD600of ca. 1.0 was reached.
Expression of the recombinant PFV PR-RT-6His gene
was then induced by the addition of 0.2 mM isopropyl-
thiogalactoside (IPTG) at 16°C over night. Cells were har-
vested by centrifugation at 5000 g for 20 min at 4°C.
Purification of SFVmac and PFV PR-RT
SFVmac PR-RT was purified as described previously
[14]. PFV PR-RT was purified as follows by a combina-
tion of Ni-affinity and hydrophobic interaction
chromatography:
Ni-NTA affinity chromatography
Cells were resuspended in 50 mM Na-phosphate pH 7.4,
300 mM NaCl, 10 mM imidazole, 0.5 mM dithiothreitol
(DTT). After addition of lysozyme, DNase I and one
protease inhibitor cocktail tablet (Complete, EDTA-free,
Roche Diagnostics GmbH, Mannheim) the suspension
was stirred on ice for 30 min. After cell lysis using a
microfluidizer (Microfluidics, Newton, MA, USA) the
suspension was centrifuged at 19100 g for 30 min at 4°
C. Purification of the protein was performed by a step
gradient applying increasing concentrations of up to 500
mM imidazole on a HisTrap column (HisTrap, GE
Healthcare, München, Germany).
Hydrophobic interaction chromatography
Fractions containing PFV PR-RT were pooled and dia-
lyzed (Spectra/Por, MWCO 50 000 Da) twice for at
least 2 h against 50 mM Na-phosphate pH 7.4, 300 mM
NaCl, 1 M (NH4)2SO4 and 0.5 mM DTT and then
loaded onto a 5 ml butyl column (ButylFF, GE Health-
care, München, Germany). The protein was eluted by
applying a step gradient from 1 M (NH4)2SO4 and 300
mM NaCl to 0 M (NH4)2SO4 and 0 M NaCl. After elec-
trophoresis of the fractions on 10% SDS-polyacrylamide
gels the relevant fractions were concentrated with
Table 3 Kinetic parameters of the RNase H activities of
SFVmac and PFV PR-RT
enzyme KM
RNase H (nM)
kcat (s
-1)
PFV PR-RT 17.1 (± 1.2) 0.017 (± 0.0003)
SFVmac PR-RT 18.1 (± 0.6) 0.020 (± 0.0003)
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Vivaspin concentrators (MWCO 10 000 Da) to a
volume of 200 μl and dialyzed against 50 mM Na-phos-
phate pH 7.4, 100 mM NaCl 0.5 mM DTT.
Analyses using circular dichroism (CD) spectra and
size exclusion chromatography were performed with
freshly purified SFVmac and PFV PR-RT. For PR, poly-
merization and RNase H measurements the PFV PR-RT
was dialyzed (Spectra/Por, MWCO 50 000 Da) against
50 mM Na-phosphate pH 7.4, 100 mM NaCl, 0.5 mM
DTT and 15% glycerol over night, the glycerol concen-
tration was then increased to 50% and the protein
stored at -20°C.
Peptide mass fingerprint (PMF) analysis
Protein bands of ca. 1 mm × 3 mm were excised from
10% SDS-polyacrylamide gels and the integrity and iden-
tity of PFV PR-RT was confirmed by peptide mass finger-
printing (ZMMK Köln, Zentrale Bioanalytik, Germany).
Circular dichroism
Far UV circular dichroism (CD) spectra of wild-type
SFVmac and PFV PR-RT were acquired at 20°C using a
Jasco J-810 spectropolarimeter (Japan Spectroscopic,
Gross-Umstadt, Germany) at a band width of 1 nm, a
sensitivity of 100 mdeg and a data density of 5 points/
Figure 5 Qualitative RNase H assay. The DNA/RNA P/T substrate is shown on top. The cleavage sites determined for SFV and PFV PR-RT are
indicated by arrows. 320 nM of DY-647 labeled P/T substrate was incubated with 50 nM of SFVmac or PFV PR-RT in 50 mM Tris/HCl, pH8.0, 80 mM
KCl, 6 mM MgCl2 for the times indicated on top of the gel. Reaction products were analyzed on a 15% polyacrylamide sequencing gel and
visualized by detection of the fluorescence emission of the RNA template strand at 670 nm upon excitation at 633 nm. The cleavage sites are
indicated on the left. The first nucleotide of the RNA hybridized to the 3’-OH nucleotide of the DNA primer is denoted -1. The partially hydrolyzed
RNA on the right was used for the determination of the cleavage sites. Numbers on the right indicate the length of the RNA in nucleotides.
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nm in a 0.1 cm cell. 0.5 μM of each enzyme was mea-
sured in 25 mM Na-phosphate pH 7.4 and 5 mM NaCl.
At least 12 scans in the range between 260 and 190 nm
were averaged for each measurement, and the resulting
spectrum was smoothed and normalized to a mean resi-
dual weight ellipticity [ΘMRW] (deg·cm
2·dmol-1) using
Jasco Spectra Manager Software. For secondary struc-
ture predictions based on the CD data the program
CDSSTR (Dichroweb) [14,27] was used.
Size exclusion chromatography
For analytical gel filtration of PFV PR-RT a Superdex
200 HR 10/30 column (GE Healthcare, Munich,
Germany) calibrated with catalase (232 kDa), aldolase
(158 kDa), ovalbumine (43 kDa) and chymotrypsinogen
(25 kDa) (GE Healthcare, Munich, Germany) was used
at a flow rate of 0.5 ml/min. The column was loaded
with 10 nmol PFV PR-RT in 50 mM Na2HPO4/
NaH2PO4 pH 7.4, 300 mM NaCl and 0.5 mM DTT.
PR activity assay
PR activity was measured as described before using a
substrate which contained the SFVmac Pol cleavage
site ATQGSYVVH↓CNTTP that can also be used by
PFV PR-RT. Control digests with TEV protease were
performed with the same substrate since it harbors a
TEV cleavage site adjacent to the FV PR cleavage site
[15].
Polymerization assays
RNA-dependent DNA polymerase activity was quantitated
on a poly(rA)/oligo(dT)15 substrate (0.2 U/ml) (Roche
Diagnostics GmbH, Mannheim, Germany) in a standard
assay (30 μl reaction volume) as described previously [14].
For the determination of KM, vmax and kcat values, reac-
tions were performed with increasing concentrations of
TTP of 25, 50, 75,125 or 250 μM. For the determination
of kinetic parameters on a heteropolymeric substrate 100
nM of single stranded M13mp18 DNA and 15 nM of PR-
RT was used. dNTP concentrations of 25, 50, 75, 125 and
250 μM were added, using [3H]-TTP (3000 Ci/mmol,
Hartmann Analytic GmbH, Braunschweig, Germany) as a
tracer. KM-values were calculated by linear regression
using Eadie-Hofstee plots. kcat is defined as vmax/enzyme
concentration. Qualitative DNA polymerization assays on
denaturing polyacrylamide/urea gels using single stranded
M13mp18 DNA as a substrate were performed as
described previously [14].
Fluorescence anisotropy measurements
Fluorescence equilibrium titrations were performed to
determine the dissociation constants (KD) for nucleic
acid binding with a 24/40 mer DNA/DNA or DNA/
RNA primer/template (P/T). Experiments and data
fitting were carried out as described [14] with15 nM
fluorescently labeled P/T at 25°C.
RNase H activity assays
Substrate preparation
The RNA-strand 5’-CCG AUG GCU CUC CUG GUG
AUC CUU UCC-6-FAM (6-carboxy-fluorescein) and the
DNA-strand 5’-Dabcyl-GGA AAG GAT CAC CAG
GAG AG were synthesized by biomers.net (Ulm, Ger-
many). The hybrid was formed by mixing the two oligo-
nucleotides at a ratio of 1:1.2 respectively in 20 mM
Tris/HCl pH 8.0 and 20 mM NaCl, followed by heating
at 95°C for 2 min and cooling down to room tempera-
ture over a time period of 2 h. The resulting substrate
was stored in aliquots at -20°C.
RNase H enzyme kinetics
Steady-state fluorescence measurements were performed
at 25°C on a Fluorolog-Tau-3 spetrofluorometer (HOR-
IBA Jobin Yvon GmbH, Unterhaching, Germany). The
assay was carried out in a total volume of 1.2 ml con-
taining 50 mM Tris/HCl pH 8.0, 80 mM KCl, 6 mM
MgCl2 and a final concentration of 1 nM PR-RT. To
determine the Michaelis-Menten kinetic parameters the
DNA-dabcyl/RNA-6-FAM P/T concentration was varied
from 10 to 200 nM. Cleavage of the RNA in the hybrid
leads to dissociation of a fluorescein labeled RNA frag-
ment from the dabcyl quencher and thus to a fluores-
cence increase. Upon excitation of the substrate at 495
nm an increase in fluorescence emission can be detected
at 520 nm. The maximum change in fluorescence inten-
sity and thus complete substrate cleavage was deter-
mined by incubating the hybrid with a large excess of
PR-RT (250 nM). Initial rates were calculated using the
linear slope of the reaction progress curve where less
than 5% of substrate was cleaved. Values for kinetic
parameters (KM and vmax) were obtained by linear
Eadie-Hofstee regression of the Michaelis-Menten equa-
tion V0 = Vmax·[S0]/(Km+ [S0]). kcat is defined as vmax/
enzyme concentration.
Qualitative RNase H assay
The gelelectrophoretic assay used a 5’ fluorescently labeled
RNA-oligonucleotide (5’- [DY-647]-CUA AUU CCG CUU
UCC CCU CUC CUG GUG AUC CUU UCC AUC C;
biomers.net, Ulm, Germany), which was purified on a 20%
denaturing polyacrylamide gel and then annealed to the
unlabeled DNA-oligonucleotide 5’-GGA AAG GAT CAC
CAG GAG AGG GGA (biomers.net, Ulm, Germany). The
hybrid was formed by mixing 2 μM Dye647-RNA with 2.4
μM DNA primer in 20 mM Tris/HCl pH 8.0 and 20 mM
NaCl, followed by heating at 95°C for 2 min and cooling at
room temperature over a time period of 2 h. The RNase H
reaction was performed at 37°C in a total volume of 30 μl
in 50 mM Tris/HCl pH 8.0, 80 mM KCl and 6 mM MgCl2
with 320 nM P/T substrate. The reaction was initiated by
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the addition of 50 nM PR-RT. Aliquots were removed at
different time points and analyzed by electrophoresis on a
15% polyacrylamide sequencing gel. Products were visua-
lized by fluorescence emission at 670 nm upon excitation
at 633 nm using a fluorescence laser scanner (FLA 3000,
raytest, Straubenhardt, Germany).
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Abstract
Azidothymidine (AZT) is a reverse transcriptase (RT) inhibitor that efficiently blocks the replication of spumaretroviruses or foamy viruses (FVs).
To more precisely elucidate the mechanism of action of the FV RT enzyme, we generated an AZT-resistant FV in cell culture. Biologically resistant
virus was obtained for simian foamy virus from macaque (SFVmac), which was insensitive to AZTconcentrations of 1 mM, but not for FVs derived
from chimpanzees. Nucleotide sequencing revealed four non-silent mutations in the pol gene. Introduction of these mutations into an infectious
molecular clone identified all changes to be required for the fully AZT-resistant phenotype of SFVmac. The alteration of individual sites showed that
AZT resistance in SFVmac was likely acquired by consecutive acquisition of polmutations in a defined order, because some alterations on their own
did not result in an efficiently replicating virus, neither in the presence nor in the absence of AZT. The introduction of the mutations into the RTof the
closely related prototypic FV (PFV) did not yield an AZT-resistant virus, instead they significantly impaired the viral fitness.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Foamy virus; Reverse transcriptase; AZT resistance
Introduction
Foamy viruses (FVs) constitute one of two subfamilies of
retroviruses and follow a unique replication pathway (for
reviews, see Linial, 2007; Rethwilm, 2003, 2005). Aside from
early studies the comparative analysis of the replication strategy
between spuma- and orthoretroviruses has only recently
focused on the biochemistry of the RT enzyme (Benzair et al.,
1982, 1983; Boyer et al., in press, 2004; Kögel et al., 1995a,b;
Liu et al., 1977; Rinke et al., 2002). Although the character-
ization of bacterially expressed PFV RT revealed many features
common to all retroviruses (Boyer et al., in press, 2004; Kögel
et al., 1995a,b), it was also shown that PFV RT is much more
processive than orthoretroviral enzymes (Rinke et al., 2002).
Furthermore, mutation of the active center of the PFV RT from
YVDD to YMDD did not result in sensitivity to the antire-
troviral drug 3TC, as in human immunodeficiency virus (HIV),
but rendered the virus replication-deficient (Rinke et al., 2002).
These studies indicated that there are similarities and differences
in the biochemistry of the RT enzymes between orthoretro-
viruses and foamy viruses.
A major difference between ortho- and spumaretroviral RT
enzymes consists in the nature of the precursor and the definite
cleavage products of the Pol protein. While in orthoretroviruses,
the enzymatic proteins are cleaved from a Gag-protease (PR)-
Pol precursor into PR, RT/RNaseH, and integrase (IN), FV Pol
cleavage products are processed from an authentic PR-Pol
precursor and cleavage between the PR and RT/RNaseH
subunits does not occur (for a review, see Linial and Eastman,
2003). Thus, the only observed end products of FV Pol precursor
cleavage are the 85-kDa PR-RT/RNaseH and the 40-kDa IN
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(Flügel and Pfrepper, 2003). This structural feature of FV RT
enzymes probably has an impact on the function that has not
been elucidated in detail yet.
In addition to tenofovir, AZT (zidovudine) is the only RT-
inhibiting drug, which is active against FVs and completely
inhibits PFV replication in cell culture at a concentration as low
as 5 μM (Lee et al., 2006; Moebes et al., 1997; Rosenblum et al.,
2001). Since the understanding of the biochemistry of the FV
RT would greatly profit from the characterization of an AZT-
resistant variant and the understanding of the mechanism of
AZT resistance in orthoretroviruses, namely, human immuno-
deficiency virus (HIV), would mutually profit from studying a
distantly related virus, we attempted to generate and character-
ize AZT-resistant FVs.
Furthermore, based on homology predictions of the PFVand
HIV RT enzyme structures, AZT resistance in PFV has been
suggested to occur by alteration of certain residues that are
known to confer AZT resistance to HIV-1 (Yvon-Groussin et al.,
2001). We also wanted to investigate this possibility because
experimental evidence for this theory does not exist.
Results
Generation of biologically AZT-resistant FV
To obtain AZT-resistant viruses we cultivated plasmid-
derived PFV, the chimpanzee FV isolate (SFVcpz), and
SFVmac virus stocks on the appropriate indicator cells and
gradually raised the AZT concentration. Although we were
successful in obtaining an SFVmac variant (SFVAZTres) that
was able to replicate in medium containing 1 mM AZT, several
attempts to similarly generate PFV or SFVcpz variants failed
(data not shown).
Genotypic analysis of AZT-resistant SFVmac
The gag and pol genes of SFVAZTres were amplified by
PCR and subjected to nucleotide sequence analysis. In com-
parison with the full-length SFVmac sequence, which was
assembled from subgenomic SFVmac molecular clones (Gen-
bank accession numbers: X58484 and M33561; see Mergia
et al., 1990a,b), six nucleotide alterations leading to amino acid
changes were found. Two of the changes were located in the gag
open reading frame (ORF) and involved R535gag and G596gag,
which were changed to Q and R, respectively. The presence of
these gag mutations in the parental infectious SFVmac clone
together with the pol mutations (as in pBK03QR-ITTK) did not
influence the AZT susceptibility compared with an SFVmac
clone having only the pol residues mutated (as in pBK04RG-
ITTK) (Table 1). We therefore regarded the Gag ORF alterations
as irrelevant for conferring AZT resistance and did not analyze
them further.
Four point mutations involving residues 211 (K211I), 224
(I224T), 345 (S345T), and 350 (E350K) were detected in pol
(Fig. 1). On the nucleic acid level, all alterations leading to these
amino acid changes required only the mutation of single nu-
cleotides. Themutations identified were at codon 211 fromAAA
to ATA, at codon 224 fromATT to ACT, at codon 345 from TCA
to ACA, and at codon 350 from GAA to AAA. One published
complete genomic sequence of SFVmac already harbors a
threonine at position 224 of the Pol protein (Kupiec et al., 1991).
224T would be more consistent with the other primate FV Pol
proteins, which all harbor a threonine in this position (Fig. 1).
Table 1
Comparison of biologically selected AZT-resistant virus withmolecularly cloned
derivatives⁎
Virus D3 D6 D9 D12 D15 D18
SK29-KISE −AZT + +++ ++++ c.d. n.d. n.d.
SFVAZTres −AZT + +++ ++++ c.d. n.d. n.d.
BK03QR-ITTK −AZT + +++ ++++ c.d. n.d. n.d.
BK04RG-ITTK −AZT + +++ ++++ c.d. n.d. n.d.
SK29-KISE +AZT (+) (+) (+) – – –
SFVAZTres +AZT + + + ++ +++ ++++
BK03QR-ITTK +AZT + + + ++ +++ ++++
BK04RG-ITTK +AZT + + + ++ +++ ++++
⁎105 BHK/LTR(SFVmac)lacZ cells were infected at a multiplicity of infection
(MOI) of 0.001 with the respective viruses either in the absence (−AZT) or
presence (+AZT) of 50 μM AZT. The cultures were stained for blue cells at the
indicated days after infection and the replication of virus was monitored.
(+), b1% infected cells; +, 1–10% infected cells; ++, 10–25% of cells were
infected; +++, 25–50% infected cells; ++++, more than 50% of the cell culture
was infected; c.d., cell culture was destroyed; n.d., not done. SK29-KISE is the
wild-type molecular clone-derived virus, SFVAZTres is the biologically selected
AZT-resistant virus, BK03QR-ITTK and BK04RG-ITTK are viruses derived
from molecular clones containing the two gag and four pol or only the four pol
gene mutations, respectively.
Fig. 1. Homology of Pol proteins of different FVand HIV-1. The RT regions of known FVs relevant to this study were aligned using the Genbank accession numbers
for SFVmac (X58484 and M33561), PFV (Y07725), the chimpanzee isolate SFVcpz (U04327), orangutan FV (SFVora; AJ544579), African green monkey virus
(SFVagm; M74895), FV from felines (FFV: AJ564746), bovines (BFV; U94514) and equines (EFV; AF20190).
152 B. Kretzschmar et al. / Virology 370 (2008) 151–157
However, the parental molecular clones pSFV-1 and pSK29-
KISE code for an isoleucine at this position. Thus, the wild-type
SFVmac may have a polymorphism at this site. Because we
found I224T in SFVAZTres, we considered I224T as a mutation
associated with AZT resistance.
Biologically selected SFVAZTres was compared with the
parental virus and the virus derived from transfection of cells
with molecular cloned variants bearing all four pol gene muta-
tions. We observed only slight differences in the development of
cell-free virus titers between the molecularly cloned and
uncloned resistant viruses in the absence or presence of AZT
(Table 1). This indicated that the four mutations identified in pol
are sufficient to confer AZT resistance to SFVmac.
Analysis of reconstituted SFVmac molecular clones
To investigate which of the pol gene mutations was res-
ponsible for the resistant phenotype of SFVmac, we generated a
series of full-length molecular clones in which all possible
combinations of the four mutations found in SFVAZTres were
represented (Fig. 2).
To analyze whether the introduced mutations affected the
stability or other properties of SFVmac Pol protein, we first
investigated the protein expression following transient trans-
fection of 293T cells with the recombinant plasmids in cellular
lysates. As shown in Fig. 3, all mutants were able to express
Gag and Pol proteins to approximately the same level as non-
mutant virus.
AZT resistance of SFVmac mutants
After demonstrating that the altered Pol proteins are ef-
ficiently expressed 293T cells were transfected with the
parental molecular clone or the variants shown in Fig. 2 and
analyzed on the appropriate indicator cells. Due to the peculiar
replication strategy of FVs, namely, reverse transcription taking
Fig. 2. Genome organization of the wild-type and mutant FV Pol open reading frames. The pol gene of SFVmac is shown in the upper panel with the relative location
of the RT active center and the four amino acid residues associated with AZT resistance. The SFVmac mutants representing all possible combinations of the four
mutations are shown in the lower panel together with the approximate levels of AZT resistance deduced from Table 2. The plasmids pBK04-ITTK and pBK64-ITTK
are identical. Plasmid pBK04-ITTKwas made by exchanging a pol gene fragment containing the four mutations and amplified from DNA of cell cultures infected with
SFVAZTres for a corresponding fragment of pSK29-KISE and pBK64-ITTK was made by in vitro mutagenesis. M108 is a PFV mutant with the changed residues
found in SFVAZTres.
Fig. 3. SFVmac protein expression. The expression of Gag (pr71/p68) and Pol (pr127) proteins was analyzed by immunoblot with polyclonal rabbit antisera in lysates
from cells transfected with the indicated plasmids.
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place already in virus producing cells (Moebes et al., 1997; Yu
et al., 1999), the production of virus after transfection of cells
and the analysis of cell-free viral titers were performed in the
absence or presence of AZT. As shown in Table 2, we observed
pronounced differences in the replication competence of the
various mutants that argue for a sequential acquisition of
SFVmac pol gene mutations for replication in the presence of
AZT.
The BK38-IITE virus, for instance, which bears the two
mutations leading to K211I and S345T, did not replicate either
in the absence or presence of AZT. Replication was also
severely limited in the BK30-IISE, BK31-IITK, and BK81-
ITSE viruses, whereas BK37-IISK, BK77-ITSK, BK80-ITTE,
SK39-KITK, and SK51-KISK were moderately impaired to
replicate irrespective of the AZT concentrations. All these
mutants have K211 changed to isoleucine in various combina-
tions (the BK viruses) or E350 modified to lysine (the SK
viruses). It is therefore unlikely that either of these changes
occurred first under drug selection. The only single mutation
that was found to result in a moderate drug resistance was that
leading to S345T (SK50-KITE). While conferring partial AZT
resistance, this mutation weakened the virus to replicate in its
absence (Table 2). Subsequent acquisition of I224T, in addition
to S345T (BK78-KTTE), resulted in an enhancement of viral
fitness and replication predominantly at low AZTconcentration.
Alternatively, threonine may be the natural residue at
position 224 in wild-type SFVmac (as discussed above), in
which case the BK78-KTTE virus would be the first variant to
emerge during AZT-induced selective pressure. Since the
K211I variant greatly decreased replication, if it occurred
before E350K (BK80-ITTE in Table 2), BK79-KTTK was
probably the next virus to emerge. BK79-KTTK was able to
replicate at 5 μM AZT and strongly enhanced replication
without the drug. Finally, the resistant virus acquired the
mutation leading to K211I in addition to I224T, S345T, and
E350K (BK64-ITTK). Compared to BK79-KTTK the replica-
tion ability of BK64-ITTK in the absence of AZT was slightly
reduced, however, it was greatly enhanced at higher drug
concentrations (Table 2).
Attempts to create an AZT-resistant PFV
The introduction of the mutations leading to R211I, S345T,
and E350K in M108 of PFV (residue 224 is already a threonine;
see Fig. 1) did not lead to AZT resistance and, compared to the
parental virus (HSRV2), severely reduced the viral fitness in the
absence of AZT (Table 2). However, we cannot formally
exclude the possibility that only one or two alterations of these
residues might induce AZT resistance to PFV, although we
regard this as very unlikely.
Discussion
The results shown here suggest that AZT resistance in
SFVmac was acquired by sequential acquisition of mutations in
the pol gene in the order: wild-type virus -NS345T -N I224T
-NE350K -NK211I (Fig. 4). However, alternative scenarios are
also possible, although less likely. In particular, the position in
the order of events of the mutation leading to I224T appears
variable (see above). The fully resistant virus was found to be
able to replicate at 1 mM AZT. As shown in Table 2 the BK64-
Table 2
AZT-sensitivity of mutant viruses⁎
Virus 0.0 μM 0.5 μM 5.0 μM 50 μM
SK29-KISE 100% 0.7±0.5% b0.1% b0.1%
BK04-ITTK 117.0±18.4% 84.3±27.8% 71.0±12.7% 34.9±12.9%
BK30-IISE 1.2±1.2% b0.1% b0.1% b0.1%
BK65KTSE 146.5±21.4% 1.2±0.9% b0.1% b0.1%
SK50-KITE 40.0±16.8% 5.6±3.2% 1.1±1.0% b0.1%
SK51-KISK 31.7±8.8% 1.8±0.8% b0.1% b0.1%
BK81-ITSE 2.5±0.6% b0.1% b0.1% b0.1%
BK38-IITE b0.1% b0.1% b0.1% b0.1%
BK31-IISK 23.0±7.9% 0.6±0.5% b0.1% b0.1%
BK78-KTTE 86.7±20.5% 18.7±12.9% 0.5±0.3% b0.1%
BK76-KTSK 175.5±33.9% 8.1±4.5% b0.1% b0.1%
SK39-KITK 20.6±5.5% 10.8±7.5% 3.0±2.1% 1.0±0.6%
BK80-ITTE 7.3±3.6% 4.0±2.7% 1.0±0.8% 0.3±0.2%
BK77-ITSK 33.6±11.3% 3.8±3.0% 0.9±0.5% b0.1%
BK37-IITK 8.6±2.7% 5.9±3.0% 2.8±1.3% 2.0±0.8%
BK79-KTTK 138.2±21.8% 86.9±11.5% 16.4±10.9% 1.4±0.4%
BK64-ITTK 113.0±19.2% 79.3±20.1% 68.8±18.8% 31.3±20.6%
HSRV2 100% 1.1±0.9% 0.4±0.1% b0.1%
M108 1.3±0.1% 0.5±0.1% 0.4±0.1% b0.1%
⁎293T cells were transiently transfected with 10 μg plasmid DNA either in the
absence or presence of the concentrations of AZT indicated. The viral titers in
the cell-free supernatants were determined on the appropriate indicator cells and
are expressed as values relative to SK29-KISE (for SFVmac mutants) or HSRV2
(for the PFV mutant) in the absence of AZT and arbitrarily set to 100%. This
corresponded to cell-free titers of 7×104 in the case of SFVmac and 6.3×104 for
PFV.
Fig. 4. Most likely order of mutagenic events resulting in AZT-resistant SFVmac.
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ITTK virus replicated only to approximately one-third the level
of wild-type virus. Thus, the acquisition of the mutations
leading to drug resistance was accompanied by a moderate
reduction of viral fitness.
The inability to obtain AZT-resistant PFV or chimpanzee
foamy virus by gradually raising the drug concentration in the
cell culture medium was surprising. Because SFVmac and PFV
derived from ourmolecular clones replicate to approximately the
same extracellular viral titers (Table 2), we regard it very
unlikely that significant differences in the replication kinetics
between the two parental viruses are responsible for our futile
attempts in generating biologically drug-resistant PFV. Both
viruses, SFVmac and PFV, have been amplified in cell culture
for years. Although FVs are known to be genetically extremely
stable (Switzer et al., 2005; Thümer et al., 2007), the cell culture-
adapted virus does not necessarily reflect the wild-type situation.
However, SFVcpzwasmolecular cloned approximately 1month
after virus isolation (Herchenröder et al., 1994, 1995). This
questions significant changes in the FV RT sequence upon cell
culture replication and points to differences between SFVmac
and FVs of the higher primates in the ability to respond to AZT
drug selection.
In addition, the introduction of the mutations conferring AZT
resistance to SFVmac into the infectious PFV molecular clone
also did not result in a drug-resistant virus. These mutations
resulted in an approximately 70% reduction in viral fitness of
SFVmac (Table 2). The reduction was much more substantial
when the same mutations were introduced into PFV (Table 2).
This may indicate that PFV is, per se, able to mutate into an
AZT-resistant variant, but that the resistant virus lost the ability
to replicate either in the presence or absence of AZT. The reason
for this currently remains unknown. Answers may emerge when
comparative biochemical analyses of PFV, SFVmac, and
SFVAZTres RT enzymes and structural information become
available.
In the HIV system, AZT resistance develops in vivo at least
under the condition of monotherapy very quickly by consecutive
mutations in the pol gene, while there exist only a few reports on
cell culture selection of AZT-resistant HIV from wild-type virus
(Dianzani et al., 1992; Gao et al., 1992; Kellam et al., 1994;
Larder et al., 1991, 1989; Larder and Kemp, 1989; Smith et al.,
1987). Nothing is known yet about the in vivo development of
AZT resistance in FV infections. The biochemical andmolecular
bases of AZT resistance in HIV-1 and HIV-2 have been thor-
oughly studied. In each virus, a different mechanism dominates
in the acquisition of AZT drug resistance (Boyer et al., 2006).
Although HIV-1 preferentially excises AZT from the growing
DNA chain, resistant HIV-2 was reported to discriminate
between the inhibitor AZTTP and TTP during incorporation
(Boyer et al., 2006). Thus, even closely related viruses can make
use of different strategies to develop drug resistance. The
homology between HIV-1 and HIV-2 RTs is around 60% (Boyer
et al., 2006), while it is approximately 90% for PFVand SFVmac
(Kupiec et al., 1991). Therefore, only subtle differences in the
primary amino acid composition of SFVmac and PFV RT en-
zymes are responsible for the inability to generate an AZT-
resistant PFV.
The analyses of FV RT enzymes revealed similarities with as
well as differences to orthoretroviral RT enzymes. Our study
shows that differences even exist within the rather homogenous
FV subfamily of retroviruses. In this respect, it would be
interesting to know whether the conversion of the active center
of the FV RT enzyme from YVDD to YMDD, which led to a
replication-deficient PFV (Rinke et al., 2002), would be
tolerated by SFVmac.
Furthermore, our results do not indicate that the residues
actually involved in FVAZT resistance, are those thought pre-
viously (Yvon-Groussin et al., 2001). In particular, the residues
I182, D209, V343, and K347 were modelled to be involved in
PFVAZT resistance. The results presented here do not support
this view, since (i) the residues identified to confer AZT
resistance to SFVmac are different and (ii) AZT-resistant PFVor
SFVcpz could not be generated at all.
Materials and methods
Cells and viruses
BHK/LTR(SFVmac)lacZ (Roy et al., 2003), BHK/LTR
(PFV)lacZ (Schmidt and Rethwilm, 1995) indicator cells, and
293T cells (DuBridge et al., 1987) were cultivated as described
(DuBridge et al., 1987; Roy et al., 2003; Schmidt and
Rethwilm, 1995). After transient transfection of cells with the
proviral plasmids pSFV-1 (Mergia and Wu, 1998), pcHSRV2
(Moebes et al., 1997), or pSFVcpz (Herchenröder et al., 1995)
viruses were cultivated on the appropriate indicator cells which
were stained for β-Gal as reported (Schmidt and Rethwilm,
1995). AZT (Glaxo) was added to the culture medium at the
concentrations indicated in the figures and tables.
To determine the susceptibility to AZT, virus was produced
by transient transfection (48 h) of 293T cells using calcium
phosphate coprecipitation with 10 μg of plasmid DNA in the
absence or presence of the drug (Moebes et al., 1997). Gene
expression was induced using Na-butyrate at a final concen-
tration of 10 mM for 8 h (Heinkelein et al., 1998). The virus
titer in the cell-free supernatant was determined on indicator
cells in the absence or presence of AZT as described (Moebes
et al., 1997). All virus titrations were performed at least three
times. Virus stocks derived from molecular clones were
abbreviated with the plasmid name lacking the “p” or “pc”.
Molecular cloning
The plasmid pSK29-KISE was obtained by treatment of
partially KpnI-digested pSFV-1 (Mergia and Wu, 1998) with T4
polymerase. This eliminated the KpnI restriction site in the
polylinker of the vector backbone.
After amplification and nucleotide sequencing of the
complete gag and pol genes of the biological resistant SFVmac,
a 3.4-kb XhoI/EcoRI fragment harboring the region with the
identified mutations was amplified and inserted into the full-
length proviral clone via a subclone containing a 8.2 kb XbaI/
KpnI fragment. Mutations were introduced into the XhoI/EcoRI
subclone by recombinant PCR following the method of Higuchi
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(1990) and then introduced back into the full-length clone as
described above. To ease the identification of amino acid
changes in Gag and Pol, relevant residues are indicated after the
plasmid name.
Because PFV already bears a threonine at position 224 of its
pol gene (see below), we constructed a triple mutant (M108) of
pcHSRV2 (Moebes et al., 1997) that contains R211I, S345T,
and E350K. PFV pol gene mutagenesis was carried out by
recombinant PCR (Higuchi, 1990) on a subcloned 1.83-kb
PacI/SwaI fragment of pcHSRV2 before reinsertion into the
full-length molecular clone.
For exclusion of inadvertent nucleotide exchanges all PCR-
generated fragments were sequenced on the level of the full-
length molecular clones. A detailed description of primers used
for mutagenesis, amplification, and sequencing can be found
online at http://viminfo.virologie.uni-wuerzburg.de/onlinema-
terial/Kretzschmar.pdf.
The complete gag and pol open reading frames (ORFs) of
SFVmac were amplified separately and inserted into the
vectors pRSET-A (Invitrogen) and pET28c (Novagen), respec-
tively. The pET28c-SFVpol plasmid was used to delete the
integrase gene via PCR in order to obtain a PR-RT subclone. A
protease active site mutant (D24A) was created thereof by
overlap PCR and transformed into the E. coli strain Rosetta
DE3 (Novagen) for expression and purification of a PR
(D24A)-RT fusion protein. Bacterial proteins were induced and
purified via the C-terminal 6xHis-tag as described (Imrich et
al., 2000) and used to generate polyclonal rabbit antisera at a
commercial facility.
Immunoblotting
After transfection of 293T cells with proviral constructs, Gag
and Pol protein expression in intracellular lysates was analyzed
by immunoblotting with the rabbit Gag and Pol antisera as
described previously (Heinkelein et al., 1998; Imrich et al.,
2000).
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ABSTRACT
Azidothymidine (AZT, zidovudine) is one of the few
nucleoside inhibitors known to inhibit foamy virus
replication. We have shown previously that up to
four mutations in the reverse transcriptase gene of
simian foamy virus from macaque (SFVmac) are
necessary to confer high resistance against AZT.
To characterize the mechanism of AZT resistance
we expressed two recombinant reverse transcrip-
tases of highly AZT-resistant SFVmac in Escherichia
coli harboring three (K211I, S345T, E350K) or four
mutations (K211I, I224T, S345T, E350K) in the
reverse transcriptase gene. Our analyses show
that the polymerization activity of these mutants is
impaired. In contrast to the AZT-resistant reverse
transcriptase of HIV-1, the AZT resistant enzymes of
SFVmac reveal differences in their kinetic proper-
ties. The SFVmac enzymes exhibit lower specific
activities on poly(rA)/oligo(dT) and higher KM-values
for polymerization but no change in KD-values for
DNA/DNA or RNA/DNA substrates. The AZT resis-
tance of the mutant enzymes is based on the
excision of the incorporated inhibitor in the pre-
sence of ATP. The additional amino acid change of
the quadruple mutant appears to be important for
regaining polymerization efficiency.
INTRODUCTION
Foamy viruses belong to the retroviridae but follow a
replication pattern unique among retroviruses: (i) reverse
transcription occurs before the virus leaves the host cell,
(ii) the pol-gene is expressed from an separate mRNA
and (iii) the viral protease is not cleaved off the
Pol-polyprotein (1,2). Only the integrase is removed from
Pol (3). Thus, the FV reverse transcriptase (PR–RT)
harbors a protease, polymerase and RNase H domain.
Apart form the nucleoside inhibitor tenofovir, only
azidothymidine (AZT, zidovudine) is known to inhibit FV
reverse transcriptase in vivo in cell culture assays at
concentrations as low as 5 mM (4–6). We have shown
recently that four point mutations involving the amino
acids 211 (K211I), 224 (I224T) 345 (S345T) and 350
(E350K) located in the PR–RT gene are involved in AZT
resistance of SFVmac. The fully resistant SFVmac virus
harboring all four mutations was able to replicate in the
presence of 1mM AZT (7). While AZT resistance in
HIV-1 is based on the excision of incorporated AZT-
monophosphate (AZTMP), AZT-resistant HIV-2 can
distinguish between AZT-triphosphate (AZTTP) and
TTP during incorporation (8–11).
For FVs, the resistance mechanism is not known. To
elucidate the mechanism of AZT resistance we set out to
express partially and fully AZT-resistant SFVmac
PR–RTs harboring either three or all four AZT resistance
mutations in Escherichia coli. We were able to show that
the mechanism of AZT resistance in SFVmac PR–RTs is
based on AZTMP excision from a terminated primer in
the presence of ATP. Although the resistant PR–RTs are
impaired in their polymerase activities, the faster excision
of AZTMP in the presence of ATP confers high resistance
against AZT. The I224 mutation appears to be primarily
important for regaining polymerization activities for
efficient viral replication.
MATERIALS AND METHODS
Cloning, expression and purification of PR–RTs
The wild-type PR–RT gene was cloned into the vector
pET28c (Novagen, Germany) via PCR amplification
and by using the restriction sites XhoI and NcoI.
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The expressed proteins contain a 6 His tag at the
C-terminus. To avoid degradation of the PR–RT by
autocatalytic activity of the PR, a mutant enzyme was
constructed harboring an active site mutation in the PR
region (D24A), which leads to an inactive PR. Thus the
AZT-resistant mutants also contain the D24A mutation in
the PR. The AZT-resistance mutations were created by
site-directed mutagenesis according to the QuickChange
kit from Stratagene (Heidelberg, Germany). The following
potentially AZT-resistant PR–RT mutants were obtained:
mt3: (D24A) K211I, S345T, E350K
mt4: (D24A) K211I, I224T, S345T, E350K
The activities of the mutants were compared to wild-
type PR–RT either without or with the PR D24A
mutation (WT and WT, respectively).
The corresponding plasmids were transformed into the
E. coli strain Rosetta (DE3) (Novagen, Germany).
Expression of the PR–RT genes was induced at an optical
density of the culture of ca. 0.8–1.0 at 600 nm by the
addition of 0.2mM IPTG and incubated further over
night at 258C. The enzymes were purified via Ni-affinity
chromatography (HisTrap, GE Healthcare, Munich,
Germany), followed by chromatography over a heparin
column (HiTrap heparin, GE Healthcare, Munich,
Germany). The integrity of the proteins was verified by
peptide mass fingerprints (Zentrale Bioanalytik, Zentrum
fu¨r Molekulare Medizin, Ko¨ln, Germany). The purity of
the proteins was >95% as judged by SDS–PAGE.
Quantitative polymerization assay
RNA-dependent DNA polymerase activity was quanti-
tated on a poly(rA)/oligo(dT)15 substrate (0.2U/ml)
(Roche Diagnostics GmbH, Mannheim, Germany) in a
standard assay (30ml reaction volume) as described
previously (12,13) with 150 mM TTP and 41.7Ci/ml
[3H]TTP (49.9Ci/mmol; MP Biomedicals Inc., Irvine,
CA, USA) in reaction buffer [50mM Tris/HCl, pH 8.0,
80mM KCl, 6mM MgCl2, 0.5mM dithiothreitol (DTT),
0.05% Triton X-100]. Samples were pre-incubated for
2min at 378C. The reaction was started by the addition of
12 nM of PR–RT. After 10min, 7.5ml aliquots were taken
out and spotted on DEAE filter paper and treated as
described (12,13). Under these conditions 1 U of enzyme
activity catalyzes the incorporation of 1 nmol of TTP into
poly(rA)/oligo(dT)15 in 10min at 378C. For the determi-
nation of KM and vmax values, reactions were performed
with increasing concentrations of TTP of 25, 50, 75 or
125mM. KM– and vmax–values were calculated by linear
regression using Eadie–Hofstee plots.
5’-end labeling of primers
One hundred picomoles of M13 primer (50-GTAAAA
CGACGGCCAGT) or P30 primer (GCTCTAATGGCG
TCCCTGTTCGGGCGCCTC) (IBA, Go¨ttingen,
Germany) was labeled with 60 mCi g[32P]-ATP with 2U
T4 polynucleotide kinase (New England Biolabs,
Frankfurt, Germany) for 1 h at 378C. After inactivation
of the kinase for 20min at 658C the primer was purified via
a MicroSpin column (GE Healthcare, Munich, Germany).
Chain termination assay
Chain termination assays were performed using single-
stranded M13mp18 (Roche Diagnostics GmbH,
Mannheim, Germany). The 50 32P-labeled M13 primer
was hybridized to a 1.2-fold molar excess of the M13
DNA in a buffer containing 50mM Tris/HCl, pH 8.0 and
80mM KCl by heating to 958C for 2min, followed by a
transfer to a heating block at 708C and slow cooling to
room temperature. Reaction mixtures contained 6 nM of
primer/template substrate (P/T), 85 nM of PR–RT,
150 mM of each dNTP and increasing concentrations of
AZTTP (GeneCraft GmbH, Lu¨dinghausen, Germany) in
a total volume of 10 ml. After a pre-incubation time of
5min, reactions were carried out for 10min at 378C in
reaction buffer (see above). Reactions were stopped by
adding 10 ml of urea loading buffer [1mM EDTA, 0.1%
xylene cyanole, 0.1% bromophenol blue, 8M urea in
1TBE (Tris/Borate/EDTA)] and analyzed by denatur-
ing gel electrophoresis (10% polyacrylamide, 7M urea).
The reaction products were visualized by autoradiography
or phosphoimaging and quantitated by densitometry
using a phosphoimaging device (FLA 3000, raytest,
Straubenhardt, Germany).
Fluorescence anisotropy measurements
Fluorescence equilibrium titrations were performed to
determine the dissociation constants (KD) for nucleic acid
binding with a 24/40-mer DNA/DNA or DNA/RNA
P/T substrate with the following sequences for the primer
50-ATCACCAGGAGAGGGGAAAGCGGA and tem-
plate 50-DY647-CTAATTCCGCTTTCCCCTCTCCTG
GTGATCCTTTCCATCC (biomers.net GmbH, Ulm,
Germany). The RNA template sequence was identical,
containing U instead of T. The templates harbored the
fluorescent dye DY647 at their 50 ends. Titrations were
performed in fluorescence buffer (50mM Tris/HCl, pH
8.0; 80mM KCl, 10mM EDTA, 0.5mM DTT) in a total
volume of 1 or 2ml using a 10 4mm quartz cuvette
(Hellma GmbH, Mu¨hlheim, Germany). The excitation
wavelength was at 552 nm, and the emission intensity was
measured at 573 nm. Slit widths were set at 4.9 and 5.0 nm
for excitation and emission, respectively. All anisotropy
measurements were performed at 258C with 15 nM of
fluorescently labeled P/T using an L-format Jobin-Yvon
Horiba Fluoromax fluorimeter equipped with an auto-
matic titration device (Hamilton). Following sample
equilibration, at least six data points with an integration
time of 1 s were collected for each titration point.
Data fitting. Data were fitted to a two-component
binding equation to determine the equilibrium dissocia-
tion constant (KD) using standard software. The aniso-
tropy was calculated from:
A ¼ fcomplex Acomplex þ fRNA ARNA 1
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where A, Acomplex and ARNA represent the anisotropy
values and fcomplex, fRNA the fractional intensities. The
change in fluorescence intensity has to be taken into
account, so that the fraction bound is given by
½complex
½RNA0
¼ A ARNAðA ARNAÞ þ RðAcomplex  AÞ 2
with
½complex ¼ KD þ P½ 0þ RNA½ 0
 

ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
KD þ P½ 0þ RNA½ 0
 24 P½ 0 RNA½ 0
q 
 2 RNA½ 0
3
where A is the anisotropy, ARNA is the initial free
anisotropy, Acomplex is the anisotropy of the protein–
RNA complex and P0 and RNA0 represent the total
protein and RNA concentrations, respectively. R is the
ratio of intensities of the bound and free forms.
Termination of the radioactively labeled P/T with AZTTP
The [32P] end labeled P30 DNA primer was hybridized to a
template deoxyoligonucleotide T50 (5
0-GCTGTGGAAAA
TCTCATGCAGAGGCGCCCGAACAGGGACGCCA
TTACAGC) (IBA; Go¨ttingen, Germany) as described
for the M13 DNA and used for incorporation of AZTTP.
P30/T50 measuring 100 nM were mixed with 100 mM
AZTTP and 150 nM WT PR–RT in reaction buffer and
incubated for 2 h at 378C. After phenol extraction and
ethanol precipitation, the P/T substrate was purified over
two MicroSpin columns (GE Healthcare, Munich,
Germany) to eliminate protein and excess AZTTP.
Excision assay
Ten nanomolar of the [32P] P30-AZTMP/T50 substrate were
incubated with 20 nM PR–RT in a volume of 10 ml in
reaction buffer for the times indicated. Either 150 mM of
Na-pyrophosphate (PPi) or 5mM of ATP was present in
the mixture. Reactions were started by the addition of
enzyme. Where stated, the samples were pre-incubated for
5min with 0.02U of pyrophosphatase (Sigma–Aldrich
Chemie GmbH, Taufkirchen, Germany). When different
concentrations of PR–RTs were tested, the reactions were
stopped after 20min. An equal volume of urea loading
buffer was added and the products were analyzed as stated
above on denaturing polyacrylamide urea gels.
Primer rescue
One hundred micromolar of dCTP, dGTP, TTP and
ddATP was added to the samples with 5mM ATP
described above to allow for elongation by 4 nt once the
AZTMP is excised. Samples were pre-incubated for 5min
with 0.02U of pyrophosphatase before the reaction was
started with 40 nM of PR–RT. Reactions were stopped
after 10min and treated further as described above.
RESULTS
We have shown previously that it is possible to generate
AZT-resistant SFVmac in cell culture which is able to
replicate in medium containing 1mM AZT (7). Four
mutations were necessary to confer high resistance to the
virus: K211I, I224T, S345T and E350K. Since one
published genomic sequence of wild-type SFVmac already
harbors a threonine at position 224 of Pol and since
several other primate FV Pol proteins also possess a
threonine at position 224, the wild-type SFVmac might
have a polymorphism at this site. Thus, we decided to
analyze a triple mutant PR–RT lacking the I224T
mutation [mt3; (D24A), K211I, S345T and E350K] as
well as the quadruple mutant harboring I224T [mt4;
(D24A), K211I, I224T, S345T and E350K]. To avoid
autoprocessing of the PR domain, the enzymes also
contained a D24A amino acid exchange in the active site
of the PR. Our data below indicate that this mutation does
not influence the polymerization activities of the mutants.
The purified enzymes were used to determine kinetic
parameters of polymerization and to analyze the AZT
resistance mechanism.
Polymerization activities
In order to characterize the AZT-resistant PR–RT
enzymes we performed various polymerization assays.
First, the specific activities of the enzymes were deter-
mined by observing the 3H-TTP incorporation into
poly(rA)/oligo(dT)15 (Table 1). Our results indicate that
the D24A mutation of the WT does not interfere with
polymerization activities. Furthermore, the activity of mt3
is reduced to 38% of WT activity, whereas the
additional mutation I224T of mt4 helps this enzyme to
regain activity (80% of WT). These effects are even more
pronounced regarding the replication activity of the
corresponding mutant viruses (7): the virus replication
activity of the virus containing mt3 was severely reduced
(8.6% of WT) whereas the virus containing mt4 displayed
a replication activity similar to the WT virus (113%
of WT).
Dissociation constants
As shown above, polymerization activities of the two
mutants are impaired. Since this might have an impact on
AZT resistance, we wanted to analyze some kinetic
parameters. To check if the reduced polymerization
activity is due to changes in the affinity for nucleic acids,
Table 1. Quantitative analysis of RNA-dependent DNA polymerase
activities on a homopolymeric substrate
Enzyme U/mg protein 10min
WT 30.9 ( 0.9)
WT 31.5 ( 0.1)
mt3 11.6 ( 0.2)
mt4 24.6 ( 0.7)
Activities are given in units per microgram of protein, where 1U
catalyzes the incorporation of 1 nmol TTP in poly(rA)/oligo(dT)15 in
10min at 378C.
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we determined the KD-values for nucleic acid binding.
Measurements were performed using fluorescence aniso-
tropy titrations with 24/40mer DNA/RNA or DNA/DNA
P/T substrates harboring a fluorescent dye (DY647) at the
50 end of the template strand (Table 2, Figure 1). The
KD-values obtained show that there is no significant
difference in substrate binding affinities of WT and mutant
enzymes, implying that neither the D24A mutation nor the
AZT-resistance mutations influence substrate binding.
The affinity for the DNA/RNA substrate appears to be
slightly higher than for DNA/DNA.
Determination ofKM and vmax values
This analysis was performed using poly(rA)/oligo(dT)15 as
a substrate (Table 2). Both AZT-resistant enzymes, mt3
and m4, reveal elevated KM-values as compared to the two
WT proteins. However, the vmax value of mt4 is higher
than that of mt3 and comparable to the WT proteins,
indicating that mt4 is able to exhibit similar polymeriza-
tion activities like the WT at saturating dNTP concentra-
tions. This might explain the high virus replication
activities observed with mt4 containing virus in cell
culture assays (7).
Polymerization in the presence of AZTTP
Two mechanisms for AZT resistance have been described.
HIV-2 RT controls the incorporation of the inhibitor
nucleotide AZTTP (11), whereas for HIV-1 RT excision of
the incorporated AZTMP has been recognized as the
mechanism of resistance (8–10). Thus, we first analyzed
the polymerization behavior of the enzymes in the
presence of AZTTP to check for incorporation control.
We performed polymerization assays on poly(rA)/
oligo(dT)15 in the presence of increasing AZTTP concen-
trations up to 150 mM (Figure 2A). The TTP concentra-
tion was kept constant (150mM) in all assays. Our data
indicate that mt3 and mt4 do not exhibit AZT resistance
in this assay.
We then used the heteropolymeric single-stranded M13
substrate with a 32P-endlabeled DNA-primer for poly-
merization in the absence of inhibitor or in the presence of
5 and 50 mM AZTTP and analyzed the polymerization
products on denaturing polyacrylamide gels (Figure 2B).
As already described for the homopolymeric substrate, all
enzymes are sensitive to AZTTP addition in the M13
assay. This result is reminiscent of HIV-1 RT (14), where
the AZT resistance was also not visible in steady-state
polymerization assays or during pre-steady-state analyses
and could only be detected with an AZTMP-terminated
P/T substrate (8–10). Our results indicate that the
resistance mechanism of SFVmac PR–RTs is not compar-
able to HIV-2 RT where discrimination between the
inhibitor and TTP takes place during incorporation (11).
AZTMP excision form a terminated primer
For HIV-1 RT, it has been shown previously that AZTMP
can be excised from an AZTMP-terminated P/T substrate
in the presence of PPi or ATP (8–10). We thus tested these
possibilities.
The 32P-endlabeled and AZTMP-terminated substrate
P30-AZTMP/T50 was incubated with 150 mM Na-PPi or
5mM ATP and PR–RT. Time course experiments were
performed (Figures 3 and 4) and aliquots were analyzed
on denaturing sequencing gels and quantified by densito-
metry. Our data indicate that in the presence of PPi the
WT PR–RT can excise AZTMP from the terminated
primer with similar efficiency as mt3 or mt4 (Figure 3B).
Obviously, the ability to perform the reverse reaction of
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Figure 1. Determination of KD-values by fluorescence anisotropy
measurements. Fifteen nanomolar of a fluorescently labeled DNA/
DNA (A) or DNA/RNA (B) P/T substrate was titrated with different
PR–RTs at 258C. The curves show the best fit to Equation (3)
(‘Materials and methods’ section) describing the binding equilibrium
with KD-values shown in Table 2.
Table 2. Parameters for P/T binding and the incorporation of dNTPs
Enzyme KD
DNA/RNA
(nM)
KD
DNA/DNA
(nM)
KM (mM) Vmax
(pmol/min)
WT 32.4 ( 4.2) 36.4 ( 2.4) 40.1 ( 4.0) 29.6 ( 1.7)
WT 30.4 ( 2.4) 44.0 ( 3.7) 40.3 ( 4.0) 29.6 ( 1.3)
mt3 28.3 ( 2.7) 39.5 (3.0) 103.0 ( 16.0) 25.8 ( 2.5)
mt4 31.3 ( 3.2) 42.4 ( 3.0) 112.0 ( 4.0) 30.1 ( 3.3)
KD-values were obtained by using Equation (3) to fit a curve to
the titration data (see ‘Materials and Methods section’). KM- and
vmax-values were determined by Eadie–Hofstee plots.
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nucleotide incorporation is an intrinsic property of RTs
and might be used as a general proof reading function.
In contrast, when ATP is added (Figure 4), even after an
incubation time of 20min the WT enzyme does not
exhibit significant AZTMP removal activity, whereas mt3
and mt4 are able to excise AZTMP efficiently. To exclude
an influence of PPi in the excision reaction, an additional
assay was performed after pre-incubating the reaction mix
with pyrophosphatase (Figure 4B). The results shown in
Figure 4A and B look very similar, indicating that only
insignificant amounts of PPi were present in the reactions.
Quantification of the data of Figure 4B by densitometry
(Figure 4C) demonstrates that the excision reactions of
mt3 and mt4 are much faster than that of the WT.
However, they slow down when about 10% of the
incorporated AZTMP is eliminated from the primer.
This might be due to product inhibition by AZTp4A (15).
These data clearly indicate that AZTMP excision in the
presence of ATP is the valid mechanism for AZT
resistance of SFVmac.
To substantiate our results, we performed the excision
reactions with ATP using increasing concentrations of
enzyme (Figure 5). The assays were also pre-incubated
with pyrophosphatase. Again, our results demonstrate
very clearly that in the presence of ATP the mutant
enzymes are more efficient in AZTMP removal than the
WT. Furthermore, in the case of the mutants, large excess
of enzyme leads to the excision of more than one
nucleotide.
Primer rescue
The data delineated above are further confirmed by testing
the enzymes in the presence of dNTPs to allow for
extension of the primer after AZTMP removal (Figure 6).
The assay was performed in the presence of ATP and
pyrophosphatase. Due to the addition of ddATP, elonga-
tion of the primer comes to a halt after the incorporation
of 4 nt. Figure 6 shows that only mt3 or mt4 can rescue
DNA synthesis, whereas the WT enzyme is not able to
extend the primer.
We thus conclude that AZT resistance of SFVmac
is due to AZTMP removal by ATP. Furthermore, the
AZTMP excision activity obtained with the triple mutant
is comparable to that of mt4. This data indicates that the
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Figure 2. Polymerization activities in the presence of AZTTP. (A)
Specific activities on 6 nM of poly(rA)/oligo(dT)15 with 12 nM of the
various SFVmac PR–RTs, 150mM TTP and 0, 0.5, 5.0, 30.0 or 150mM
AZTTP. The reaction was stopped after 10min at 378C. (B) Chain
termination by AZTMP incorporation during DNA polymerization
with M13 ssDNA (for conditions and analysis see ‘Materials and
methods’ section). Either no AZTTP (lane 1), 5 mM (lane 2) or 50 mM
(lane 3) of AZTTP was added to the PR–RTs. DNA size markers are
indicated on the left.
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Figure 3. Time course of AZTMP removal in the presence of PPi.
(A) One hundred micro molar NaPPi was present in a mix containing
10 nM of an AZTMP-terminated P/T P30-AZTMP/T50 that was labeled
with 32P at the 50 end of the primer. The reaction was started by the
addition of 20 nM of the different PR–RTs and stopped at the time
points indicated. Lane C, no enzyme added. (B) Quantification of
pyrophosphorolytic removal of chain-terminating AZTMP was
achieved by densitometry. The percentage of remaining terminated
primer is shown.
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additional I224T change of mt4 is not important for the
AZT-resistance mechanism but is necessary to improve
the polymerization efficiency.
DISCUSSION
We have shown previously that SFVmac can gain
resistance to the nucleoside inhibitor AZT (7). Here, we
analyzed the corresponding mutated PR–RTs to elucidate
the mechanism of AZT resistance. Our results obtained
with purified SFVmac PR–RTs demonstrate that in the
case of SFVmac the AZT-resistance mechanism is due to
AZTMP removal in the presence of ATP. Remarkably,
mt3 which exhibited severely impaired polymerization
activities on homo- and heteropolymeric substrates
(Table 1 and Figure 2) also shows higher AZTMP
excision activities than the WT enzyme when ATP is
present in the reaction (Figures 4–6). Although mt3 and
mt4 are also able to excise AZTMP in the presence of PPi
(Figure 3) the WT PR–RT exhibits similar efficiency in
this reaction, indicating that this cannot be the mechanism
of AZT resistance.
Interestingly, compared to the WT SFVmac PR–RTs,
mt3 and mt4 exhibit differences in kinetic parameters. This
is also noteworthy since the AZT-resistant HIV-1 RT did
not differ from the WT HIV-1 RT in its kinetic parameters
(14,16–18). The KM values of the mutant SFVmac
PR–RTs are about 2.5-fold higher than those of the WT
PR–RTs. While mt3 also shows a reduced value for vmax,
the I224T mutation of mt4 is obviously responsible for an
increase of vmax similar to that of the WT levels (Table 2),
implying that if saturating dNTP concentrations are
present in infected cells, reverse transcription will not be
greatly impaired in SFVmac viruses harboring mt4. This
result indicates that the mutation I224T is important for
viral fitness since it can reconstitute the polymerization
activity of mt4 in SFVmac-infected cells (7).
It has been demonstrated previously that the RTs of
HIV-1 and HIV-2 use different mechanisms for AZT
resistance. HIV-2 can discriminate between AZTTP and
TTP during nucleotide incorporation (11). In contrast,
although certain HIV-1 RT mutations confer a 100-fold
decrease in the sensitivity to AZT in vivo (19,20), this effect
could not be demonstrated in in vitro assays (14,16–18),
indicating that HIV-1 RT is not able to discriminate
between AZTTP and TTP. In fact, the mechanism appears
to be due to a removal of the chain terminating AZTMP
residue after it has been incorporated in the DNA chain.
The mutations involved in the enhanced excision of
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Figure 4. Time course of AZTMP removal in the presence of ATP.
(A) Five millimolar ATP was present in a mix containing 10 nM of the
AZTMP-terminated P/T P30-AZTMP/T50 that was labeled with
32P at the
50 end of the primer. The reaction was started by the addition of 20 nM
of the different PR–RTs and stopped at the time points indicated.
(B) Addition of 0.02U pyrophosphatase to the mixture described in
(A) 5min before the PR–RT enzymes were added. Lane C, no enzyme
added. (C) Quantification of (B) by densitometry. The percentage of
remaining terminated primer is shown.
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Figure 6. ATP-dependent rescue of AZTMP terminated DNA synth-
esis. (A) Primer rescue reactions using 10 nM P30-AZTMP/T50 were
performed with 5mM ATP, 0.02U pyrophosphatase and 100 mM
dCTP, dGTP, TTP and ddATP. Lane C, no enzyme added.
(B) Quantification of (A) by densitometry. The percentage of the
remaining unextended primer is shown.
Figure 5. AZTMP removal by ATP in the presence of pyrophosphatase
using increasing PR–RT concentrations. Five millimolar ATP and
10 nM of P30-AZTMP/T50 were pre-incubated for 5min at 378C in
reaction mix. The reaction was started by the addition of different
concentrations of the various PR–RTs as indicated and stopped after
20min. Lane C, no enzyme added.
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AZTMP in HIV-1 RT are M41L, D67N, K70R, T215Y/F
and K219Q/E (Figure 7) (8–10,21,22). Removal of the
inhibitor was suggested to be accomplished by two
mechanisms that use different substrates to carry out the
reaction. AZTMP removal can take place either in the
presence of PPi or ATP. The chemistry involved in
pyrophosphorolysis and the ribonucleotide-dependent
phosphorolysis reaction is similar. Removal of the
chain-terminating AZT results from nucleophilic attack
of a polyphosphate in the phosphodiester bond between
the last but one nucleotide and the AZTMP. In case of
PPi, this leads to removal of the 3
0 AZTMP by creating
AZTTP.
There is evidence that the phosphate donor in the
excision reaction of AZT-resistant HIV-1 RT is ATP,
leading to an ATP-AZTMP dinucleotide-tetraphosphate
(adenosine-30azido,30deoxthymidine-50-50-tetraposphate,
AZTp4A). For HIV-1 RT it was concluded from
biochemical and structural data that the exchange of
T215 to an aromatic residue (T215F/Y) enhances binding
of ATP, but not PPi, thus facilitating excision. The model
suggests that in the AZT-resistant enzyme, the adenine
moiety of the incoming ATP makes – interactions with
the aromatic ring of the mutated amino acid (22–26).
Our results obtained with SFVmac PR–RT are espe-
cially interesting when comparing the AZT-resistance
mutations of HIV-1 RT and SFVmac PR–RT since in
the latter enzyme no mutation leading to an aromatic side
chain is present. In addition, sequence alignments of the
polymerase domains of HIV-1 and SFVmac reveal that
the amino acid exchanges obtained with SFVmac are not
the ones corresponding to the exchanges in HIV-1 RT
(Figure 7). Furthermore, although the homology between
PFV and SFVmac is around 90%, introduction of
the SFVmac RT mutations into PFV did not result in
AZT-resistant viruses (7).
These findings might indicate structural differences
between HIV-1 and SFVmac RTs. This appears to be
plausible since the RT domains of HIV-1 and SFVmac are
phylogenetically rather distantly related (27). Thus, the
interpretation of alignment data is also rather difficult. In
addition, differences in the mechanism of ATP binding
and/or ATP-mediated excision are possible. Structural
analysis of WT and AZT-resistant SFVmac PR–RT are
under way and will help to elucidate the differences
between WT and mutant PR–RTs and also between
HIV-1 and SFVmac.
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Abstract The backbone and side chain assignments of
the retroviral aspartate protease from Simian Foamy Virus
from macaques (SFVmac) have been determined by triple
resonance NMR techniques.
Keywords SFVmac  Retroviral protease 
Heteronuclear NMR  Sequence-specific assignment
Biological context
Spumaviruses, or Foamy Viruses (FV), belong to the ret-
roviridae and follow a replication pattern unique among
retroviruses: (a) reverse transcription occurs before the
virus leaves the host cell, (b) the pol-gene is expressed from
a separate mRNA and (c) the viral protease is not cleaved
off the Pol polyprotein (Linial 2007; Rethwilm 2003). Thus,
the reverse transcriptase (PR-RT) harbors a protease,
polymerase and RNase H domain. Genetic analysis has
shown that the FV protease (PR) is absolutely required for
infectivity and processing (Konvalinka et al. 1995).
Retroviral proteases belong to the family of aspartic acid
proteases and have been shown to be active as homodi-
mers. The active site amino acid residues Asp-Thr/Ser-Gly
from each chain contribute to the symmetric active site of
the enzyme (Pearl and Taylor 1987). A second sequence
motif Gly-Arg-Asp/Asn that can be found in most retro-
viral PRs corresponds to Gly-Arg-Lys in FV PRs (Pearl
and Taylor 1987). However, apart from these two motifs,
FV PRs show very little sequence homology to other
retroviral PRs. Moreover, the molecular weight of mono-
meric FV PRs is around 18 kDa whereas other retroviral
PR monomers possess a molecular weight of ca. 10 kDa.
For further analysis of FV PRs we used the PR domain of
Simian Foamy Virus from macaque (SFVmac). Sequence
comparisons of human immunodeficiency virus type 1
(HIV-1) PR (96 residues) and SFVmac PR (143 residues)
showed that the two enzymes exhibit about 30% sequence
similarity only in the N-terminal part of the SFVmac pro-
tein. The extended C-terminus which cannot be found in
other retroviral PRs does not show any similarity, indi-
cating that it might not be necessary for activity.
Furthermore, gel filtrations experiments with the purified
PR-RT of our group (data not shown) indicate that PR-RT
is monomeric, raising the interesting question, how and
when in the viral life cycle SFVmac PR dimerizes and
functions. To further address this question, a high-resolu-
tion structure of SFVmac PR is desirable. As an initial step
we cloned and expressed a recombinant SFVmac PR,
called SFVmac PRshort (aa1-102), lacking the C-terminal
region. The purified protein also elutes as a monomer as
shown by gel filtration experiments (data not shown). We
virtually completely assigned the 1H, 13C and 15N reso-
nances of SFVmac PRshort with multidimensional
heteronuclear NMR and determined the secondary struc-
ture by chemical shift analyses.
Methods and results
The DNA coding for SFVmac PRshort was cloned into
pET28c (Novagen). The protein was expressed in the
Escherichia coli strain Rosetta DE3 (Novagen) and con-
tained a 6 · His tag at the C-terminus. Expression was
induced by adding 0.2 mM IPTG at 16C over night. The
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protein was purified by immobilized Ni2+ affinity chro-
matography under native conditions.
The enzymatic activity of the purified PRshort was
tested using a synthetic peptide (TQGSYVVH;CNTTP)
harboring the natural cleavage site of the PR in the Pol-
precursor protein which is located between the reverse
transcriptase and integrase domains. PRshort proved to be
active and was able to cleave the peptide at the predicted
position, as indicated by the arrow. Cleavage products were
detected by ESI mass spectrometry (data not shown).
For NMR studies SFVmac PRshort was dissolved at a
concentration of 2 mM in 50 mM Na-phosphate pH 7.4,
100 mM NaCl, 0.5 mM DTT, and 10% (v/v) D2O.
All NMR spectra were acquired at 25C on a Bruker
Avance 700 MHz spectrometer equipped with a cryogen-
ically cooled probe. HNCO, HNCACB, CBCA(CO)NH,
CCONH, HBHA(CO)NH, HC(C)H-TOCSY (Bax and
Grzesiek 1993; Sattler et al. 1999) 3D NMR experiments
were recorded for backbone and aliphatic side chain reso-
nance assignment. Assignment of aromatic resonances was
achieved with a [1H, 13C]-HSQC spectrum recorded in the
aromatic region and 3D 13C-edited NOESY experiments.
The NMR data was processed using in-house written
software and analyzed with the program package NMR-
view (B.A. Johnson, Merck, Whitehouse Station, NJ,
USA).
Fig. 1 (A) [1H, 15N] spectrum of the uniformly 15N/13C labeled
SFVmac PRshort. NH2 side chains are connected by lines, the
arginine eNH, and the tryptophane NH are marked by ‘sc’. (B)
Secondary chemical shift indices for Ha, Ca, CO nuclei, and the
consensus of SFVmac PRshort. Deduced b strands are represented by
arrows, and helical regions by cylinders
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Extent of assignment and data deposition
Analysis of triple resonance data allowed the assignment of
backbone resonances for all residues except Met1-Asp2,
Ile51 and the carboxyterminal region Leu98-His107 con-
taining the hexa-His-Tag. Side chain 1H and 13C shifts are
nearly complete for the sequence region Pro3-Pro97 with
few exceptions of some longer side chains. An assigned
[1H, 15N] HSQC spectrum is shown in Fig. 1.
The secondary chemical shifts of 1Ha, 13Ca and 13CO
indicate a mainly b sheet protein. The location of the b
strands along the primary sequence is similar to the HIV
protease.
The SFVmac-PRshort assignments have been deposited
in the BioMagResBank, accession code 15403.
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In contrast to orthoretroviruses, foamy viruses (FVs) express their Pol
polyprotein from a separate pol-specific transcript. Only the integrase
domain is cleaved off, leading to a protease-reverse transcriptase (PR-RT)
protein. We purified the separate PR domain (PRshort) of simian FV from
macaques by expressing the recombinant gene in Escherichia coli.
Sedimentation analyses and size exclusion chromatography indicate that
PRshort is a stable monomer in solution. This allowed us to determine the
structure of the PRshort monomer using 1426 experimental restraints
derived from NMR spectroscopy. The superposition of 20 conformers
resulted in a backbone atom rmsd of 0.55 Å for residues Gln8–Leu93.
Although the overall folds are similar, the macaque simian FV PRshort
reveals significant differences in the dimerization interface relative to other
retroviral PRs, such as HIV-1 (human immunodeficiency virus type 1) PR,
which appear to be rather stable dimers. Especially the flap region and the
N- and C-termini of PRshort are highly flexible. Neglecting these regions,
the backbone atom rmsd drops to 0.32 Å, highlighting the good definition
of the central part of the protein. To exclude that the monomeric state of
PRshort is due to cleaving off the RT, we purified the complete PR-RT and
performed size exclusion chromatography. Our data show that PR-RT is
also monomeric. We thus conclude adoption of a monomeric state of PR-
RT to be a regulatory mechanism to inhibit PR activity before virus
assembly in order to reduce packaging problems. Dimerization might
therefore be triggered by additional viral or cellular factors.
© 2008 Elsevier Ltd. All rights reserved.
Edited by M. F. Summers
Keywords: retroviral protease; foamy virus; NMR spectroscopy; monomer;
protein structure
Introduction
Spumaviruses or foamy viruses (FVs) possess a
genomic organization typical for retroviruses, har-
boring the genes gag, pol and env. Furthermore,
similar to HIV-1 (human immunodeficiency virus
type 1), they express additional so-called accessory
genes, which are important for regulatory processes.
However, the replication of FVs differs from that of
orthoretroviruses in some aspects.1 Reverse tran-
scription takes place to a large extent before the
progeny virus leaves the cell, resulting in a double-
stranded DNA genome.2–4 Furthermore, the proper-
ties of the Pol protein and the reverse transcriptase
(RT) are different.5 In typical retroviruses, Pol and
thus protease (PR) are part of the Gag–Pol precursor
protein. FVs synthesize Pol from a separate mRNA,
and the N-terminal PR of the Pol precursor is not
cleaved off the RT. Thus, the mature RT found in
virions is actually PR-RT.6,7 Genetic analyses have
shown that PR activity is absolutely required for FV
infectivity and processing.8 The activity of the FV PR
must be highly regulated to avoid premature
processing of Gag and Pol prior to virus assembly.
Retroviral PRs are aspartyl PRs and have been
shown to be only active as symmetric homodimers
with a single active site formed by the residues DS/
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Abbreviations used: FV, foamy virus; GFP, green
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TGoriginating fromeachmonomer.9–11 Three-dimen-
sional structure analyses of several retroviral PRs by
either NMR or X-ray crystallography show that
despite large differences in the amino acid sequences,
the global folds of these PRs are rather similar.10–13
Retroviral PRs consist mainly of β-strands and a few
short α-helical regions. The number and lengths of
these elements vary depending on the PR species. In
general, the PR monomer exhibits four characteristic
structural elements: (1) a hairpin containing the A1
loop; (2) a large B1 loop, or “fireman's grip,” contain-
ing the conserved DS/TG motif forming the active
site; (3) an α-helix; and (4) a second large loop D1,
which is also called the “flap” region. The fireman's
grip, the flap region and the N- and C-terminal
regions, which form a four-stranded β-sheet, are
essential for PR dimerization.
Here, we present the structure of the PR domain
(PRshort) from simian FV frommacaques (SFVmac).
Our results show that PRshort is a stable monomer
but that, under certain conditions using high NaCl
concentrations of 2–3 M, PR activity can be
observed. Since the PR of FVs is not cleaved off the
RT during virus maturation, we also analyzed the
monomer/dimer state of recombinant PR-RT from
SFVmac. Gel filtration analyses indicate that PR-RT
is also monomeric. Our results have implications on
the regulation of PR activity during virus assembly
and maturation.
Results
Analytical ultracentrifugation and size exclusion
chromatography
Experiments using prototype FV (PFV, formerly
HFV) PR implied that a potential cleavage site between
the PR and RT domains is located after residue Asn143
of the Pol protein.14 Since PFV and SFV exhibit high
sequence homology and possess the same putative
cleavage site between PR and RT,14 we expressed the
corresponding 143-amino-acid-long SFVmac PR. The
18-kDa PR domain of SFVmac PR-RT exhibits proteo-
lytic activity at NaCl concentrations of 2 M and higher
when expressed separately. At low NaCl concentra-
tions, no activity can be detected (data not shown). Gel
filtration experiments indicated a high tendency of the
protein to aggregate.
Sequence comparisons of HIV-1 PR (99 residues)
with the 18-kDa SFVmac PR (143 residues) revealed
a sequence similarity of about 29%, albeit only in the
N-terminal part of the SFVmac protein. The C-
terminal region of SFVmac PR does not show any
homology (Fig. 1). Possibly, the non-homologous
region serves only as a flexible linker between the PR
and polymerase domains. We thus decided to
construct an SFVmac PR that is similar in size to
HIV-1 PR. SFVmac PRshort spans the region
homologous to HIV-1 PR and has a molecular
mass of approximately 12.6 kDa, including a C-
terminal 6× His tag.
Analysis of the protein by size exclusion chroma-
tography indicated that SFVmac PRshort is a
monomer. Tests were done in a buffer containing
either 300 mM (data not shown) or 2 M NaCl, since
we could detect proteolytic activity of SFVmac
PRshort at the latter concentration. However, even
at 2 M NaCl, no dimer is detectable (Fig. 2a). This
was surprising since retroviral PRs are only active as
homodimers.10,11 To confirm our results, we deter-
mined the molecular mass of PRshort by analytical
ultracentrifugation (Fig. 2b). Sedimentation analysis
resulted in a molecular mass of 11.6 kDa, proving
the protein to be monomeric.
To exclude the possibility that the monomeric
state of SFVmac PRshort is an artifact due to
expression of the separate PR domain, we also
performed size exclusion chromatography of recom-
binant SFVmac PR-RT, which represents the mature
polymerase in FV virions. Analyses were done at
300 mM (data not shown) and 2MNaCl (Fig. 3). The
results of the two experiments were comparable,
and our data indicate clearly that PR-RT is also
monomeric.
PR activity
Activity of retroviral PRs is exhibited only by the
PR dimer.10,11 We thus determined whether PRshort
and PR-RT do possess PR activity. A GB1–green
fluorescent protein (GFP) fusion protein harboring
the natural Pol cleavage site between GB1 and GFP
was used as a substrate. Since it was shown
previously that PFV PR is only active at high salt
concentrations,15,16 PR activities were analyzed at
0.1, 2 and 3 M NaCl. Our data show clearly that at
0.1 M NaCl, no cleavage product can be detected
Fig. 1. Sequence comparison of
HIV-1 and SFVmac PRs. The amino
acid sequence of SFVmac PRshort is
highlighted in gray.
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even after an incubation time of 16 h at 37 °C (Fig. 4).
However, cleavage can be observed at 2 M and is
even more pronounced at 3 M NaCl, indicating that
dimerization is facilitated at higher NaCl concentra-
tions. Furthermore, although we were able to detect
cleavage of the GB1–GFP substrate, we did not
observe any cleavage of the PR-RT due to autopro-
cessing. This is an additional confirmation that
cleavage between PR and RT does not take place in
the FV life cycle.
Additionally, we analyzed by NMR spectroscopy
whether a peptide representing the cleavage site
between the RNase H and IN domains could bind to
SFVmac PRshort and initialize dimerization. Addi-
tion of a threefold excess of peptide to 500 μMprotein
at a NaCl concentration of 100 mM did not lead to
any signal changes in 1H,15N heteronuclear single
quantum coherence spectra, indicating no binding
under these conditions. High NaCl concentrations
(2 M) led to insufficient quality of the spectra.
Fig. 2. Size exclusion chromatography and analytical ultracentrifugation of PRshort. (a) Chromatogram of SFVmac
PRshort using an S75 HR 10/30 column. The run was performed in 100 mMNa–phosphate buffer, pH 7.4, 2 M NaCl and
0.5 mM DTT. The positions of the standard proteins used for column calibration are indicated. (b) Sedimentation velocity
analysis of SFVmac PRshort at 60,000 rpm in 50 mMNa–phosphate buffer, pH 7.4, and 100 mMNaCl. The sedimentation
profiles (top) were monitored at a wavelength of 280 nm and fitted as described in Materials and Methods. The symbols
represent the raw sedimentation data; the lines, theoretical fitted data. The fitting residuals are shown underneath
(middle). The S value, normalized for water at 20 °C [Sw(20,w)], was 1.4415. The bottom panel shows the continuous
sedimentation coefficient distribution of SFVmac PRshort. The calculated molecular mass for SFVmac PRshort is
11,613 Da with a best-fit friction ratio of 1.283. The peak represents 93.488% of the total peak areas.
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NMR structure and dynamics
NMR analyses were performed with ca 1 mM
PRshort in 50 mM Na–phosphate buffer, pH 7.4,
0.5 mMDTTand 10% (v/v) D2O, containing 100mM
NaCl, thus favoring the monomeric state of PRshort.
From the multidimensional NMR experiments, 1426
restraints were derived (Table 1). The final structure
calculation resulted in an ensemble with no distance
restraint violation larger than 0.1 Å and no dihedral
angle restraint violation larger than 3.1° together
with good stereochemical properties displayed by
89%of the residues in themost favored regions of the
Ramachandran map. The superposition of the 20
conformers results in a backbone atom rmsd of
0.55 Å for residues Gln8–Leu93, showing that the
structure is well defined except for the unstructured
N- and C-termini (Fig. 5). Neglecting the flap region
(Pro42–Asp58), which shows significant flexibility
on the picosecond-to-nanosecond timescale as deter-
mined from {1H}15N heteronuclear nuclear Over-
hauser enhancement (NOE) measurements (Fig. 6),
the backbone atom rmsd drops to 0.32 Å, high-
lighting the good definition of the central part of
SFVmac PRshort.
The solution structure of PRshort (Fig. 5) consists of
seven β-strands (β1=Leu10–Ile14, β2=Thr17–Trp23,
β3=Thr30–Pro33, β4=Gln44–Lys49, β5=Glu54–
Val66, β6=Lys70–Ser78, β7=Ile83–Leu85) and a
helical turn (Glu34–Leu37). The β-strands form a
closed barrel-like β-sheet with the strand order
β1–β2–β7–β3–β6–β5(Val59–Val66)–β1. The strands
β2 and β7 are arranged in parallel, while all other
strands are arranged in an anti-parallel manner. The
amino-terminal halves (Glu54–Asp58) of β5 and β4
form a β-hairpin corresponding to the flap region of
retroviral and non-viral aspartate PRs.10 This β-
hairpin is well defined locally by 92 inter-strand
NOEs and backbone ϕ/φ angles, derived from
secondary chemical shifts typical for an extended
conformation for all residues except Ile51 and His52.
Due to missing contacts of residues Gln44–Gln56 to
the core of the protein, a defined orientation of the flap
could not be determined.
The overall fold shows significant similarity with
the monomeric HIV-1 PR (1–95),18 which also
resembles the structure of one subunit of the native
dimeric HIV-1 PR. The backbone heavy atom rmsd
between SFVmac PRshort and HIV-1 PR (1–95) is
1.6 Å, excluding the flap region. Superposition of 11
residues of the loop containing the active site (Lys20–
Thr30) results in a backbone rmsd of 0.32 Å to the
solution structure of the monomeric HIV-1 PR18 and
that of 0.64 Å to the crystal structure of the active
dimeric HIV-1 PR (Protein Data Bank accession code
3HVP).12 The necessary backbone conformation of
the active site is therefore preformed in the mono-
meric structures. The side chains do not show a
defined conformation (e.g., Ser25 of the “fireman's
grip”). Due to their solvent accessibility, highmobility
is expected.
15N relaxation NMR experiments (Fig. 6) were
performed to characterize the dynamics of SFVmac
PRshort. From 15N longitudinal relaxation (1.28±
0.07 s−1 for residues with {1H}15N NOE N0.65) and
15N transverse relaxation (12.99±1.20 s−1 for resi-
dues with {1H}15N NOE N0.65) rates, a rotational cor-
relation time τc of 9.5 ns at a temperature of 298 K for
isotropic rotational diffusion can be derived. Taking
temperature and temperature-dependent solvent
viscosity into account, the expected correlation time
of SFVmac PRshort at 293 K would be 10.9 ns,
which is comparablewith the relaxation data ofHIV-1
PR at 293 K.19–21 This is roughly the average of the τc
values determined for the HIV-1 PR dimer (12.8 ns at
293 K)20 and the HIV-1 PR monomer (8.6 ns at
293 K).21 However, direct comparison is difficult, as
Fig. 4. PR activity assay. The
reaction products were analyzed by
19% SDS-PAGE. A total of 10 μM
GB1–GFP substrate was incubated
with 10 μM SFVmac PR-RTor 10 μM
PRshort at 37 °C for 16 h in a reaction
buffer (50 mMNa–phosphate buffer,
pH 7.4, and 0.5 mM DTT) with
increasing NaCl concentrations as
indicated. C, control, substrate clea-
vage with Tev PR; (−), uncleaved
substrate; and M, molecular weight
standard, with the sizes of the stan-
dard proteins indicated on the right.
Fig. 3. Size exclusion chromatography SFVmac PR-RT.
Chromatogram of SFVmac PR-RTusing an S200 HR 10/30
column. The run was performed in 100 mM Na–
phosphate buffer, pH 7.4, 2 M NaCl and 0.5 mM DTT.
The positions of the standard proteins used for column
calibration are indicated.
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SFVmac PRshort contains a C-terminal His tag,
adding 13 amino acids, which will lead to an in-
creased correlation time.22
SFVmac PRshort, accidentally truncated by pro-
teolytic cleavage at sequence position Gln99–
Leu100, showed a 15N transverse relaxation rate of
10±1 s−1 and an average longitudinal relaxation rate
of 1.5±0.1 s−1, which in turn yielded a rotational
correlation time of 7.3 ns, corresponding to 8.3 ns at
293K. This value is very close to that for theHIV-1 PR
monomer, suggesting that SFVmac PRshort is
monomeric to a very high extent at concentrations
of 1–2 mM. Furthermore, these data imply that the
His tag does not affect the oligomerization state of
the PR.
Fig. 5. Solution structure of the
SFVmac PRshort monomer. A car-
toon representation of the structure
is shown on the left, whereas super-
position of the 20 lowest energy
structures is shown on the right.
The residues of the flap region
Pro42–Asp58 were not included in
coordinate fitting. The figure was
generated using MOLMOL.17
Table 1. Structural statistics
Experimentally derived restraints
Distance restraints
NOE 1338
Intra-residual 205
Sequential 350
Medium range 227
Long range 556
Hydrogen bonds 17
Dihedral restraints 57
Restraint violation
Average distance 0.0037±0.0005 Å
Maximum distance b0.1 Å
Average dihedral 0.21±0.11
Maximum dihedral 3.2°
Deviation from ideal geometry
Bond length 0.00072±0.00004 Å
Bond angle 0.14°±0.008°
Coordinate precisiona (Å)
Gln8–Leu93
Backbone heavy atoms 0.55
All heavy atoms 1.05
Gln8–Arg41; Val59–Leu93
Backbone heavy atoms 0.30
All heavy atoms 0.89
Ramachandran plot statisticsb (%)
Most favored 89.3
Additionally allowed 10.5
Generously allowed 0.1
Disallowed 0.1
a The precision of the coordinates is defined as the average
atomic rmsd between the accepted simulated annealing structures
and the corresponding mean structure calculated for the given
sequence regions.
b Ramachandran plot statistics were determined using
PROCHECK.
Fig. 6. 15N relaxation data of SFVmac PRshort. Long-
itudinal (R1, top) and transverse (R2, middle)
15N
relaxation rates and steady-state heteronuclear {1H}15N
NOE at 14.1 T of SFVmac PRshort at 298 K as a function of
the sequence position.
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The presence of the long unstructured termini of
SFVmac PRshort alters the rotational diffusion
tensor on the timescale of the rotational correlation
time, rendering the separation of overall tumbling
and internal motion difficult and thus preventing
more detailed analysis of the relaxation data.
Therefore, the internal dynamics were characterized
qualitatively using steady-state {1H}15N heteronuc-
lear NOE measurements (Fig. 6). The heteronuclear
NOE shows values larger than 0.68 for residues
Leu10–Gln44 and Val59–Trp92, indicating these
residues to be highly restricted on the picosecond-
to-nanosecond timescale, an observation character-
istic for folded proteins.23 The heteronuclear NOE
decreases towards the amino- and carboxy-termini,
reflecting their high level of flexibility. The residues
of the flap region also show a decreased hetero-
nuclear NOE towards the tip of the flap, indicating a
high level of flexibility on the picosecond-to-nano-
second timescale for these residues.
Discussion
Retroviral PRs are only active as homodimers,
with the catalytic site positioned between the two
identical subunits.10–12,24 Extensive studies with the
HIV-1 PR revealed the regions and sequence posi-
tions important for dimer formation: the essential
structural feature for dimerization is the inter-
monomeric four-stranded β-sheet involving the
amino- and carboxy-termini of retroviral PRs. Since
the carboxy-termini of both monomers form the
inner strands of this β-sheet, truncation of the
carboxy-terminus results in loss of dimer formation.
The amino-termini stabilize the structure. Addition-
ally, Arg87 of HIV-1 PR forms an intra-monomer
hydrogen bond with Asp29. This interaction was
suggested to orient the carboxy-terminus to form the
β-sheet,19,25 and, together with the adjacent residues
(the triad Gly86–Arg87–N/D88), it is highly con-
served in retroviral PRs.10
In SFVmac PRshort, this conserved arginine is
replaced by a proline; therefore, this intra-monomer
hydrogen bond cannot be formed. Furthermore, the
sequence region Asn86–Leu99 (SFVmac PRshort)
contains three prolines (Pro87, Pro91 and Pro97) at
positionswhere retroviral PRs harbor α-helix C2 (e.g.,
HIV-1 PR, Gly86–Gly94) and the terminal β-strand
(HIV-1 PR, Thr96–Phe99). Additionally, a proline
(Pro3) is located in the amino-terminal sequence
region of SFVmac PRshort, corresponding to the
outer strand of the inter-monomeric β-sheet of retro-
viral PRs. The steric requirements for a prolinemake a
location inside a helix or a β-strand unfavorable. This
might prohibit the formation of the essential inter-
monomeric β-sheet in SFVmac PRshort that is
important for dimerization of HIV-1 PR. Thus,
SFVmac PR lacks several important structural fea-
tures necessary for dimer formation as observed for
other retroviral PRs.
Mason–Pfizer monkey virus PR also exists as a
monomer in solution.26,27 For this retroviral PR, the
formation of an intra-molecular disulfide bridge
between a cysteine near theN-terminus and a second
one near the C-terminus is proposed to be the
activating mechanism for dimerization.27,28 SFVmac
PRshort does not contain cysteines at the N- or C-
terminus, rendering such a mechanism impossible.
Finally, SFVmac PR harbors a Ser in the conserved
DT/SG motif of the fireman's grip. For HIV, a
mutation resulting in an exchange of Thr to Ser
resulted in destabilization of the native dimer.29
Furthermore, it was suggested that the fireman's
gripmediates the initial contact of the twomonomers,
which leads to the proper conformation and orienta-
tion of the two polypeptide chains in the dimer,29 in
accordance with a higher dimer instability of FV PRs.
The high level of flexibility observed for SFVmac
PRshort was also found in the truncated monomer19
as well as in the unligated dimer20 of HIV-1 PR. The
tip of the flap is glycine-rich in all retroviral PRs.10 The
sequence region Gly48–Phe53 of HIV-1 PR contains
four glycines (Gly48, Gly49, Gly51 andGly52). Except
for Gly48, all glycines are conserved in retroviral PRs.
PRs, such as feline immunodeficiency virus and Rous
sarcoma virus PRs, where Gly48 is exchanged for
another amino acid contain a glycine at sequence
position 53 (numbering corresponding to HIV-1 PR).
Molecular dynamics calculations suggest that the
opening of the flap of the dimeric retroviral PRs is
essential for substrate entry.30–34 The high number of
glycines introduces the required flexibility by occupy-
ing regions of the Ramachandran map unfavorable
for other amino acids.34 The flap region ofHIV-1 PR is
very intolerant against glycine exchange, highlighting
the important role of this amino acid for activity.35 In
contrast to other retroviral PRs, SFVmac PR contains
only a single glycine, Gly53 (corresponding to Gly52
in HIV-1 PR), in the flap region. Despite the lack of
three glycines in the tip of the flap, a high level of
flexibility on the picosecond-to-nanosecond timescale
still persists as shown by the {1H}15N NOE data.
Gly51Asn substitution in HIV-1 PR in silico demon-
strates a reduced flexibility during molecular dyna-
mics simulations.34 Our experimental data on
SFVmac PRshort suggest that the glycines themselves
are not responsible for increased flap dynamics per se
but probably increase the population of conforma-
tions necessary for substrate binding as proposed by
molecular dynamics simulations.34
The monomeric state of SFVmac PR may be key in
the regulation of the viral life cycle. PR activity is
highly undesirable before polyproteins are packaged
as, otherwise, proteins such as the viral IN, which
does not harbor a packaging signal, will not be taken
up into the virus particle.36 Thus, PR activity is
relevant and tolerable only after complete assembly
of the virus particle, a problem faced by all retro-
viruses. It has been suggested that activation of
retroviral PRs is not solely due to mass action (i.e.,
increase of protein concentration in the virus).37
Even at concentrations of 1 mM protein and in the
presence of a peptide substrate, dimerization of
SFVmac PRshort cannot be detected by NMR,
suggesting that FV PR dimerization can only take
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place under particular conditions that we can mimic
using high NaCl concentrations. How SFVmac PR is
activated is still an unresolved issue, and viral or
even cellular factors may be necessary for PR
dimerization and activation.
Materials and Methods
Protein expression and purification
The plasmid pET28c-SFVmacPRshort38 harboring the
N-terminal 101 amino acid residues of SFVmac PR was
expressed in the Escherichia coli strain Rosetta DE3
(Novagen, Darmstadt, Germany) grown in M9 minimal
medium39 supplementedwith trace element solution TS240
and with (15NH4)2SO4 and 0.4% uniformly labeled
13C
glucose as the onlyN and C sources, respectively.When an
OD600 (optical density at 600 nm) of 0.8–1.0 was reached,
expression was induced by adding 0.2 mM IPTG and the
cells were incubated further at 16 °C overnight. After the
addition of lysozyme, DNase I and one PR inhibitor
cocktail tablet (ethylenediaminetetraacetic acid free; Com-
plete, Roche Diagnostics GmbH, Mannheim, Germany),
cells were lysed by sonication (3×60 s, pulse=1.0, 100%
amplitude) in binding buffer (50 mM Na2HPO4/
NaH2PO4, pH 7.4, 300 mM NaCl, 10 mM imidazole and
0.5 mMDTT) and then centrifuged at 19,000g for 30 min at
4 °C. The protein was purified from the supernatant via the
C-terminal 6× His tag by immobilized Ni2+ affinity
chromatography (1 ml of IMAC, BioRad, Munich, Ger-
many) under native conditions using an imidazole step
gradient and dialyzed against 50 mM Na2HPO4/
NaH2PO4, pH 7.4, 100 mM NaCl and 0.5 mM DTT.
Purification of recombinant SFVmac PR-RT was per-
formed as described previously.41 As judged by SDS-
PAGE, the purity of all proteins used was N95%.
PR activity assay
The SFVmac RT IN cleavage site of the Pol polyprotein
(ATQGSYVVH↓CNTTP) was cloned into the vector
pETGB1a (G. Stier, EMBL, Heidelberg, Germany) between
the GB1 and GFP coding sequences downstream of the
sequence coding for a Tev cleavage site via PCR amplifica-
tion and by using the restriction sites NcoI and PstI in order
to obtain a substrate for SFVmac PR. The plasmid was
transformed into the Escherichia coli strain Rosetta (DE3)
(Novagen). Gene expression was induced at an OD600 of ca
0.8–1.0 by addition of 0.2 mM IPTG to obtain the fusion
protein. Cells were grown overnight at 25 °C. After cell
lysis (as described above), purification of the protein was
done via Ni affinity chromatography (His-Trap, GE
Healthcare, Munich, Germany), followed by chromatogra-
phy over a QXL column (HighTrap, GE Healthcare).
PR activity assays were carried out using 10 μM
concentration of the purified GB1–GFP fusion protein.
GB1–GFP was incubated with 10 μM SFVmac PRshort or
PR-RT or 0.5 μM Tev PR (positive control) at 37 °C for 16 h
in a total volume of 300 μl. The reactions were carried out
in 50 mM Na2HPO4/NaH2PO4, pH 7.4, and 0.5 mM DTT
with 100 mM, 2 M or 3 M NaCl. Reaction products were
analyzed by 19% SDS-PAGE.
Size exclusion chromatography
For analytical gel filtration of SFVmac PRshort, a
Superdex 75 HR 10/30 column (GE Healthcare) was
used. The column was loaded with 140 nmol PRshort in
50 mM Na2HPO4/NaH2PO4, pH 7.4, 0.5 mM DTT and
300 mM or 2 M NaCl. Calibration was performed with
albumin (67 kDa), ovalbumin (43 kDa), chymotrypsino-
gen (25 kDa) and RNase A (13.7 kDa; GE Healthcare)
using the same buffer. In the same way, 13 nmol SFVmac
PR-RTwas analyzed on a Superdex 200 HR 10/30 column
(GE Healthcare) calibrated with catalase (232 kDa),
aldolase (158 kDa), ovalbumin (43 kDa) and chymotryp-
sinogen (25 kDa; GE Healthcare).
Analytical ultracentrifugation
Sedimentation velocity experiments were performed on
an Optima XL-I analytical centrifuge (Beckman Inc., Palo
Alto, CA) using an An60Ti rotor and double-sector 12-mm
centerpieces. Measurements were performed with
0.73 mg/ml of SFVmac PRshort in 50 mM Na–phosphate
buffer, pH 7.4, containing 100 mM NaCl. Buffer density
was measured to 1.01024 kg/l using a DMA 5000
densitometer (Anton Paar, Graz, Austria). Protein con-
centration distribution was monitored at 280 nm and at
60,000 rpm. Time-derivative analysis was computed using
the SEDFIT software package,42 resulting in a g(s*)
distribution and an estimate for the molecular weight
(from the sedimentation and diffusion coefficients,
inferred from the peak width).
NMR spectroscopy
All NMR experiments were conducted at 298 K on a
BrukerAvance 600- or 700-MHz (equippedwith a cryogenic
probe) spectrometer. In addition to the previously described
experiments for resonance assignment,38 the experiments
subsequently discussedwere conducted to obtain structural
and dynamic data.
HNHB, 13CO and 15N spin-echo difference experiments
were performed forχ1 restraints.
43 15N- and 13C-editedNOE
spectroscopy (NOESY) experiments (mixing time=120 ms)
were acquired for obtaining distance restraints.
For the characterization of overall and internal motions,
15N longitudinal (R1) and transverse (R2) relaxation rates,
together with the steady-state {1H}15N NOE, were
recorded using standard methods at 600.2 MHz 1H
frequency at a calibrated temperature of 297.7 K. For 15N
R1, the delays for the relaxation delay were 10.75 (3×),
268.17 (3×), 643.58 (3×), 1072.62 (3×), 1930.70 (3×) and
2258.42 (3×) ms. For 15N R2, delays of 7.82 (3×), 23.52 (3×),
39.20 (3×), 78.40 (3×), 117.60 (3×), 156.80 (3×) and 196.00
(3×) ms were used. The steady-state {1H}15N NOE spectra
were measured with a 6 s relaxation delay. For the
saturated subspectrum, 120° pulses with 5 ms inter-pulse
delay were applied during the final 3 s of the relaxation
delay. Relaxation delays of R1 and R2 relaxation experi-
ments were fitted to a mono-exponential decay using the
program CURVEFIT (A.G. Palmer, Columbia University,
USA). The correlation timewas determined for an isotropic
tumbling model using the TENSOR2 package.44
NMR titration experiments were carried out using a
synthetic peptide (Thermo Electron, Dreieich, Germany)
corresponding to the RT IN cleavage site (indicated by an
arrow) in the Pol polyprotein (TQGSYVVH↓CNTTP).
Structure calculations
Distance restraints for structure calculation were derived
from 15N- and 13C-edited NOESY spectra. NOESY cross-
peaks were classified according to their relative intensities
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and converted to distance restraints with upper limits of
3.0 Å (strong), 4.0 Å (medium), 5.0 Å (weak) and 6.0 Å (very
weak). For ambiguousdistance restraints, the r−6 summation
over all assigned possibilities defined the upper limit.
Experimental NOESY spectra were validated semi-quanti-
tatively against back-calculated spectra to confirm the
assignment and to avoid bias of upper distance restraints
by spin diffusion.
Hydrogen bonds were included for backbone amide
protons in a regular secondary structure, when the amide
proton does not show a water exchange cross-peak in the
15N-edited NOESY spectrum. Dihedral restraints for χ1
angles based on 3J(N,Hβ), 3J(N,CH3) and
3J(CO,CH3)
coupling constants were included as restraints for the
most probable rotamer with 30° tolerance. Dihedral
restraints for φ angles were obtained from secondary
chemical shifts andwere included as (−120°±40°) restraints
for residues in β-strands or (−60°±40°) restraints for
residues in helical regions.
The structure calculations were performed with the
program Xplor-NIH 1.2.145 using a three-step simulated
annealing protocol with floating assignment of prochiral
groups including a conformational database potential. The
20 structures showing the lowest values of the target
function excluding the database potential were further
analyzed with Xplor,45 MOLMOL17 and PROCHECK
3.5.4.46
Accession codes
The structure coordinates were deposited in the Protein
Data Bank under accession code 2JYS. Chemical shift
assignments38 were deposited in the BioMagResBank
under accession code 15403.
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Formation of transient dimers by a retroviral protease
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Retroviral proteases have been shown previously to be only
active as homodimers. They are essential to form the separate
and active proteins from the viral precursors. Spumaretroviruses
produce separate precursors for Gag and Pol, rather than a
Gag and a Gag–Pol precursor. Nevertheless, processing of Pol
into a PR (protease)–RT (reverse transcriptase) and integrase is
essential in order to obtain infectious viral particles. We showed
recently that the PR–RT from a simian foamy virus, as well
as the separate PRshort (protease) domain, exhibit proteolytic
activities, although only monomeric forms could be detected.
In the present study, we demonstrate that PRshort and PR–RT
can be inhibited by the putative dimerization inhibitor cholic
acid. Various other inhibitors, including darunavir and tipranavir,
known to prevent HIV-1 PR dimerization in cells, had no effect on
foamy virus protease in vitro. 1H-15N HSQC (heteronuclear single
quantum coherence) NMR analysis of PRshort indicates that
cholic acid binds in the proposed PRshort dimerization interface
and appears to impair formation of the correct dimer. NMR
analysis by paramagnetic relaxation enhancement resulted in
elevated transverse relaxation rates of those amino acids predicted
to participate in dimer formation. Our results suggest transient
PRshort homodimers are formed under native conditions but are
only present as a minor transient species, which is not detectable
by traditional methods.
Key words: cholic acid, foamy virus, NMR, paramagnetic
relaxation enhancement (PRE), protease, spin label, transient
dimer.
INTRODUCTION
The virus family of retroviridae consists of the two subfamilies
orthoretrovirinae and spumaretrovirinae or FVs (foamy viruses).
Retroviruses create viral proteins by producing large polyprotein
precursors, derived from the three genes gag, pol and env.
gag encodes the structural proteins (e.g. capsid, matrix and
nucleocapsid protein), pol harbours the ORFs (open reading
frames) for the viral enzymes [PR (protease), RT (reverse
transcriptase) and integrase] and env encodes for the surface and
transmembrane proteins, which are localized in the viral lipid
envelope and are essential for binding to the cellular receptors.
The Gag and Pol polyprotein precursors are processed by the viral
PR during virion maturation [1].
FVs differ in several aspects from orthoretrovirinae, e.g. FVs
synthesize separate Gag and Pol precursors whereas in the case
of orthoretrovirinae a Gag and a Gag–Pol precursor are formed.
In FVs the PR domain, which is located at the N-terminus of the
Pol precursor protein, is not cleaved off from the RT. Only the
C-terminal integrase is removed from Pol, thus leading to a mature
PR–RT enzyme [2–5]. In contrast, in orthoretrovirinae the PR is
created by autoprocessing of the Gag–Pol precursor protein and
is subsequently present as a separate enzyme [6,7].
PRs from retroviruses are members of the well-characterized
family of aspartic PRs [8,9]. This group also includes cellular
mammalian PRs such as chymosin and pepsin. In contrast with
the cellular proteases, which are monomers with distinct N- and C-
terminal domains, retroviral PRs are homodimers [10]. In order
to create the active site of retroviral PRs each subunit of the
homodimer contributes one catalytic aspartate residue located in
the conserved motif Asp-Thr/Ser-Gly. Moreover, the flap and the
C- and N-termini are important for formation of the active dimer
[7].
In orthoretroviruses the viral genomic RNA and the precursor
proteins are packaged to form the viral particles. Therefore
regulation of the activity of retroviral PRs during the viral life
cycle is absolutely required to avoid premature processing of the
precursors. If untimely cleavage of the polyproteins happened
before virus assembly, this would lead to incomplete uptake of
various viral proteins as not all of them harbour independent
packaging signals.
For HIV-1 it has been shown that regulation of PR activity in
the Gag–Pol precursor protein is modulated by the N-terminal
flanking transframe region sequence [11–16], whereas the
C-terminal RT domain does not significantly influence the PR
activity of the precursor [17,18]. The presence of the N-terminal
extension leads to the formation of weak dimers with low PR
activity. Once the N-terminal region is cleaved off, stable and
active PR dimers can be formed [19]. This type of regulation
cannot take place with the FV PR as there is no Gag–Pol precursor
and thus no N-terminal extension of the PR. How FV PRs are
activated is still unknown. Nevertheless, dimerization, in order to
form the catalytic centre, also appears to be a prerequisite for FV
PR activity.
We have demonstrated recently that PRshort (the separate
PR domain) of SFVmac [SFV (simian foamy virus) from
macaques], as well as the full length PR–RT, exhibit proteolytic
activity. Nevertheless, both enzymes appear as monomeric protein
species when analysed by size-exclusion chromatography or
analytical ultracentrifugation [20]. Furthermore, determination of
the solution structure of PRshort by NMR also corroborated the
existence of a monomeric protein [20]. We thus postulated that
Abbreviations used: FV, foamy virus; GB1, immunoglobulin-binding domain B1 of streptococcal protein G; GFP, green fluorescent protein; HSQC,
heteronuclear single quantum coherence; oxyl-1-NHS, 1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate N-hydroxysuccinimide ester; PR, protease; PRE,
paramagnetic relaxation enhancement; PRshort, separate PR domain; RT, reverse transcriptase; SFV, simian foamy virus; SFVmac, SFV from macaques.
1 To whom correspondence should be addressed (email birgitta.woehrl@uni-bayreuth.de).
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PRshort, as well as the PR domain of PR–RT, have to form weak
transient dimers that are only present under certain conditions and
are only populated to a low fraction and are not detectable by the
methods and/or conditions applied previously.
Thus we set out to analyse the monomer/dimer status of PRshort
by PRE (paramagnetic relaxation enhancement) analysis, a NMR
method exquisitely suited for detecting the presence of minor
species, in our case the postulated transient dimer [21–23].
A transient state is characterized by an equilibrium between a
lowly populated short-lived state in high-dynamic exchange with
the ground state. The fast exchange of the different states causes
an averaging of observable properties. If the lowly populated
transient state does not contribute significantly to the observed
parameters it remains undetected. This could be the reason why
several techniques for apparent molecular mass determination of
PRshort could not detect a dimer.
PRE relies on the fact that the nuclear spins can be influenced
by an unpaired electron of a paramagnetic molecule in close
proximity, i.e. less than approx. 20 Å (1 Å= 0.1 nm) away.
Depending on the distance, the interaction of the nuclear spin
with the unpaired electron can enhance transverse relaxation
rates up to several decades; a paramagnetic centre of a nitroxyl
group located approx. 8 Å from a given amide proton adds
approx. 1800 Hz to the transverse relaxation rate, typically in the
range 30–50 Hz in the diamagnetic state. Therefore even a low
fraction of transient states contributes significantly to the observed
population averaged rate and allows the detection of these states.
In the case of transient interactions between different molecules
(e.g. dimer formation) the interaction can be detected elegantly
by placing the nuclear spins observed by NMR spectroscopy and
the paramagnetic centres on different molecules [21–23].
In the present study, we show for the first time by biochemical
and NMR analyses, using a PR inhibitor and PRE, that indeed a
transient SFVmac PR homodimer is formed.
EXPERIMENTAL
Gene expression and protein purification
Expressions and purifications of 15N-labelled and unlabelled
SFVmac PRshort and PR–RT and the PR substrate GB1
(immunoglobulin-binding domain B1 of streptococcal protein
G)–GFP (green fluorescent protein) were performed as described
previously [20,24,25].
PR inhibition assay
The proteolytic activities of SFVmac PR–RT and PRshort
were tested as described previously [20] in buffer [50 mM
Na2HPO4/NaH2PO4, pH 6.4, containing 3 M NaCl and 0.5 mM
DTT (dithiothreitol)] for 2 h at room temperature (20 ◦C ) using
substrate and enzyme concentrations of 10 and 5 µM respectively.
The inhibitor tipranavir was dissolved in 5% (v/v) ethyl acetate to
a concentration of 500 µM. Darunavir and the peptidyl inhibitor
indinavir sulfate were dissolved in water to concentrations of
250 and 500 µM respectively. These three reagents were obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, National Institute of Allergy and Infectious
Diseases (NIAID), National Institutes of Health. Cholic acid,
betulinic acid (both Roth) and lithocholic acid (Sigma–Aldrich)
were dissolved in 100% DMSO at concentrations of 600, 530
and 130 mM respectively. The final DMSO or ethyl acetate
concentration in the activity assays was 1%.
The final concentrations of cholic acid in the assays are
indicated in Figure 1. Reaction products were separated by
electrophoresis on 10% Bis-Tris gels (Invitrogen) in buffer
(50 mM Mes, pH 7.3, containing 50 mM Tris base, 0.1% SDS
and 1 mM EDTA) and quantified by analysing the bands
densitometrically using the software Quantity One on a Gel
Doc 2000 device (Bio-Rad Laboratories). The concentration of
inhibitor at which half of the PR activity was measured was
defined as IC50. To determine the IC50, a curve was fitted to the
data using a 4PL (four-parameter logistic model), also called Hill
slope model [26], with the slope describing the steepness of the
curve:
% activity = min+ max−min
1+ ([inhibitor]/IC50)slope
where min is the percentage minimal enzyme activity and max is
percentage maximal enzyme activity.
Tissue culture assays
Antiviral activity of cholic acid was analysed essentially as
described previously [27]. In brief, HEK-293T cells [HEK (human
embryonic kidney)-293 cells expressing the large T-antigen of
SV40 (simian virus 40)] were transfected with pcHSRV2, SFV-1
and NL4-3. The supernatants were removed 16 h after transfection
and replaced by fresh pre-warmed medium containing cholic acid
at final concentrations from 0.125 to 2 mM or a DMSO solvent
control. All cholic acid titrations were performed in independent
triplicate assays. Cells were harvested 48 h after infection [27],
washed twice with PBS and lysed with 200µl sample buffer
[27], and Gag expression was analysed by Western blotting.
Infectious viral titres were determined on indicator cells, which
expressed the LacZ gene from an LTR (long terminal repeat)
promoter responsive to the respective viral transactivator.
Spin labelling of PRshort
Spin labelling of the ε-amino groups of lysine residues
was performed essentially as described previously [28,29].
Freeze-dried SFVmac PRshort was dissolved in 10 mM
Na2HCO3, pH 9.2, to a final concentration of 9.4 mg/ml.
Oxyl-1-NHS (1-oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylate
N-hydroxysuccinimide ester; Toronto Research Chemicals) was
dissolved in 100% DMSO and added to the PRshort solution at
an approx. 5-fold molar excess over the basic ε-amino groups
of PRshort. The solution was incubated using an end-over-end
shaker at room temperature for 1 h followed by 1 h at 4 ◦C.
Buffer exchange was performed by dialysing the solution against
buffer (50 mM Na2HPO4/NaH2PO4, pH 7.4, containing 300 mM
NaCl) using a Vivaspin concentrator with a molecular mass cut-
off of 5000 (Sartorius). The efficiency of the labelling procedure
was analysed by MALDI–TOF (matrix-assisted laser-desorption
ionization–time-of-flight) at the Zentrale Bioanalytik, Universita¨t
Ko¨ln, Germany, and indicated a mixture of different PRshort
species containing one to all nine labelled lysine residues (results
not shown). The labelled species were almost equally distributed
with a slightly increased peak for the doubly labelled species.
Owing to the solvent-exposed position of all lysine residues in
PRshort we assume a random distribution of the spin label in cases
of incomplete labelling. The fractional presence of completely
labelled PRshort in the mass spectrum showed that all lysine
residues are accessible for labelling. The reaction was not driven
further to completion in order to avoid large influences of the spin
label on the PR structure or on dimer formation.
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NMR measurements
NMR experiments were recorded on Bruker Avance 600 MHz,
700 MHz (equipped with a CryoProbe) and 800 MHz (equipped
with a CryoProbe) spectrometers at a sample temperature of
298 K.
NMR samples contained 100–200 µM 15N-labelled SFVmac
PRshort in 50 mM Na2HPO4/NaH2PO4, pH 7.4, containing
100 mM NaCl and 1 mM DTT. Samples used for PRE
measurements did not contain DTT to avoid reduction of the
spin label. Cholic acid was added to the desired concentration
from a stock solution in DMSO. Addition of the same amount
of free DMSO to the PR solution did not result in any chemical
shift changes. This verifies the absence of DMSO binding to
PRshort. Resonance assignments were taken from the literature
[20,24]. PREs of amide protons were determined using a two-
point measurement with an HSQC (heteronuclear single quantum
coherence)-based experiment [30]. The dissociation constant for
cholic acid was determined by fitting the chemical shift changes
to a two-state model during successive addition of cholic acid in
a series of HSQC experiments.
RESULTS
In vitro inhibition of PR activity by cholic acid
We have shown previously by prevalent methods that FV PR
behaves like a monomeric protein [20]. However, dimerization
is a prerequisite for functional retroviral PRs. As we were able
to detect proteolytic activities with FV PR, we postulated that
a low population of the protein is present as a dimer. Thus
potential protease dimerization inhibitors should be able to inhibit
proteolytic activity.
For HIV-1, triterpenes and steroids have been shown
to inhibit PR activity [31]. Molecular modelling studies
with HIV-1 PR suggested that these substances work by
inhibiting dimerization or formation of the correct, and
thus active, dimer [32]. The structures of retroviral PRs
are very similar, even if their primary sequences exhibit
large differences [7,33]. The monomer structure of SFVmac
PRshort reveals high structural homology with the HIV-1
PR monomer, as well as to the monomeric subunits of the
homodimer, even though the similarity on the amino acid level is
only approx. 29% [20,34,35]. Therefore we tested whether the
steroid inhibitors cholic acid, lithocholic acid and betulinic acid,
which have been shown to inhibit HIV-1 PR activity [32], are
also able to inhibit PR activity of SFVmac PRshort and of full
length PR–RT. The IC50 values for in vitro HIV-1 PR inhibition
by these substances were approx. 350 µM for cholic acid, 10 µM
for lithocholic acid and 2.5 µM for betulinic acid [32].
The proteolytic activities of PRshort and the full length PR–
RT were tested with a GB1–GFP fusion protein, a substrate used
previously, harbouring the natural SFVmac PR cleavage site of
the Pol precursor between the GB1 and GFP domains [20]. As
we have shown previously that, similar to other FV PRs, SFVmac
PRshort is only active at high salt concentrations, the pH optimum
for PR activity was determined using NaCl concentrations of 3 M
[20]. Our results indicated the highest cleavage activity at pH 6.4
(results not shown), thus these conditions were used for further
analyses.
Our results using cholic acid (Figure 1) show that substrate
cleavage can be inhibited in vitro at increasing cholic acid
concentrations, implying that this HIV-1 PR inhibitor is functional
with SFVmac PRshort as well as PR–RT. Quantification of the
cleavage products yielded comparable IC50 values for cholic acid,
approx. 0.6 mM for SFVmac PRshort and 0.75 mM for PR–RT.
Figure 1 PRshort and PR–RT inhibition by cholic acid
Inhibition of 5µM SFVmac PR–RT (!) or PRshort (") by increasing concentrations of cholic
acid. The IC50 values for PR–RT (749+− 32µM) and PRshort (615+− 70µM) were determined.
The curves show the best fit to the data using the equation given in the Experimental section.
Testing the inhibitory effect of cholic acid against SFVmac in
tissue culture assays was prevented by the toxicity of the substance
for the cells at concentrations higher than 500 µM. The IC50 values
for PR–RT using lithocholic acid was approx. 1 mM, whereas the
IC50 of betulinic acid could not be determined due to enzyme
precipitation upon addition (results not shown).
As the IC50 values obtained with the steroid derivatives are
relatively high, we tested additional substances known to inhibit
the PR activity of HIV-1 at much lower concentrations than
cholic acid. Two non-peptidyl inhibitors, namely darunavir and
tipranavir, are used for the treatment of HIV infections in patients.
They have been shown to inhibit HIV-1 replication by blocking
the formation of active PR dimers at the stage of PR matu-
ration [36–38]. However, they fail to dissociate mature PR
dimers [36]. These inhibitors prevent HIV-1 PR dimerization at
concentrations as low as 0.01 µM [36]. As the largest portion of
FV PR–RT is monomeric, these inhibitors appeared to be good
candidates to prevent FV PR dimerization. However, neither of
these substances was able to inhibit the proteolytic activity
of PR–RT at concentrations up 100 µM in our assays (results
not shown).
Furthermore, the peptidomimetic HIV-1 PR inhibitor indinavir,
an active-site transition state analogue, was also not capable of
inhibiting FV PR–RT at concentrations up to 100 µM. Thus we
used cholic acid for further analysis.
Cholic acid binds in the putative dimerization interface of SFVmac
PR
To determine the inhibitor-binding interface and to confirm the
integrity of the three-dimensional structure of PRshort after
inhibitor addition, we analysed PRshort in the absence and
presence of increasing concentrations of cholic acid by observing
chemical shift perturbations in 1H-15N HSQC experiments
(Figure 2A). Addition of cholic acid to 15N-labelled PRshort, up
to a protein/inhibitor ratio of 1:150, led to gradual chemical shift
changes in the 1H-15N HSQC spectra, characteristic for complex
formation in the fast-exchange regime of the NMR time scale.
Residues showing chemical shift perturbation upon addition of
cholic acid were found in (or sequentially close to) the active-
site loop (e.g. Trp23, Ala27, Thr28, Thr30 and Val32), the flap region
(Ile43, Thr45, Met46, Lys49, Thr50, His51 and Gln57) and in the C-
terminal region (Leu93, Met94, Lys96 and Leu100). All of these
regions contribute to the known dimer interface for retroviral PRs,
e.g. the essential intermonomeric antiparallel β-sheet involving
the N- and C-termini, as well as contacts close to the active site
and the flap region [7,33,34] (Figures 2B–2D).
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Figure 2 Determination of the inhibitor-binding interface
(A) Overlay of 1H-15N HSQC spectra recorded during titration with different protein (100µM)/inhibitor ratios. Black 1:0; red 1:5; green 1:50; and blue 1:150. (B) Determination of the dissociation
constant for cholic acid. Normalized chemical shift changes of residues Thr28 (K d of 5.1 mM), Thr45 (K d = 4.3 mM) and Thr50 (K d of 6.6 mM) are shown exemplarily as a function of the cholic
acid ([L])/PRshort ([P]) ratio. (C) Normalized chemical shift changes for PRshort upon cholic acid binding. Changes larger than 0.05 p.p.m. were considered significant. Changes from 0.05 to 0.15
p.p.m. were assigned as weak,>0.15–0.25 p.p.m. as medium, and>0.25 p.p.m. as strong. (D) Observed chemical shift changes colour coded on a ribbon diagram of the PRshort monomer (PDB
code 2JYS). The amino acids showing significant chemical shift changes are indicated in yellow (weak), orange (medium) and red (strong). The structure and relative size of cholic acid is shown on
the right-hand side.
From the chemical shift changes obtained upon addition of
cholic acid, the dissociation constant (Kd) could be determined
assuming a two-state binding model. Exemplified titration curves
for some of these residues are shown in Figure 2(B). The Kd
values determined for all of the amino acids analysed were in
the range of 5.3+− 0.9 mM. For residues spatially close to the
N- and C-terminus (Leu10 and Met94) slightly weaker affinities
were observed (a Kd of 10 mM). Comparison of the dimensions of
the interaction surface, defined by strongly shifting residues, with
the size of cholic acid reveals a region significantly larger than
cholic acid (Figure 2D). The chemical shift changes observed may
arise from direct interaction of amino acid residues with cholic
acid or by subtle structural changes (e.g. side chain rotations)
transmitted to regions farther away from the exact binding site.
Therefore determining a more detailed location of the binding
site on SFVmac PRshort is difficult. Taken together, our results
suggest that the inhibitor impairs the formation of an active
PRshort dimer which in turn hinders the ability of PR to catalyse
substrate cleavage.
Specific transient dimerization detected by PRE
Electron–nuclear spin interactions that result in a dramatic
enhancement of transverse relaxation rates of protons close to
a paramagnetic centre [22,23,40], could be assigned to residues
from the N- and C-terminal regions (Figure 3A) (e.g. Leu7, Leu8,
Lys96 and Leu98), from the active-site loop (e.g. Trp23, Asp24, Ser25,
Thr28 and Ile29) and from the flap region (e.g. Lys49 and Gln56). All
of these regions are known to contribute to the dimer formation of
active retroviral PRs [7,41]. These results clearly demonstrate an
interaction of spin-labelled with 15N-labelled SFVmac PRshort.
The transversal relaxation rates, Γ 2, after the addition of spin-
labelled PRshort indicated that the residues affected are located
in the putative dimerization region of the PRshort monomer
(Figure 3B). Amide protons of residues far from the dimerization
interface do not exhibit significant changes in the transversal
relaxation rates, demonstrating that the transient dimerization of
SFVmac PR is structure-specific (Figure 3C).
Despite the large distance between Gln67 and Lys70 and the
dimerization interface, significantΓ 2 values were observed. These
residues are located in the β-sheet strand 6 and the preceding loop.
Inspection of the dimeric structure of HIV-1 PR reveals that this
region is close to the intermonomeric β-sheet [34]. Therefore
short distances to residues of the C-terminal region of the other
monomer carrying spin-labelled lysine residues can be expected.
To support the hypothesis of the role of cholic acid as a
dimerization inhibitor, the inhibitor was added to the mixture of
15N- and spin-labelled PRshort (Figure 4). Chemical shift changes
c© The Authors Journal compilation c© 2010 Biochemical Society
Transient retroviral protease dimers 201
Figure 3 Determination of the dimer interface
(A) Overlay of 1H-15N HSQC spectra of 15N-labelled PRshort recorded in the absence (black) or presence (red) of equimolar amounts of PRshort labelled at lysine residues with the paramagnetic spin
label oxyl-1-NHS. (B) The PREs of 15N-labelled PRshort after the addition of the spin-labelled PRshort. The relevant regions of the protein are indicated at the top of the Figure. (C) Three-dimensional
structure representing the hypothetical SFVmac PR dimer. The structure is based on the crystal structure of HIV-1 PR (PDB code 3HVP). The left half of the molecule represents the 15N-labelled
monomer with colour coded PREs upon addition of spin-labelled PR. Residues with PREs>20 Hz are coloured red, with PREs>10 Hz are coloured orange. Spin-labelled lysine residues are
highlighted in green on the right-hand monomer subunit.
Figure 4 PREs in the presence of cholic acid
The PREs of 15N-labelled PRshort after the addition of cholic acid to the mixture. Numbers
indicate the sequence position and the relevant regions of the protein are labelled at the top of
the figure.
observed for the 15N-labelled PRshort are virtually identical with
the values found in the previous titration experiments presented
in Figure 2 where 15N-labelled PRshort is titrated with cholic
acid. These results confirm the binding of cholic acid. The
titration curves reveal saturation with cholic acid to an extent
of approx. 70%. The PRE rates observed for the mixture of
15N-labelled and spin-labelled PRshort in the presence of cholic
acid (Figure 4) show slightly reduced values (approx. 80% of the
original values), but are still present for all regions, indicating that
formation of the correct dimer is impaired, but not dimerization
as such.
In summary the results of the present study reveal for the first
time the transient nature of the SFVmac PRshort dimer.
DISCUSSION
The active site of retroviral PRs is composed of residues from two
monomeric subunits. Therefore dimerization is a prerequisite for
PR activity [7,33,34].
The NMR structure of the PR domain from SFVmac, as
well as analytical ultracentrifugation and size-exclusion analyses,
revealed previously that the protein is a monomer in solution
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[20]. This is in strong contrast with HIV-1 PR, where several
mutations were necessary to obtain the monomeric form [42–44].
Despite the exclusive detection of this apparent monomeric state
for SFVmac PRshort under prevalent experimental conditions,
proteolytic activity could be observed [20]. Thus a small fraction
of an active dimeric species was hypothesized to exist. To test this
hypothesis, we analysed SFVmac PR activity in the presence of
several HIV-1 PR inhibitors, which had been suggested to impair
PR dimerization. Indinavir, a peptidomimetic HIV-1 PR inhibitor,
which binds to the active site, was also tested for comparison,
but did not have any impact on FV PR activity. Tipranavir
and darunavir, which inhibit HIV-1 PR at concentrations as
low as 0.01 µM by preventing dimerization in cells, showed
no inhibitory effect on SFVmac PR. This could be due to the
assay conditions which included 3 M NaCl (the inhibitors might
not be able to bind to the PR in high-salt buffers). Furthermore,
deviations in the dimer interfaces of HIV-1 and FV PRs, which are
based on low sequence homologies, obviously result in dissimilar
monomer/dimer states of the two proteins, indicating that these
differences are too large to allow for the inhibitors to bind to FV
PR.
Of the steroid derivatives suggested to inhibit HIV-1 PR
dimerization cholic acid and lithocholic acid were able to impair
FV PR activity. However, as cholic acid showed lower IC50 values,
of 0.6–0.75 mM, this inhibitor was used for further analyses.
Our results have shown that SFVmac PR activity is reduced
in the presence of cholic acid (Figure 1), and NMR titration
experiments (Figure 2) revealed the interaction sites of cholic
acid with SFVmac PRshort.
The mode of action of cholic acid as a dimerization inhibitor for
HIV-1 PR was proposed by an in silico study that suggested a bind-
ing site of cholic acid between the active-site loop and the inter-
monomeric β-sheet of the PR [32]. This is consistent with the
large number of chemical shift perturbations of SFVmac PRshort
observed in our titration experiments for residues in the N- and
C-terminal regions as well as for residues in the active-site loop.
In addition, we observed strong chemical shift changes in the
flap region, which is located at the opposite site of the protein
(Figure 2). This region is flexible in solution and forms the gate
for the substrate [7,41]. The chemical shift changes observed
could be explained by large structural rearrangements throughout
the protein should cholic acid bind between the intermonomeric
β-sheet and the active-site loop.
Alternatively, a second independent binding site could exist
between the active-site loop and the flap region, either close to or in
the active-site cavity. However, we were unable to directly deduce
whether there was a second binding site from the titration curves
(Figure 2), as the Kd values for cholic acid were too weak and the
inhibitor concentration could not be increased due to solubility
problems. More than one binding site for an HIV-1 PR inhibitor
has been detected previously by high-resolution crystallography
[45].
Our PRE measurements using spin-labelled SFVmac PRshort
clearly show the presence of intermonomeric contacts even in the
presence of cholic acid (Figure 4). The reduction of the PREs after
the addition of cholic acid is smaller than expected for the case
of complete suppression of dimer formation, implying that cholic
acid only hinders the concerted interaction of regions necessary
to form the correct dimer interface. Thus the action of cholic acid
should be better characterized as impairing the formation of the
active dimer rather than completely preventing dimerization.
The existence of specific contacts between different monomers
can be shown explicitly by the observation of PREs on the 15N-
labelled SFVmac PRshort after mixing with the spin-labelled PR
species (Figure 3). The PREs were detected on HSQC signals
corresponding to the monomeric protein, demonstrating that the
interaction is in fast exchange and transient. This is in agreement
with the recent observation of transient events during N-terminal
autoprocessing of HIV-1 PR [19]. The observed monomer/dimer
equilibrium probably regulates PR activity, as for retroviruses
timely processing of the Gag–Pol or, in the case of FVs, the
Pol precursor protein is essential for virus maturation. Premature
autoprocessing of the precursors is deleterious for the virus,
as uptake of all viral proteins necessary for formation of the
infectious virus particle would be prevented.
For HIV-1 PR it has been shown that autoprocessing of the
N-terminus of the PR at the Gag–PR junction is essential for
the regulation of activity and occurs via an intramolecular
first-order cleavage of the precursor, whereas processing at the
C-terminus of the PR does not appear to be important [12,46,47].
However, this regulatory mechanism cannot be responsible for
PR activation in FV, as no Gag–Pol precursor exists and FV PRs
already comprise the N-terminus of the Pol precursor. Thus other,
as yet unknown, regulatory mechanisms for the activation of the
PR appear to be important during the life cycle of FVs.
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Abstract 
The foamy virus Pol protein is translated independently from Gag from a separate mRNA. 
Thus, in contrast to orthoretroviruses no Gag-Pol precursor protein is synthesized. Only the 
integrase domain is cleaved off from Pol resulting in a mature reverse transcriptase harboring 
the protease domain at the N-terminus (PR-RT). We have demonstrated recently that FV 
protease is an inactive monomer with a very weak dimerization tendency and postulated 
protease activation through dimerization. Protease activity has to be strictly regulated in order 
to avoid its premature stimulation before Pol has been taken up into the virus. Here, we 
analyzed the CasI and CasII sequences of the pregenomic viral RNA and determined their 
impact on protease activity. CasII harbors the cPPT, which consists of the four purine rich 
elements A-D. Our data show that an RNA comprising the AB-elements is sufficient for 
protease stimulation. Electrophoretic mobilty shift assays and crosslinking reactions 
demonstrate an oligomeric binding of PR-RT to RNA. Although RNA is also bound non-
specifically, only RNA sequences containing the A- and B-element result in significant 
activation of the protease. Structure analysis of AB-RNA by selective 2’ hydroxyl acylation 
analyzed by primer extension predicts a distinct RNA folding, which is necessary for protease 
activation and thus virus maturation.  
 
 
Key words: foamy virus, Pol, protease activation, polypurine tract, CasI CasII 
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Introduction 
The replication of spumaretroviruses or foamy viruses (FVs) differs in several aspects from 
that of the orthoretroviruses. One important deviation from the replication strategy concerns 
the time point of reverse transcription, which in FVs takes place before the virus particles 
leave the cell, whereas orthoretroviruses reverse transcribe their RNA genome shortly after 
they have entered the host cell [1-3] (for reviews see [4-6]). As a consequence, FVs possess a 
double stranded DNA instead of a single stranded RNA genome. However, it has been shown 
that part of the DNA genome is still single stranded, indicating that plus strand DNA 
synthesis is not complete once progeny viruses are budding [7,8]. Another difference is the 
mode of pol expression. In orthoretroviruses, in addition to the Gag polypeptide a Gag-Pol 
fusion protein is synthesized at a ratio of approximately 1:20. Both polypeptides are taken up 
into the virus particle by interaction of the Gag region with the viral RNA (reviewed in [9]). 
In contrast FV Pol is synthesized from a separate mRNA independently from Gag, leading to 
a Pol precursor protein [10-12]. Consequently the uptake mechanism for FV Pol must be 
different. It has been shown that the C-terminus of FV Gag as well as parts of the FV genome 
contain determinants important for Pol uptake [13-16].  
Once assembly of the viral components has taken place, the viral protease (PR) processes the 
Gag and Pol precursor proteins into mature structural and functional proteins. In FV only the 
viral integrase is cut off from Pol, whereas the protease (PR) remains covalently linked to the 
RT domain, thus leading to a mature protease-reverse transcriptase (PR-RT) protein [17]. It 
has been shown previously that the PFV and SFVmac PR-RT as well as the SFVmac PR 
domain are monomeric [18-20]. The PR domain forms only transient dimers, which constitute 
a very small fraction (< 5 %) of PR molecules [21]. Retroviral PRs have been shown to be 
active as homodimers [22]. 
Consequently, since they are predominantly monomeric proteins, SFVmac PR and PR-RT 
lack proteolytic activity under physiologically relevant conditions in vitro. So far, the 
regulatory mechanism for PR activation is not understood. Activation of the PR either in the 
separate PR domain or in the context of PR-RT could be achieved at very high NaCl 
concentrations of 2 – 3 M [19-21]. It is obvious that these conditions do not reflect the 
situation in living cells but somehow create an environment that facilitates dimerization, 
probably by hydrophobic interaction of two monomers.  
To identify the factors that might be important for PR stimulation in vivo we set out to 
analyze relevant regions of the pregenomic viral RNA that might be able to stimulate PR 
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dimerization and thus activity. We postulated that RNA regions, which are essential for virus 
replication and/or Pol uptake might play a stimulatory role in PR activation as well.  
In previous studies two cis-acting sequences, CasI and CasII, have been shown to play a role 
in the transfer of FV vectors [13,23-25], indicating an important role in virus assembly. CasI 
spans the region from nucleotide 1-645 and CasII from 3869-5884 of the pregenomic RNA 
from prototype FV (PFV). It has been demonstrated that FVs harbor a second, so called 
central polypurine tract (cPPT) in addition to the 3’ PPT [8,16,26,27]. The latter is located 
upstream of the 3’ long terminal repeat (LTR) and is required for plus strand DNA synthesis. 
FV share this feature of two PPTs with the lentiviruses, although they are members of 
different subfamilies. The cPPT is located in the pol open reading frame of the pregenomic 
viral RNA and thus is part of the CasII sequence. In FVs it is comprised of four purine rich 
regions (elements A-D, Figure 1) [26]. The A and B elements play a role in Pol protein 
encapsidation, whereas the C element is required for regulation of gene expression. Although 
only the sequence of the D element is 100 % identical to the 3’ PPT region, no definite 
function could be determined. Mutations in D resulted in 50 % reduction of the virus titer 
[26]. 
We thus analyzed the influence of an in vitro transcribed RNA containing the CasI and CasII 
elements on PR activity. Our data show that cleavage of a model substrate by the PR-RT of 
PFV and simian FV from macaques (SFVmac) is strongly activated by an RNA fragment 
comprising the A and B elements of the cPPT, whereas the C and D elements exhibited only 
minor stimulation of PR activity.  
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Materials and Methods 
Purification of SFVmac and PFV PR-RT. SFVmac and PFV PR-RTs, and the GB1-GFP 
PR substrate were purified as described previously [19,20,28].  
 
RNA synthesis. Synthesis of all RNAs used in this study was done with the T7 or T3 
MEGAscript® Kit (Applied Biosystems, Austin, USA). To obtain 32P labeled RNA, 20 !Ci 
"[32P]-UTP (Hartmann Analytic GmbH, Braunschweig, Germany) were included in the in 
vitro transcription assay. All RNAs were purified over MicroSpin columns (GE Healthcare, 
Munich, Germany). The integrity of the RNAs was checked by denaturing gel electrophoresis 
(5 to 10 % polyacrylamid, 7 M urea). RNA folding was performed in the corresponding 
buffers used for the experiments by incubation for 2 min at 95 °C, followed by 10 min at 
65 °C and slow cooling to 30 °C within 45 to 60 min directly before use. 
 
PR activity assays. PR activity assays were performed as described previously [19] with 
minor changes. In summary, 10 !M of the GB1-GFP substrate, containing the SFVmac RT-
IN cleavage site of the Pol polyprotein (ATQGSYVVH!CNTTP) between GB1 and GFP, 
were incubated with 2.5 !M PR-RT and 0.5 !M DNA or RNA as indicated for 2 h at 37 °C in 
50 mM Na2HPO4/NaH2PO4 pH 6.4 and 100 mM NaCl in a total volume of 20 !l. The 
products were then separated by electrophoresis on 10 % BisTris gels (Invitrogen, Karlsruhe, 
Germany) in 50 mM MES buffer pH 7.3, 50 mM Tris base, 0.1 % SDS, 1 mM EDTA. 
 
Protein-Protein crosslinking. For crosslinking reactions 2 !M PFV or SFVmac PR-RT was 
incubated with 0.1 mM bis-sulfosuccinimidyl suberate (BS3) (Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany) in the presence or absence of 0.5 !M RNA as indicated, for 15 min at 
room temperature in 50 mM Na2HPO4/NaH2PO4 pH 6.4, 100 mM NaCl in a total volume of 
5 !l. For each condition, control reactions were performed without BS3. The reactions were 
stopped by the addition of an equal volume of 1 M Tris pH 9. To hydrolyze the RNA, the 
mixture was then incubated for 15 min at 45 °C. Reaction products were separated by 
electrophoresis on 10 % BisTris gels (Invitrogen, Karlsruhe, Germany) in 50 mM MES buffer 
pH 7.3, 50 mM Tris base, 0.1 % SDS, 1 mM EDTA. 
 
Electrophoretic mobility shift assay. For electrophoretic mobility shift assays (EMSAs) 
0.5 !M sense or antisense [32P] labeled RNA-AB was mixed with 0 to 2.5 !M PFV or 
SFVmac PR-RT as indicated in 50 mM Na2HPO4/NaH2PO4 pH 6.4, 100 mM NaCl and 10 % 
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glycerol in a total volume of 10 !l. The mixture was incubated at room temperature for 5 min. 
Half of the mixture was loaded on a 6% DNA Retardation Gel (Invitrogen, Karlsruhe, 
Germany). Electrophoresis was carried out in 0.5 x TBE buffer (89 mM Tris/HCl pH, 8.0 
89 mM borate and 20 mM EDTA) at 100 V for 3 h at 4 °C. RNA bands were visualized using 
a phosphoimaging device (FLA 3000, raytest, Straubenhardt, Germany). 
 
 
5’-end labeling of DNA oligonucleotides. 100 pmol of 3’AB primer (5’-
GGTCTTCCTACTAGCAGTTTAGTTAAAAGTCGTTTTATATC) (IBA, Göttingen, 
Germany) were labeled with 100 !Ci # [32P]-ATP (Hartmann Analytic GmbH, Braunschweig, 
Germany) and 4 U T4 polynucleotide kinase (New England Biolabs, Frankfurt, Germany) in a 
total volume of 20 !l at 37 °C for 1 h, followed by inactivation of the kinase for 20 min at 
65 °C. The labeled primer was finally purified via a MicroSpin column (GE Healthcare, 
Munich, Germany). 
 
 
SHAPE. Selective 2‘ hydroxyl acylation analyzed by primer extension (SHAPE) [29-31] was 
used to determine the secondary structure of RNA-AB. In principle, the protocol developed 
by Wilkinson et al. [32] was used. A total of 2 pmol RNA-AB in 12 !l 0.5 x TE buffer 
(10 mM Tris/HCl pH 8.0 and 1 mM EDTA) was heated to 95 °C for 2 min and then put on ice 
for 2 min. Folding of the RNA was completed by the addition of 6 !l RNA folding mix 
(333 mM HEPES pH 8.0, 20 mM MgCl2 and 333 mM NaCl) and incubation for 20 min at 
37 °C. Half of the mixture was removed and modified by adding 18 mM N-methylisatoic 
anhydride (NMIA; Invitrogen, Karlsruhe, Germany), dissolved in 100 % DMSO, and 
incubation for 45 min at 37 °C. The other half served as a control and was treated with DMSO 
only. Both samples were ethanol precipitated and the resulting pellet was dissolved in 10 !l 
0.5 x TE buffer. 
For primer annealing 100 nM [32P]-labeled 3’AB primer was incubated for 5 min at 65 °C. 
The reaction mixture was then slowly cooled down to 35 °C within 1 h. Reverse transcription 
was carried out in 50 mM Tris/HCl pH 8.3, 50 mM KCl, 3 mM MgCl2, 5 mM DTT and 
500 !M of each dNTP for 10 min in a total volume of 20 !l. The reaction mixture was 
preincubated for 1 min at 52 °C. Then the reaction was started by the addition of 200 U of 
Superscript III reverse transcriptase (Invitrogen, Karlsruhe, Germany) and further incubation 
at 52 °C for 10 min. Subsequently, to degrade the RNA template, 1 !l of 4 M NaOH was 
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added and the mixture was incubated for 5 min at 95 °C. Finally, an equal volume of 8 M urea 
in 1 M Tris/HCl pH 8.0, 50 mM boric acid and 50 mM EDTA, containing traces of 
bromophenol blue and xylene cyanol, was added. 8 !l samples were analyzed by denaturing 
gel electrophoresis (10 % polyacrylamide, 7 M urea). The reaction products were visualized 
and quantified by densitometry using a phosphoimaging device (FLA 3000, raytest, 
Straubenhardt, Germany) and the software AIDA (version 4.15; raytest, Straubenhardt, 
Germany).  
For calculation of relative SHAPE intensities the difference between the integrated band 
intensities of the reactions with and without NMIA was divided by the highest measured 
value in the experiment. Relative SHAPE intensities higher than 0.35 were considered 
significant. The RNA secondary structure was predicted using RNAfold [33,34]. Nucleotides 
(nt) showing significant SHAPE intensities (for exceptions see results) were assumed not to 
pair.  
 
Sequencing. To assign the SHAPE reaction products, sequencing reactions were run in 
parallel using the same [32P] endlabeled 3’AB primer and a vector harboring the CasI-CasII 
DNA sequences as a template. Sequencing reactions were performed with the Sequenase 7-
deaza-dGTP Sequencing Kit (usb, Cleveland, USA) using the 32P endlabeled 3’ AB primer. 
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Results 
To analyze the PR activity, we used the recombinant PR-RTs of PFV and SFVmac purified 
from Escherichia coli (E. coli) [20,28] and added different RNAs containing either the 
complete CasI and CasII sequences or shorter versions thereof, as indicated in Figure 1.  
 
 
 
Figure 1:  Sequence comparison of PFV and SFVmac purine rich elements and schematic 
representation of RNA fragments used in this study.  
   (a), Purine rich sequences of the PFV and SFVmac cPPT are shown. The core 
sequences are highlighted. (b), Overview of the RNAs examined for PR activation. The 
relative positions of the polypurine rich sequences A to D and the lengths of the 
different RNAs are displayed. 
 
PR activity was examined using a model substrate described previously, which contains the 
natural PR cleavage site in the Pol precursor between the GB1 and GFP protein domains [19]. 
We showed previously that in the absence of other factors, PR could only be activated at high 
NaCl concentrations of 2 - 3 M [19,20]. Here, we decreased the NaCl concentration to 
100 mM, to achieve conditions that are biologically more relevant. Analysis of the cleavage 
products by SDS-PAGE reveals that the CasI-CasII RNA can stimulate PR activity (Figure 2). 
To identify the RNA sequence sufficient for stimulation we created two shorter RNA 
fragments CasI-CasII$3’, and CasII-3’ harboring the cPPT (Figure 1). Since the stimulatory 
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effect of CasII-3’ was much more pronounced, we created 5’ deletions in CasII-3’ to 
determine the minimal region necessary for PR stimulation. The in vitro transcribed RNAs 
harbored various regions of the cPPT A-D elements of PFV: ABCD; AB; CD; A; B and AB!, 
which contains a deletion of the 3’ region of the B element. In addition, antisense RNAs of 
CasI-CasII (=anti-CasI-CasII) and of AB (=anti-AB) were tested (Figure 1). We used these 
RNAs to investigate the PR activities of both, PFV and SFVmac PR-RT. 
 
Figure 2:  Proteolytic activities of PR-RT in the presence of various RNAs.  
  Activity assays with different RNAs were performed with (a) PFV and (b) SFVmac PR-
RT. 10 !M GB1-GFP substrate was incubated with 2.5 !M PR-RT and 0.5 !M RNA as 
indicated at 37°C for 2 h in 50 mM Na2HPO4/NaH2PO4 pH 6.4, 100 mM NaCl. 
Reaction products were analyzed by 10 % BisTris gels. S: uncleaved substrate; M, 
molecular weight standard. The sizes of the standard proteins are indicated on the left.  
 
Figure 2 shows that the cleavage activity of both enzymes in the presence of AB is 
comparable with that of the ABCD or the CasII 3’ RNAs, whereas neither A nor B alone 
could not stimulate PR in a similar manner. Also truncation of AB at the 3’ end (AB!) by 
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57 nt resulted in a weaker PR activity, which was similar to that of anti-AB. Obviously, RNA 
in general had a weak stimulatory effect on PR activity, whereas we could not observe any 
change in PR activity when DNA-CasI-CasII, -ABCD or –AB was added (data not shown). 
However, strong activation appeared to be dependent on the presence of AB-RNA, whereas 
CD-RNA resulted only in weak stimulation. Interestingly, the PFV AB-RNA stimulated 
SFVmac PR-RT to a similar extent, although the sequence of the A-element differs by two 
bases (Figure 1a). Addition of 6 mM MgCl2 to the reaction mixture or refolding of the RNAs 
after in vitro transcription and purification did not change the results (data not shown).  
Secondary structure prediction of the PFV cPPT AB-RNA reveals a molecule with several 
hairpin loop structures (data not shown). To determine the actual structure of the PFV AB-
RNA we performed SHAPE analyses. NMIA preferentially reacts with conformationally 
flexible nucleotides, e.g. nucleotides that are not base paired, at the 2’ OH of the ribose. 
Sequencing reactions of RNA treated with NMIA will stop at positions modified with NMIA. 
Thus, nucleotides showing significantly higher band intensities in sequencing reactions after 
treatment with NMIA correspond to single-stranded RNA regions.  
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Figure 3:  SHAPE analysis of RNA-AB. 
   (a) Relative SHAPE intensities as a function of nucleotide position. (b) RNA secondary 
structure model of RNA-AB using SHAPE constraints. Bases with relative SHAPE 
intensities higher than 0.35 are highlighted in purple. (*): significant intensities were only 
measured at NMIA concentrations higher than 14 mM NMIA and the corresponding 
bases not constrained in the RNA secondary structure calculation. 
 
Our data (Figure 3A) indentified several regions in the RNA-AB sequence, which were 
unpaired. Calculations of the RNA secondary structure including constraints for the unpaired 
regions (Figure 3B) confirmed the predicted RNA secondary structure to a great extent. The 
RNA consists of three hairpin loop structures and a central as well as a 3’ unpaired region 
(nt 86 to 95 and 134 to 150). The A and B elements are each located in a hairpin of 
approximately 15 nt in length. Upstream of the A- as well as the B-element an accumulation 
of purines can be observed starting at the beginning of the loop. Thus, in both cases the region 
3’ of the loop almost exclusively consists of purines. 
Two nt (68 and 125) showed an unusual behavior. Only NMIA concentrations higher than 
14 mM resulted in strong signals at these nt, implying that they were in an unpaired region, 
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whereas lower NMIA concentrations did not show this effect (Table 1). Thus, nt 68 and 125 
were not considered to be unpaired in our secondary structure calculations.  
 
Table 1: Relative SHAPE reactivity of selected nucleotides. 
 
nt 11 mM NMIA 14 mM NMIA 18 mM NMIA 
68 0.07 0.10 0.40 
94 0.49 0.55 0.62 
97 0.07 0.11 0.09 
125 0.04 0.06 0.74 
 
To confirm the hypothesis that the PR-RTs bind to RNA-AB in order to enhance PR activity, 
we performed EMSAs with PFV PR-RT and RNA-AB as well as anti-AB (Figure 4). Our 
experiments with AB indicated that RNA binding might be a prerequisite for PR activation. 
Not surprisingly, since RTs are nucleic acid binding proteins, that bind to RNA or DNA also 
non-specifically, anti-AB RNA was shifted, too.  
 
Figure 4:  Electrophoretic mobility shift assay with different RNAs. 
  500 nM of a radioactively labeled RNA (a) AB or (b) anti-AB was incubated with 
increasing concentrations of PFV PR-RT in 50 mM Na2HPO4/NaH2PO4 pH 6.4, 
100 mM NaCl and 10 % glycerol at RT for 5 min. Complexes were separated on 6 % 
DNA retardation gels at 4 °C. 
Multiple shift bands indicated that dimers and higher multimers were formed. However, 
binding to AB appeared to be slightly stronger than for anti-AB. Similar results were obtained 
with SFVmac PR-RT (data not shown).  
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Since dimerization of the PR domain is a prerequisite for PR activity, we analyzed whether 
binding to AB-RNA or anti-AB actually initiated PR-RT dimerization. PFV PR-RT, was 
crosslinked with the corsslinking reagent BS3 in the presence or absence of RNA-AB or anti 
AB, respectively. To exclude crosslinking of PR-RT to RNA, RNA hydrolysis under alkaline 
conditions was performed before the samples were analyzed by SDS-PAGE (Figure 5).  
 
Figure 5:  Protein crosslink of PFV PR-RT.  
   Crosslinking reactions were performed with 2 !M PFV PR-RT and 0.1 mM BS3 in the 
presence or absence of different RNAs (0.5 !M) as indicated for 15 min at RT in 
50 mM Na2HPO4/NaH2PO4 pH 6.4, 100 mM NaCl. After RNA hydrolysis, reaction 
products were separated on 10 % BisTris gels. The proposed oligomerization state is 
indicated on the left, the sizes of the standard proteins are displayed the right. 
 
Clearly, dimers and, however to a much lower extent, tetramers of PFV PR-RT could be 
detected with the samples containing RNA. No dimers or multimers are visible in the control 
assays without RNA. Again, dimerization in the presence of RNA-AB is slightly more 
pronounced as compared to anti-AB. Comparable results were obtained using SFVmac PR-
RT (data not shown). The protein crosslink proves that FV PR-RTs dimerize when binding to 
RNA. Specific RNA sequences appear to stimulate binding and dimerization of the PR-RTs to 
a greater extent than RNAs that do not harbor the AB sequences (Figure 4, 5).  
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Discussion 
It has been shown previously that PFV as well as SFVmac PR-RT behave like monomers 
under biologically relevant conditions [18-20]. Although dimerization is needed for a 
catalytically active PR [22], only a small fraction (< 5 %) was dimerized [21]. Activation of 
FV PR in vitro could be accomplished at high salt concentrations (2 – 3 M NaCl) [19,20]. 
However, how dimerization is achieved during the viral life cycle remained unclear.  
Orthoretroviral PRs investigated so far are present in the virion as rather stable dimers with 
catalytic activity [22,35]. Recently, a study showed that the HIV-1 PR domain can form 
transient dimers in the Gag-Pol precursor protein [36]. Thus, premature activation of PR can 
be prevented before virus assembly. Packaging of the Pol proteins in HIV-1 is mediated by 
RNA binding of Gag within the Gag-Pol polyprotein (reviewed in [9]) and this process 
probably activates PR. Since FVs express Gag and Pol independently, Pol packaging and PR 
regulation have to be different. 
The C-terminus of Gag as well as the A and B elements of the FV cPPT have been identified 
as determinants for Pol uptake [14-16]. Here, we show that CasI-CasII RNA enables PR-RT 
to form a proteolytically active dimer. Truncating the CasI-CasII RNA at the 5’ and 3’ ends 
allowed us to define the minimum sequence needed for PR activation (Figure 2). Our data 
indicate that important interactions between Pol and the A and B elements of the cPPT occur 
during virus assembly and maturation [26]. Therefore, RNA binding of Pol is not only 
required for Pol encapsidation, but for PR activation as well. 
Secondary structure analysis by SHAPE showed similar folds of the A and B elements 
(Figure 3). Each sequence is part of a hairpin loop structure. The loop and the 3’ sequence of 
the stem are formed almost exclusively by purines. The polypurine sequences of the HIV 
RNA/DNA hybrid have been associated with bent structures and deviations from Watson-
Crick base pairing have been reported [37,38]. 
Unusual behavior of nt 68 and 125 of the AB-element of the PFV PPT was observed. While 
low NMIA concentrations predicted paired bases, high NMIA concentrations indicated that 
they were not paired (Table 1). We cannot exclude that high NMIA concentrations themselves 
caused changes in RNA folding and led to a modification of the 2’ OH ribo-group of the two 
nt. Noticeably, only nt 68 and 125 were affected. Both are located in the center of a 
polypurine hairpin loop structure. This might indicate that indeed a distinct RNA tertiary 
structure was formed, which is recognized by PR-RT, leading to the formation of a 
proteolytically active PR-RT dimer upon binding. Thus, even though the PFV PPT is built by 
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double stranded RNA, its structure reveals similar abnormal behavior as the RNA/DNA 
hybrid of the HIV PPT [37,38]. 
EMSA analyses proved PR-RT binding to RNA (Figure 4). PR-RT appears to bind to RNA 
independently of the sequence. Shifts corresponding to multiple binding of PR-RT were 
obtained for RNA-AB and anti-AB with only minor differences. Crosslinking experiments 
revealed similar results (Figure 5). Without RNA PR-RT is monomeric as has already been 
shown previously [18-20]. In the presence of RNA-AB as well as anti-AB, dimers and even 
tetramers could be detected. EMSA and protein crosslinking are in good agreement with PR 
activity assays, where all RNA sequences had at least a low stimulatory effect on PR activity. 
In conclusions, our data indicate that PR-RT dimerizes upon RNA binding. However, RNA 
containing the A and B elements with a distinct RNA folding appears to be required to form a 
stabile PR-RT dimer with high catalytic activity. 
We propose that PR in FVs is inactive after expression within the Pol polyprotein due to 
inefficient dimerization [21]. Packaging of Pol is achieved through binding of Pol via the PR-
RT domain to the A- and B- RNA sequences of the FV cPPT [13,26], whereas Gag is 
recruited via its C-terminus [14]. Only PR-RT bound to the cPPT RNA is able to form 
proteolytically active dimers thus allowing cleavage of Pol and Gag, which results in mature 
virus particles.  
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